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Volumetric muscle loss (VML) is a debilitating injury associated with chronic disability, 
and existing treatment options remain unsatisfactory. The current therapeutic gold standard is 
autologous free-flap grafting; however, the efficacy of this treatment option is limited(Corona, 
Rivera, Owens, Wenke, & Rathbone, 2015). Biologic scaffolds composed of extracellular matrix 
(ECM) provide an inductive microenvironment that promotes functional, site appropriate tissue 
deposition(Dziki, Sicari, Wolf, Cramer, & Badylak, 2016; Dziki, Wang, et al., 2017) and 
modulation of local immune responses, in particular macrophages. ECM bioscaffolds promote a 
transition from a pro-inflammatory, M1-like to a pro-healing, M2-like macrophage phenotype that 
is critical for skeletal muscle tissue healing(Brown, Londono, et al., 2012). However, the 
component(s) of ECM that govern this phenotypic transition remain poorly understood. Recent 
studies suggest that matrix-bound nanovesicles (MBV), a component of ECM, may be responsible 
for ECM-mediated macrophage phenotype activation(L. Huleihel, J. G. Bartolacci, et al., 2017). 
MBV are an abundant source of extracellular IL-33. IL-33, signaling through the ST2 receptor, is 
an established mediator of macrophage phenotype(Joshi et al., 2010; H. Xu et al., 2019). Evidence 
supports non-canonical, ST2-independent IL-33 signaling as a mechanism by which MBV 
promote a pro-healing macrophage phenotype(G. S. Hussey et al., 2019). However, the nature of 
MBV-associated IL-33 signaling remains unexplored. The objectives of the present thesis were to 
determine the phenotypic response of macrophages and muscle stem cells to MBV-associated IL-
33, to establish a mechanism for MBV uptake and the resulting localization of delivered MBV 
 v 
cargo, and to interrogate the effects of IL-33 deletion on macrophage phenotype and functional 
recovery in a mouse model of muscle injury. Results show that ST2-independent IL-33 signaling 
results in an M2-like macrophage phenotype. MBV-associated IL-33 is internalized by clathrin-
mediated endocytosis and is trafficked to the host cell nucleus. IL-33 deletion severely alters the 
macrophage response to injury and reduces functional recovery in a mouse model of acute skeletal 
muscle injury. Importantly, delivery of IL-33+ MBV reduced M1-like macrophages and increased 
force generation. Together, these data show that MBV-associated IL-33 is required for effective 
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1.0 The Skeletal Muscle Response to Injury 
1.1 Clinical Significance of Skeletal Muscle Injury 
Volumetric skeletal muscle loss (VML) as a result of traumatic injury is a significant 
clinical problem in both military and civilian populations with an estimated annual economic 
burden of $4 billion(Grasman, Zayas, Page, & Pins, 2015). Within military populations, VML 
underlies 65% of disability in discharged veterans(Corona et al., 2015), and are the most common 
non-fatal injuries in civilian populations(Corona et al., 2015; Grogan, Hsu, & Skeletal Trauma 
Research, 2011). Skeletal muscle has robust inherent regenerative capacity. However, defects 
greater than 20% of total muscle mass within a given muscle group overwhelms the ability of 
resident stem/progenitor cells to fully reconstitute the absent tissue and, instead, fibrotic tissue fills 
the void(Qazi, Mooney, Pumberger, Geissler, & Duda, 2015). Fibrosis negatively impacts muscle 
function and is a significant factor in the morbidity and reduced quality of life associated with 
VML(Cholok et al., 2017; Garg, Corona, & Walters, 2015). Current therapeutic standard of care 
includes rigorous physical therapy, use of orthotics, and/or autologous flap grafting, and, more 
recently, acellular bioscaffolds composed of extracellular matrix (ECM). Autologous flap grafting 
often has limited donor site availability, can incur donor site morbidity, and both grafting and 
orthotics have limited success in restoring appreciable function(Koul, Patil, & Nahar, 2013).  
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1.2 The Cellular Response to Acute Skeletal Muscle Injury 
1.2.1 Muscle Stem Cell Response to Acute Muscle Injury 
Skeletal muscle tissue frequently experiences injury as a result of normal function and 
physical exercise. Endogenous repair of muscle tissue is therefore required for the maintenance of 
proper function and for an organism to adapt to a changing environment. As a result, skeletal 
muscle tissue has a robust regenerative potential that is reliant upon resident muscle 
stem/progenitor cells, immune cells, and an intact extracellular matrix(Grasman et al., 2015). In 
particular, satellite cells, a resident population of muscle stem cells characterized by their 
expression of Pax7(Glass, 2003; Tidball, 2017), play an integral role in recovery from injury. 
Satellite cells reside in a quiescent state between the basal lamina and sarcolemma of 
neighboring myofibers. In response to an acute injury, inflammatory signals promote satellite cell 
re-entry to the cell cycle and asymmetric proliferation, thereby expanding the pool of stem cells. 
A portion of activated satellite cells are subsequently directed to commit to the myogenic lineage 
and differentiate to myotubes and eventually myofibers that repair damaged muscle tissues in 
response to pro-regenerative signaling cues.  
However, in injuries of great volume or severity, the traditional signaling mechanisms 
needed for the recruitment, activation, and differentiation of satellite cells are overwhelmed. 
Sustained pro-inflammatory signaling results in a failure of satellite maturation to myoblasts and 
integration with or replacement of myofibers. Instead, damaged muscle is replaced with fibrotic 
and adipogenic infiltrates that further compromise muscle structure and function, which can lead 
to significant reductions in quality of life(Greising, Dearth, & Corona, 2016; Grogan et al., 2011). 
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1.2.2 The Role of Host Immune Response to Skeletal Muscle Injury 
Skeletal muscle is an immune cell dense tissue. Recent estimates show that muscle tissue 
is contains nearly 1 x 109 leukocytes/L of muscle, which, compared to ~1 x 1011 leukocytes/L of 
plasma, is high, is composed primarily of monocytes and macrophages(Tidball, 2017), and are 
critical for muscle homeostasis. Resident leukocytes in muscle connective tissue in a quiescent 
state, but can be activated in response to injury or physical exertion. The host immune response to 
skeletal muscle injury has been extensively characterized and is consistent regardless of injury 
origin, involving communication between immune cells and stem cells(Tidball & Villalta, 2010). 
The innate immune response, in particular the macrophage component, plays a central role in 
governing the behavior of stem/progenitor cells in the days and weeks following acute muscle 
injury. Macrophages, one of the earliest cell types to arrive in response to muscle injury, are a 
phenotypically plastic cell type, with the ability to transition between pro-inflammatory, M1-like 
and pro-healing, M2-like states in response to cues from the local microenvironment(Tidball, 
2005, 2017; Tidball, Dorshkind, & Wehling-Henricks, 2014; Tidball & Villalta, 2010). Both 
macrophage phenotypes have been shown to be essential to the healing response, as a reduction of 
macrophage infiltration or appropriate phenotypic activation can severely delay and impair 
recovery from muscle injury(Cheng, Nguyen, Fantuzzi, & Koh, 2008; Londhe & Davie, 2013; 
Tidball & Wehling-Henricks, 2007). 
Macrophage phenotype is spatially and temporally controlled and the earliest population 
to arrive after injury are M1-like macrophages within 1-3 days(Tidball, 2005; Tidball & Villalta, 
2010; Warren et al., 2005), during which time these cells promote activation and expansion of the 
satellite cell pool. For successful repair, M1-like macrophages must transition to M2-like 
macrophages between 4- and 14-days post-injury(B. Deng, M. Wehling-Henricks, S. A. Villalta, 
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Y. Wang, & J. G. Tidball, 2012; J. L. Dziki et al., 2016). This transition is critical as M2-like 
macrophages help coordinate early stages of myogenic differentiation to myotubes(L. Arnold et 
al., 2007; St Pierre & Tidball, 1994a). Without an appropriate timed phenotypic transition, muscle 
healing can be severely delayed or impaired, as has been observed in large muscle injuries(B. Deng 
et al., 2012). Stated differently, the macrophage response is a central and indispensable component 
of the host response to muscle injury.  
Although innate immune cells represent the majority of muscle leukocytes, multiple studies 
have shown that lymphoid cells, ulterior innate immune cell types, and mesenchymal cells play 
critical regulatory roles(W. Kuswanto et al., 2016; K. Sadtler, K. Estrellas, et al., 2016). A 
population of CD8+ T cells was shown to be among the first responders to skeletal muscle injury, 
and ablation of this population delayed muscle healing, however more work is needed to determine 
what role these cells play. A large body of work is also emerging with respect to FoxP3+ TREG 
cells. TREG cells follow similar kinetics to M2-like macrophages, arriving by ~4-10 days post-
injury and secrete potent cytokines, IL-10 and amphiregulin, whose bioactivity on macrophages 
and activated satellite cells, respectively, promote the macrophage phenotype transition away from 
a predominantly M1-like macrophage population towards a predominantly M2-like macrophage 
population, and promote differentiation of activated satellite cells(Tidball, 2005; Tidball et al., 
2014; Villalta et al., 2014). Eosinophils have also been reported to be important in the macrophage 
phenotype transition and in regulating the behavior of fibro-adipogenic precursors (FAPs) through 
the release of IL-4. Specifically, eosinophil-derived IL-4 sustains macrophage phenotype 
transition stimuli and increased FAP phagocytic capacity to increase debris clearance. FAPs have 
also been shown to interact with infiltrating macrophages(Heredia et al., 2013). Subsequently, M2-
like macrophages release factors that promote differentiation of FAPs along the fibroblastic 
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lineage, resulting in the deposition of new muscle matrix and providing guidance to differentiating 
muscle stem cells(Heredia et al., 2013; Tidball, 2017). Taken together, muscle immunobiology is 
spatially and temporally controlled with several supporting cell types helping to orchestrate 
macrophage phenotype and modulate cytokine signaling in the muscle microenvironment. 
1.2.3 Macrophage-Mesenchymal Cell Crosstalk 
The central role of immune cells in tissue healing is derived from their ability to 
communicate with mesenchymal cell types, including fibroblasts and stem/progenitor cells, and 
modify their behavior. These macrophage-mesenchymal cell interactions have been reported in 
many tissue types, including skeletal muscle, and are thought to be critical for tissue 
homeostasis(Kumar, Alvarez-Croda, Stoica, Faden, & Loane, 2015; St Pierre & Tidball, 1994a, 
1994b; J. G. Tidball & M. Wehling-Henricks, 2015; Tidball & Welc, 2015; Verheijden, Schepper, 
& Boeckxstaens, 2015; Villalta, Nguyen, Deng, Gotoh, & Tidball, 2009; Wei & Besner, 2015; Wu 
et al., 2015). For example, the role of macrophages in mediating satellite cell recruitment, 
proliferation, and differentiation in response to skeletal muscle injury(Tidball, 2005, 2017; Tidball 
et al., 2014; Tidball & Villalta, 2010; Tidball & Wehling-Henricks, 2007), is well characterized 
and is thought to be exemplary of repair processes in other organ systems, as well.  
In skeletal muscle, macrophages direct the proliferation or differentiation of satellite cells, 
the native skeletal muscle stem cell type, as a function of macrophage phenotype. M1-like, pro-
inflammatory macrophages are required for the expansion of the satellite cell pool in response to 
muscle injury, ensuring that sufficient cells are available for subsequent differentiation and 
replacement of lost myotubes. Following macrophage phenotype transition to a pro-healing, M2-
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like phenotype, macrophages direct the differentiation of activated satellite cells to myotubes and, 
eventually, myofibers to replete muscle tissue lost to injury. 
Macrophage-mesenchymal cell crosstalk is, however, bidirectional. Recent reports suggest 
that the secreted products of myoblasts exposed to serial strain promote the expression of M2-
associated markers Arg1 and Fizz1 by bone marrow-derived macrophages (BMDM)(J. L. Dziki et 
al., 2016; Dziki, Wang, et al., 2017). Further, it has been reported that the secreted products of 
mesenchymal stem cell (MSC) can promote the expression of M2-associated marker Arg1 in 
treated BMDM(Zhou, Yamamoto, Xiao, & Ochiya, 2019). Separate studies have shown that co-
culture of MSCs and BMDM resulted in a reduction in expression of M1-like markers TNF-a, IL-
6, and iNOS, while promoting expression of M2-like markers CD206, IL-4, and IL-10(Cho et al., 
2014). In vivo, it has been shown that MSCs exposed to LPS preferentially recruit M2-like 
macrophages, and reprogram M1-like macrophages towards an M2-biased phenotype through the 
production of prostaglandins. Targeting these interactions, either by focusing on macrophages or 
their communication counterparts, could be effective therapeutic strategies to improve tissue 
engineering outcomes. 
1.3 Current Treatment Options for Large Muscle Injuries 
1.3.1 Muscle Grafting 
To date, the standard of care for large muscle injuries is autologous free-flap or rotational 
grafts, most commonly muscles of the thigh or back(Bertelli & Ghizoni, 2016; Klinkenberg et al., 
2013). Muscle transposition has less than satisfactory success rates, in part due to a high rate of 
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graft infection and necrosis, and a limited availability of donor tissue without incurring donor site 
morbidity(Corona, Wenke, & Ward, 2016). As a result, such procedures often fail to provide 
efficient reconstruction or restoration of lost muscle function. Stated differently, the current 
standard of care does not address the underlying pathophysiology underlying the chronic 
functional deficits arising from large muscle injuries, and as a result do not address persistent 
strength and functional deficits which ultimately contribute to morbidity and and reduced patient 
quality of life(Grogan et al., 2011; C. H. Lin, Lin, Yeh, & Chen, 2007; Moneim & Omer, 1986; 
Tu et al., 2008). 
1.3.2 Physical Rehabilitations and Orthotics 
Physical rehabilitation and the use of orthotics can improve patients’ ability to perform 
activities of daily living when muscle function has been severely compromised due to skeletal 
muscle injury, and can help augment endogenous healing. It has been shown that mechanically 
loading skeletal muscle can modify the post-injury remodeling process to improve strength 
maintenance, endurance, fatigue resistance, and regeneration(Shwartz, Blitz, & Zelzer, 2013). 
Studies have shown that early rehabilitation following skeletal muscle injury improved functional 
output(Hwang, Ra, Lee, Lee, & Ghil, 2006). Specifically, physical rehabilitation has been shown 
to modulate immune cell phenotypes(Dziki et al., 2018), activate satellite cells and improve 
alignment of nascent myotubes following acute injury(Ambrosio et al., 2009). The mechanisms 
underlying these cellular events are an active area of investigation and remain only partially 
understood. It has been shown that mechanotransduction can promote the expression of genes 
encoding extracellular matrix components by fibroblasts and promote satellite cell reentry to the 
cell cycle(Greising et al., 2018; Nuutila et al., 2017). These effects may, at least in part, be 
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accounted for by increasing the compliance of the skeletal muscle extracellular matrix, thereby 
increasing the ability of satellite cells and other stem cells to reconstitute missing tissue(Ambrosio 
et al., 2014; Stearns-Reider et al., 2017). However, it has been shown that physical rehabilitation 
alone following volumetric muscle loss injuries was not sufficient to improve muscle function 
across animal models, but that physical rehabilitation in combination with biomaterials and/or stem 
cell therapies were synergistic(Greising, Corona, McGann, Frankum, & Warren, 2019). Stated 
differently, physical rehabilitation is a powerful tool that can augment endogenous repair 
processes, but cannot recapitulate strength lost due to injury when used alone. 
1.3.3 Cell-based Strategies 
A Tissue engineering and regenerative medicine strategies to address VML have been 
primarily cell-centric. Exogenous delivery of stem cells to repopulate missing muscle tissue has 
shown moderate success in preclinical studies(Deasy, Jankowski, & Huard, 2001; Huard, Cao, & 
Qu-Petersen, 2003). However, technical, economic, and regulatory hurdles including low 
engraftment efficiency and low viability after injection have limited the success of clinical 
translation(Ezquer, Ezquer, Vicencio, & Calligaris, 2017; Schwartz, Brick, Nethercott, & Stover, 
2011; Swijnenburg et al., 2008).  In addition, cell isolation and maintenance requirements are 
costly, and allogeneic cell-sourcing necessitates concomitant immunosuppression(Vats, Tolley, 
Bishop, & Polak, 2005). Nonetheless, results of preclinical work show that some cell-seeded 
scaffolds can provide more significant gains of function in skeletal muscle regeneration than 
acellular materials alone(Borschel, Dennis, & Kuzon, 2004; Borschel, Dow, Dennis, & Brown, 
2006; Garg, Ward, Rathbone, & Corona, 2014; Kin et al., 2007). The use of different cell types, 
different animal models, and different analyses have yielded conflicting results, however. The cell 
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types used in preclinical animal models do not have uniform characteristics and the ability of these 
cells to promote muscle repair varies widely. It is helpful to understand these differences to better 
compare results and guide future strategies for skeletal muscle tissue engineering.  
Most cell types that have been investigated for skeletal muscle repair are autologous or 
allogeneic stem cells that have been isolated and expanded in vitro before seeding and 
reimplantation. Autologous cells are advantageous because there is no immune-mediated rejection, 
even in the absence of immunosuppression. Allogeneic cells require prolonged 
immunosuppressive therapy(Swijnenburg et al., 2008) that can adversely affect healing, foster 
fibrosis(Anderson & Hamm, 2012), and disrupt constructive macrophage phenotype 
transitions(Salehi & Reed, 2015). Autologous, induced pluripotent stem cells and allogeneic 
embryonic stem cells can theoretically be passaged indefinitely(Schwartz et al., 2011), affording 
much larger populations of cells for seeding compared to satellite cells, which are very limited in 
their passage potential(Danoviz & Yablonka-Reuveni, 2012). Cell survival is a concern as it has 
been shown that the vast majority of transplanted cells will fail to integrate with host tissue. Low 
engraftment efficiency is multifactorial(Ezquer et al., 2017), but a lack of a vascular supply and 
an inflammatory host environment have been implicated as key contributors to this phenomenon(S. 
Lee, Choi, Cha, & Hwang, 2015). The number of cell layers that can be seeded, for example, is 
limited by the ability of nutrients and gases to diffuse from a medium to the cells. Specifically, in 
the absence of a vascular network, cells in excess of 1 mm distance from a nutrient and gas rich 
medium will have difficulty surviving(Griffith et al., 2005).  
Nutrient diffusion presents a particularly challenging obstacle for cell seeded scaffolds that 
lack a vascular network. Attempts have been made to design scaffolds with provisional vascular 
conduits(Lesman et al., 2011), but insufficient preclinical animal modeling has been conducted 
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and is an ongoing topic of research. Further, induced pluripotent stem cells (iPSCs) require 
complex growth factor cocktails to support appropriate differentiation, often have low viability, 
and there is concern surrounding the retroviruses used to induce pluripotency(Puri & Nagy, 2012). 
An appropriate level of safety must be considered, prior to large scale clinical application, which 
in itself can be particularly challenging since no technology exists that can sterilize a scaffold 
without killing embedded cells. Stated differently, all steps in the manufacture of a cell seeded 
scaffold must be conducted under sterile conditions, which adds time, cost, and potential risks to 
the development of these personalized devices. For these stated reasons, exogenously supplied 
autologous and allogeneic stem cells have achieved limited success. 
1.3.4 Bioscaffolds 
VML results in extensive damage to connective tissue and basement membrane 
architecture. Skeletal muscle tissue is a highly organized tissue and effective tissue repair requires 
that therapeutic strategies have a three-dimensional structure that resembles the native 
microenvironment. Ideally, scaffolds for the repair of skeletal muscle injuries should be 
immunomodulatory, allow for the transduction of forces, stimulate angiogenesis to support the 
requirements of tissue regeneration, and serve as a provisional matrix or substrate for host tissue 
integration, endogenous cell migration, proliferation, and differentiation during the remodeling 
process. Several biomaterial-based strategies have been investigated to reconstitute injured or 
missing soft tissue and restore lost function. Due to the highly dynamic cellular response to skeletal 
muscle injury, scaffolds are effective tools which can be designed to help regulate one or more 
components of the host response. 
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The formation of a vascular supply to sustain tissue healing is a particularly important need 
in tissue engineering. To address this need, growth factor-eluting materials have been developed 
to release VEGF over long periods of time to stimulate endogenous vascularization. Results of 
these studies have shown that the released growth factors can be temporally controlled to sustain 
angiogenesis and vessel maturation(Brudno, Ennett-Shepard, Chen, Aizenberg, & Mooney, 2013; 
Geer, Swartz, & Andreadis, 2005). Drug-eluting microspheres have also been used in conjunction 
with naturally derived polymers such as alginate, collagen, and fibrin, among others, to achieve 
functional restoration in animal models of volumetric muscle loss. One study found that the use of 
IGF-1 and VEGF-eluting PLG microspheres embedded in alginate hydrogels promoted early 
vasculogenesis and a significant increase in regenerating myotubes, resulting in near-complete 
functional recovery in a rodent model of ischemic muscle injury(Shvartsman et al., 2014). Other 
studies have evaluated vascular networks that were manufactured in vitro using three-dimensional 
fibrin-PGA/PLLA seeded with endothelial cells, fibroblasts, and myoblasts. Results showed that 
the engineered constructs were capable of supporting blood flow in vivo(Lesman et al., 2011), but 
functional testing was not performed. Determining the correct combinations, dosages, and dose 
regimens of growth factors and other bioactive molecules to obtain effective results is an active 
area of investigation(Lawrence & Diegelmann, 1994).Taken together, polymeric biomaterials are 
valuable research tools, but have not yet convincingly demonstrated translational potential in 
preclinical animal testing. 
Bioscaffolds composed of acellular mammalian extracellular matrix (ECM) have shown 
notable success in promoting functional tissue remodeling in multiple anatomic sites(Agarwal et 
al., 2015; Atala, Bauer, Soker, Yoo, & Retik, 2006; Badylak et al., 2011; Gerdisch, Shea, & Barron, 
2014; Kissane & Itani, 2012; Ladowski & Ladowski, 2011; Lecheminant & Field, 2012; B. M. 
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Sicari, J. P. Rubin, et al., 2014). ECM bioscaffolds retain local tissue ultrastructure and a variety 
of signaling factors that contribute to stem/progenitor cell recruitment(Agrawal, Tottey, et al., 
2011; Reing et al., 2009; Vorotnikova et al., 2010), immunomodulation, angiogenesis(Hammond 
et al., 2011; Voytik-Harbin, Brightman, Kraine, Waisner, & Badylak, 1997), and more(Allen et 
al., 2010; Hammond et al., 2011; Reing et al., 2009; Vorotnikova et al., 2010). A recent meta-
analysis of preclinical animal models, the use of ECM bioscaffolds with or without a cellular 
component resulted in the greatest improvement in functional remodeling of skeletal muscle 
injury(Greising et al., 2019). The beneficial effects on muscle healing are multifactorial, but rely 
on modulation of the host immune response towards a TH2/M2-like pro-healing response and 
direct myogenic effects on muscle stem cells(J. Dziki et al., 2016; J. L. Dziki et al., 2016; L. 
Huleihel, J. L. Dziki, et al., 2017; K. Sadtler, K. Estrellas, et al., 2016). Importantly, the use of 
ECM bioscaffolds to treat VML in a human clinical cohort trial resulted in an average of ~250% 
gain of function and ~35% improvement in functional output(J. Dziki et al., 2016). Taken together, 
the complex variety of bioactive components make ECM bioscaffolds a viable option for the 
treatment of volumetric muscle loss. 
1.4 Future Perspectives 
The development of next-generation tissue engineering solutions for large muscle injuries 
will need to carefully consider the complex skeletal muscle injury microenvironment in order to 
be successful. To accomplish this, a multidisciplinary approach will be essential. In particular, 
combinatorial approaches that incorporate cells, scaffolds, and rehabilitation show functional 
muscle improvements beyond the use of cells or scaffolds alone(Corona, Ward, Baker, Walters, & 
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Christ, 2014). To meet these ends, there is a particular need for standardization in the animal 
models used, the metrics used to assess recovery, and the molecular characterization of 
transplanted cells. A rigorous, prospective study comparing the effect of different cell types and 
optimal scaffolds in functional recovery from large muscle injuries should be performed to provide 
an optimized platform for future work. 
Clinical translation of tissue engineering approaches to skeletal muscle injury will require 
that these strategies be modular. Pre-existing medical conditions are common in the surgical 
patient population, and these risks increase in more advanced age patients(Hewitt et al., 2016). 
Although ECM bioscaffold use has shown successful restoration of function in humans, the cohort 
of patients was relatively small. Understanding the underlying changes to native extracellular 
matrix or the cellular responses to implanted biomaterials in patients with multiple comorbidities 
could expand the number of patients who could benefit from the products of tissue engineering 
and regenerative medicine research(Garg, Corona, & Walters, 2014). For example, the use of 
biomaterials in animal models of metabolic disease, one of the most common comorbidities, would 
be an important area for future investigation to  achieve this end(Safdar, Saleem, & Tarnopolsky, 
2016). 
1.5 Conclusions 
The host response to skeletal muscle healing is multifaceted and relies on a dynamic 
interaction between immune and stem cell players. In skeletal muscle, the critical balance between 
pro-inflammatory and pro-healing signals can quickly become disrupted in response to volumetric 
muscle loss, resulting in a sustained pro-inflammatory bias with accompanying fibrosis and loss 
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of function. Existing treatment options for large muscle injuries remain unsatisfactory. Although 
cell-centric regenerative medicine approaches have achieved some success, the use of an inductive 
scaffold, such as those composed of extracellular matrix, can help normalize aberrant endogenous 
repair processes, potentially circumventing the need for exogenously provided cells. Although 
tissue engineering efforts utilizing ECM bioscaffolds have shown promising early clinical 
translation, more work is needed to determine the mechanisms by which these materials induce 
functional, site-appropriate tissue remodeling. 
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2.0 Mechanisms of ECM Bioscaffold-mediated Endogenous Repair. 
2.1 Overview 
Bioscaffolds composed of acellular mammalian extracellular matrix (ECM) are complex 
materials with myriad bioactive components. ECM bioscaffolds have been used for decades to 
treat soft tissue pathology resulting from trauma or disease in a wide variety of anatomical sites. 
Host degradation of implanted ECM biomaterials is critically important for endogenous, functional 
and site appropriate tissue repair. Specifically, the use of ECM bioscaffolds has been associated 
with angiogenesis, stem/progenitor cell recruitment and differentiation, and immunomodulation. 
Several components have been attributed to these inductive effects, including the release of 
retained growth factors, cryptic peptides, and the mechanical properties of the material, however, 
a definitive mechanism for ECM bioscaffold-mediated immunomodulation has been established. 
The present manuscript will discuss the known bioactive components of the extracellular matrix 
as they pertain to tissue healing and remodeling, and discuss future avenues of investigation with 
respect to immunomodulatory mechanisms. 
2.2 Introduction 
The current standard of care for surgical scaffolds remains the use of synthetic, non-
absorbable materials. However, non-absorbable polymers have been associated almost universally 
with the formation of a maladaptive host response termed the foreign body reaction (FBR), 
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comprising foreign body giant cells (FBGCs), chronic pro-inflammatory signaling, and fibrous 
encapsulation of implanted material(Roth, Brathwaite, Hacker, Fisher, & King, 2015; 
Schumpelick, Klinge, Rosch, & Junge, 2006). Over the long term, the FBR can result in damage 
to neighboring healthy tissue(Gandhi et al., 2011) and contracture of the fibrous capsule(Baylon 
et al., 2017; Nolfi et al., 2016), which can lead to reduced patient quality of life or even mandate 
surgical reintervention. These clinical observations obviate the need for biomaterials that can 
modulate immune cell phenotypes and promote tissue healing(Dort, Fabre, Molina, & Dumont, 
2019; Mahdavian Delavary, van der Veer, van Egmond, Niessen, & Beelen, 2011; Tidball & 
Wehling-Henricks, 2007), stimulate angiogenesis to support the requirements of infiltrating 
cells(Aamodt & Grainger, 2016), and serve as a provisional matrix or substrate for host tissue 
integration, endogenous cell migration, proliferation, and differentiation(J. L. Dziki et al., 2016; 
Saldin et al., 2019) during the remodeling process.  
ECM bioscaffolds have been investigated as a biomaterial for decades, at least in part due 
to the preservation of tissue architecture and cell signaling motifs, but numerous reports of tissue 
remodeling have resulted in a large body of research demonstrating the bioactivity of multiple 
ECM components. Studies have repeatedly demonstrated that the application of ECM bioscaffolds, 
when properly prepared, can promote angiogenesis(Billaud, Hill, Richards, Gleason, & Phillippi, 
2018; Singelyn et al., 2009), recruitment of stem/progenitor cells(Agrawal, Tottey, et al., 2011; 
Brown, Chung, et al., 2012; J. L. Dziki et al., 2016), immunomodulation(Brown, Londono, et al., 
2012; J. L. Dziki et al., 2016; Dziki, Wang, et al., 2017; L. Huleihel, J. L. Dziki, et al., 2017), and 
de novo, site appropriate, functional tissue deposition(J. Dziki et al., 2016). These outcomes have, 
to date, been linked to retained growth factors and cytokines, matricryptic peptides produced 
during scaffold degradation and remodeling, ligand-integrin interactions, and more recently, 
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matrix-bound nanovesicles (MBV). The objective of the present manuscript is to describe the 
components of ECM bioscaffolds as they contribute to endogenous repair of soft tissue defects, 
hypothesize new avenues of therapeutic intervention and identify underexplored components with 
a potential role in tissue repair. 
2.3 The ECM Topographical Ligand Landscape 
ECM bioscaffolds retain many of the structural and soluble components of the parent ECM 
from which they were derived, including ground matrix, structural proteins, embedded cytokines 
and growth factors, and basal lamina components(Saldin, Cramer, Velankar, White, & Badylak, 
2017). These components, both alone and in combination, have been shown to promote cellular 
migration, proliferation, differentiation, largely through integrin and receptor-mediated signaling.  
One of the earliest known roles for ECM in modifying cell behavior came that the 
discovery that growth factors are stably stored in the extracellular matrix, often bound to sugar 
moieties on proteoglycans. Growth factors are potent mitogens independently, however, their 
actions are often potentiated in the presence of proteoglycans such as heparan sulfate proteoglycan 
(HSPG) (Chintala, Miller, & McDevitt, 1995; Klagsbrun, 1992).  For example, VEGF-mediated 
angiogenesis requires that the target cell have active integrin binding to ECM 
components(Jakobsson et al., 2006). Further, FGF-2 has been shown to promote proliferation of 
fibroblast, chondrocytes, myoblast, and endothelial cells, but only in the presence of heparan 
sulfate(Chintala et al., 1995; Klagsbrun, 1992; Rapraeger, Krufka, & Olwin, 1991; Yayon, 
Klagsbrun, Esko, Leder, & Ornitz, 1991). Free TGF-b promotes increased secretion of ECM 
components; however, it has been shown that when TGF-b is bound to decorin, a proteoglycan, 
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the production of ECM components elicited by TGF-b is reduced, suggesting a negative feedback 
loop may exist to limit overproduction of ECM(Yamaguchi, Mann, & Ruoslahti, 1990). Tissue 
epithelia secrete unique combinations of growth factors and their ECMs are comprised of different 
components, which may help explain the observation that ECM bioscaffolds derived from different 
tissues elicit different cellular responses(Dziki, Wang, et al., 2017). 
In many cases, ECM components play a critical role in maintaining cell survival and 
differentiation, even in the absence of growth factors. In fact, cells are highly sensitive to their 
niche and respond to their microenvironment through integrins. Many contact-dependent epithelia 
require integrin binding for survival and maintenance following tissue injury(Ilic et al., 1998), and 
may become disrupted in disease states. In wound healing, the role of ECM-integrin signaling is 
arguably best characterized in epidermis. For example, keratinocyte b1-integrin binding to 
fibronectin maintains an adherent, undifferentiated state(Adams & Watt, 1989; Levy, Broad, 
Diekmann, Evans, & Watt, 2000) that is critical for the integrity of the epidermis. In response to 
wounding, keratinocytes upregulate integrins with an affinity for proteins deposited in wound 
provisional matrix (i.e. laminin, tenascin C, and fibrinogen), resulting in spatially controlled 
migration that facilitates reepithelialization(Mercurio, Rabinovitz, & Shaw, 2001; Nguyen, Ryan, 
Gil, & Carter, 2000; Tamaoki et al., 2005; Trebaul, Chan, & Midwood, 2007; Whitby, Longaker, 
Harrison, Adzick, & Ferguson, 1991). The role of integrin-ligand signaling is apparent in certain 
cancers such as melanoma, in which malignant cells increase production of tenascin C, affording 
higher motility and invasiveness(Grahovac, Becker, & Wells, 2013). In skeletal muscle tissue, 
basement membrane components have been implicated in promoting survival, migration and 
differentiation of myoblasts(Foster, Thompson, & Kaufman, 1987; Sanes, 2003). In fact, the role 
of the extracellular matrix in maintaining cellular survival and terminal differentiation states is 
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readily apparent in Duchenne’s Muscular dystrophy and other muscular dystrophies. Loss of 
proteins (e.g. dystrophin) required for connection of the myofiber cytoskeleton to the extracellular 
matrix results in continuous muscle breakdown and replacement with fibrotic tissue(Nowak & 
Davies, 2004). In skin and vasculature, higher Advanced Glycation End (AGE) product burden on 
collagen fibers has been shown to promote increased oxidative stress(Vlassara, 2001) and 
increased inflammatory signaling through the acquired ability to activate the RAGE 
receptor(Pullerits, Brisslert, Jonsson, & Tarkowski, 2006). Taken together, ECM bioscaffolds 
represent a potent combination of trophic factors and structural cues that help guide and sustain 
tissue healing. The composition and integrity of applied ECM scaffolds must be discerningly 
chosen to resemble native architecture as much as possible. Tissue engineering strategies that fail 
to incorporate a biomimetic microenvironment will likely result in suboptimal, site-appropriate 
host cell integration. 
2.4 Matricryptic Peptides 
Matricryptic peptides, also known as matrikines, are a subcomponent of the ECM. 
Matricryptic peptides are typically inaccessible except in the event of a conformational change or 
proteolytic cleavage of the parent molecule, such as in a matrix turnover event(Davis, Bayless, 
Davis, & Meininger, 2000). Many ECM proteins are comprised of subdomains with similar motifs 
to known growth factors that, when released during ECM degradation, can bind cellular receptors 
and initiate signaling cascades. Laminin and tenascin C, for example, contain epidermal growth 
factor (EGF)-like repeats that are capable of binding and activating EGF receptors, albeit with 
lower affinity(Iyer et al., 2007; Swindle et al., 2001). During ECM bioscaffold degradation 
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following implantation, proteases released by infiltrating immune cells contribute to the 
production and release of these cryptic peptides and have been shown to mediate certain aspects 
of ECM-mediated endogenous repair(Giannelli, Falk-Marzillier, Schiraldi, Stetler-Stevenson, & 
Quaranta, 1997).  
Matricryptic peptides are well characterized players in wound healing. For example, 
following tissue injury, the temporal release of matricryptic peptides by proteolytic enzymes is 
known to control the formation of new vasculature into the wound site(Bornstein, 2009; Valentin, 
Badylak, McCabe, & Badylak, 2006). Although xenogeneic, the principle components of ECM 
bioscaffolds (i.e. collagen I, collagen III, laminin, etc.) are highly phylogenetically 
conserved(Ozbek, Balasubramanian, Chiquet-Ehrismann, Tucker, & Adams, 2010), and, as a 
result, have not been shown to elicit rejection responses. In particular, the application of ECM 
bioscaffolds and their degradation products has been repeatedly shown to result in the migration 
of site-specific cells(Agrawal, Brown, Beattie, Gilbert, & Badylak, 2009; F. Li et al., 2004; 
Melman et al., 2011). A specific degradation product of collagen IIIa was shown to promote bone 
remodeling(Agrawal, Kelly, et al., 2011) and the recruitment of multipotent stem cells(Agrawal, 
Tottey, et al., 2011) in a mouse model of digit amputation. Further, although intact fibronectin is 
not chemotactic for monocytes, a 120 kDa produced through enzymatic cleavage has been shown 
to recruit monocytes and fibroblasts, but not neutrophils(Clark, Wikner, Doherty, & Norris, 1988; 
Fukai, Suzuki, Suzuki, Tsugita, & Katayama, 1991). Fibronectin is a major component of both the 
provisional wound matrix and the adsorbed protein layer following biomaterial implantation. In 
this way, the sequential recruitment of neutrophils, and subsequently monocytes, is molecularly 
encoded and promotes an appropriately timed cellular response to injury. Further, angiogenesis is 
another heavily regulated process that is critical for constructive tissue remodeling to support the 
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metabolic requirements of infiltrating cells. It is logical, then, that a significant portion of 
matricryptic peptides act on vascular endothelial cells(Davis et al., 2000). In fact, several peptides 
derived from the degradation of elastin and hyaluronic acid, both of which are found in ECM 
bioscaffolds, are known to promote vessel branching and chemotaxis of endothelial cells(D. Liu 
et al., 1996; Senior, Griffin, & Mecham, 1980). 
Stated differently, ECM bioscaffold degradation is associated with the production of 
several biologically active peptides that can affect cellular function in a variety of ways. However, 
these effects are inherently transient and are not spatially orchestrated and may, therefore, have 
only a modest effect on functional remodeling response to ECM bioscaffolds. 
2.5 Mechanical Microenvironment 
Historically, tissue engineering strategies have focused on optimization of scaffold 
chemistry and the selection of biological additives including cells, growth factors, or guidance 
cues to achieve developmental control. However, the role of tissue or substrate mechanical 
properties in modulating cell behavior is an emerging field of investigation that has shown that 
local mechanical cues play a significant role in tissue development and homeostasis(Farge, 2011). 
Failure to account for mechanical forces may also help explain a failure of some in vitro assays to 
translate to preclinical animal models(Ingber, 2006).  
An extraordinary number of cellular molecules are devoted to the transduction or 
generation of mechanical forces. Stretch sensitive ion channels(Sukharev & Corey, 2004), 
integrins(Evans, Leung, Heinrich, & Zhu, 2004), and cytoskeletal molecular motors(Veigel, 
Molloy, Schmitz, & Kendrick-Jones, 2003) have all been shown to regulate gene expression in 
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response to local variation in substrate stiffness and shear stress. Importantly, it has been 
repeatedly shown that 3-dimensional culture systems yield more translatable results than 
traditional 2-dimensional culture systems(Arslan-Yildiz et al., 2016; Baker & Chen, 2012; Magin, 
Alge, & Anseth, 2016). In vivo, high resolution imaging has revealed that abnormal flow rates and 
shear stress on vascular walls results in vascular wall ECM remodeling that is pathologic and 
permissive for the development of aortic aneurysm and atherosclerotic lesions(Billaud et al., 2018; 
Cunningham & Gotlieb, 2005; Majumdar et al., 2007). Further, increased cytoskeletal tension has 
been shown to promote physical alterations in the structure of the ECM in which the cell resides, 
increasing local tissue stiffness and increasing ECM production(Baneyx, Baugh, & Vogel, 2002). 
Stated differently, ECM-cellular mechanical signaling is bidirectional. 
In skeletal muscle tissue, injuries that disrupt the high tissue organization can result in 
profound functional deficits due to the intimate relationship between muscle force generation and 
its conductance along the aponeurosis. In large muscle injuries, termed volumetric muscle loss 
(VML) injuries, functional deficits have been shown to be greater than what would be predicted 
as a function of lost muscle volume alone. In fact, untreated VML defects show greater fatty 
infiltrates and collagen abundance compared to uninjured muscle, but, perhaps more importantly, 
altered sarcomeric alignments in remaining tissue with compromised mechanics(Grogan et al., 
2011). Further, studies have shown that age-associated declines in muscle healing may be due to 
microenvironmental changes rather than cellular dysfunction(Conboy et al., 2005). Importantly, 
changes in muscle stem cell behavior with aging were shown to be at least partially mediated by 
the mechanical ECM microenvironment, with stiffer substrates promoting stem cell fibrogenic 
conversion(Ambrosio et al., 2014; Brack et al., 2007; Stearns-Reider et al., 2017). Skeletal muscle 
ECM compliance is evident in studies involving physical exercise, too, where it has been shown 
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that repeated weight bearing exercise increases collagen turnover and lowers muscle ECM 
stiffness(Kjaer, 2004). Taken together, matrix stiffness and cellular behavior are tightly coupled 
and bidirectional. 
Cellular responses to implanted materials largely mimic interactions with native connective 
tissue. It has been shown that mismatch between implanted biomaterials and local tissue 
mechanical properties can result in comorbidity and even the need for surgical reintervention. As 
an exemplary case, polypropylene surgical mesh materials have reported tensile strengths in the 
range of 150 N/cm, while the longitudinal tensile strength of native human abdominal wall was 
measured at 34 N/cm(Kalaba et al., 2016). Yet, despite theoretically providing excess mechanical 
support, nearly 1 in 3 patients will experience a hernia recurrence. The mismatch between native 
abdominal wall strength and material strength is non-trivial, and groups have found that larger 
molecular weight polymeric materials incur significantly greater patient discomfort and increased 
hernia recurrence(Anurov, Titkova, & Oettinger, 2012; Junge et al., 2001). The use of chemical 
crosslinking to increase mechanical parameters of ECM bioscaffolds has also resulted in lower 
tissue integration and an increased pro-inflammatory response(Aamodt & Grainger, 2016). 
Recently, stiff substrates were shown to promote an M1-like macrophage phenotype, in vitro, 
ostensibly providing an ulterior mechanism for the FBR to non-resorbable implants(Sridharan, 
Cavanagh, Cameron, Kelly, & O'Brien, 2019). However, hernia mesh materials with 
physiologically appropriate mechanical properties have shown reduced foreign body reaction 
(FBR) and superior host tissue integration(Klinge et al., 1998; Tran, Yang, & Ameer, 2015).  
Together, these findings suggest that biomechanical forces are critical for the appropriate 
development and maintenance of tissues. Further, evidence from pathophysiological processes and 
surgical hernia repair processes suggest that biomaterials that proactively consider local tissue 
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microenvironment may have superior clinical outcomes. Stated differently, macroscopic material 
properties are an important consideration for the future design of engineered biomaterials for tissue 
engineering applications. 
2.6 Matrix-bound Nanovesicles 
The need for a fully functional immune system in normal development(Simon, Hollander, 
& McMichael, 2015), regeneration(Godwin, Pinto, & Rosenthal, 2016), tissue 
homeostasis(Okumura & Takeda, 2016; Rogier et al., 2014; Tidball et al., 2014; Zhan et al., 2014), 
and in the constructive remodeling properties of ECM bioscaffolds(S. F. Badylak, J. E. Valentin, 
A. K. Ravindra, G. P. McCabe, & A. M. Stewart-Akers, 2008; Brown, Ratner, Goodman, Amar, 
& Badylak, 2012; Valentin, Stewart-Akers, Gilbert, & Badylak, 2009) has been recognized. 
Although, no immunosuppressive agents are used with these bioscaffold materials, this does not 
imply immune-privilege. In fact, there is a distinct immune response as described below and in 
subsequent chapters. 
ECM bioscaffolds have been associated with robust, pro-healing macrophage and TH2 
responses that are predictive of downstream constructive remodeling outcomes(Brown, Londono, 
et al., 2012). The promotion of a constructive immune response by ECM bioscaffolds was first 
reported nearly 20 years ago and have been extensively investigated since. More recently, it was 
shown that the promotion of an M2-like macrophage phenotype is required for constructive tissue 
remodeling(Sridharan et al., 2019). Interestingly, the ECM-elicited macrophage response is 
phenotypically unique with respect to IL-4-treated counterparts and with respect to the source 
tissue origin(K. Sadtler, B. W. Allen, et al., 2016).  This immunomodulatory effect could be, at 
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least in part, attributable to matrix-bound nanovesicles (MBV), an extracellular vesicle component 
of the extracellular matrix(L. Huleihel, J. G. Bartolacci, et al., 2017; Huleihel et al., 2016; George 
S. Hussey et al., 2020).  
MBV are nanometer sized extracellular vesicles found bound to the matrix with unique 
bioactive lipid, nucleic acid, and protein cargos(L. Huleihel, J. G. Bartolacci, et al., 2017; Huleihel 
et al., 2016; George S. Hussey et al., 2020). MBV miRNA cargos have been shown to contribute 
to cellular process important to tissue development and healing, and the profile of lipids contained 
within their membranes may promote activation of anti-inflammatory lipid receptors(George S. 
Hussey et al., 2020). Importantly, the macrophage phenotype elicited by MBV was nearly identical 
to that elicited by exposure to the parent ECM in vitro(L. Huleihel, J. G. Bartolacci, et al., 2017). 
In a rat model of optic nerve injury, van der Merwe et al. showed that exogenous provision of 
MBV and their miRNA cargos could successfully promote a pro-healing glial cell phenotype and 
M2-like microglia activation(van der Merwe et al., 2019; van der Merwe, Faust, & Steketee, 2017). 
Taken together, MBV are a viable mechanistic candidate for ECM-mediated macrophage 
phenotype activation, however, the specific mechanism underlying this activity are poorly 
understood.  
2.7 Conclusions 
Successful clinical translation of tissue engineering approaches requires that multiple tissue 
repair processes be modulated simultaneously, including modulation of the immune response. 
Native extracellular matrix and ECM bioscaffolds possess soluble and insoluble components that 
promote such events. It is obvious that scaffold degradation plays a central role in the generation 
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of bioactive components and, ostensibly, the successful induction of repair processes. The 
emerging role of MBV on macrophage phenotype suggests that the nature of these vesicles be 
characterized in greater detail. Further, although MBV miRNA cargos have been partially 




3.0 Strategies for Immunosuppression and Immunomodulation 
3.1 Overview 
Cells of the immune system have historically been considered one-dimensional, rigid cell 
types confined to inflammatory functions. However, it is now understood that immune cells, in 
particular innate immune cells such as macrophages, are highly phenotypically plastic, and play a 
role in homeostatic, developmental, and tissue repair processes(Wynn, Chawla, & Pollard, 2013). 
Macrophages, for example, have been shown to be critical components in the host response to 
injury, tissue regeneration, and organ development. Nonetheless, the majority of existing 
therapeutic options suppress immune cell function rather than harness it. The present manuscript 
will discuss the ways in which current pharmacological therapies affect immune cell function, the 
repercussions and advantages of these approaches, and present hypotheses for future therapeutic 
intervention.  
3.2 Introduction 
The development of immunosuppressants has led to a revolution in the number of patients 
who can benefit from whole organ transplantation. The focus of immunosuppression has been to 
reduce the host adaptive immune response to allogeneic antigens, thereby preventing destruction 
of the grafted organ(Duncan & Wilkes, 2005). However, an analogous approach to the innate 
immune response to implanted biomaterials is often inappropriate and can result in suboptimal 
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clinical outcomes(X. Liu et al., 2017). For example, it is now understood that the macrophage 
phenotype response to implanted materials is predictive of downstream clinical outcomes(Brown, 
Londono, et al., 2012). Despite the central role of innate immune cells in tissue healing and 
regeneration, few therapeutic options exist to modify their behavior rather than suppress their 
function. 
The host immune response, in particular the macrophage component, to implanted 
materials is reproducible and well characterized. Within minutes of material implantation, proteins 
from blood adsorb to the material surface and provide a provisional matrix. Within hours, 
neutrophils arrive in response to chemotactic signals release due to tissue injury and platelet 
activation. By 1-3 days, pro-inflammatory M1-like macrophages are present and assist in the 
removal of necrotic cells and debris. If the foreign material can be degraded, M1-like macrophages 
gradually transition to a pro-healing M2-like macrophages that promote angiogenesis and matrix 
deposition(Corona et al., 2016; Dort et al., 2019; J. L. Dziki et al., 2016). If the foreign material 
cannot be degraded, the macrophage phenotype will fail to transition and a chronic foreign body 
reaction (FBR) will result with sustained matrix turnover and local tissue damage(Burger, Halm, 
Wijsmuller, ten Raa, & Jeekel, 2006; Elango, Perumalsamy, Ramachandran, & Vadodaria, 2017). 
This macrophage phenotype transition is critical, as disruption of either macrophage population 
can result in fibrosis and impaired tissue function. Stated differently, it is becoming increasingly 
clear that macrophages play a central role in both homeostatic and disease processes. The present 
manuscript will discuss the ways in which available therapeutic interventions affect adaptive and 
innate immune cell function, current understanding of the role of immune cells with respect to 
tissue healing and homeostasis, and the state of the art as it relates to immunomodulation. 
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3.3 Immunosuppressants 
3.3.1 Non-steroidal Anti-inflammatory Drugs 
Non-steroidal anti-inflammatory drugs are valuable analgesic tools following injury due to 
their relatively high safety profile and anti-inflammatory effects. NSAIDs reduce prostaglandin 
production through inhibition of the cyclooxygenase enzymes COX-1 and COX-2, although other 
targets have recently been reported. While COX-1 is constitutively expressed in tissues, COX-2 is 
primarily expressed by inflammatory cells, and a reduction in COX-2 mediated prostaglandin 
synthesis by immune cells is the primary mechanism of analgesia. NSAIDs vary in their selectivity 
for COX enzymes, and the ratio of COX-1:COX-2 selectivity is predictive of adverse event 
occurrence such as gastric ulceration. 
Due to their high clinical usage rate, the role of NSAIDs in modifying the host response to 
tissue injury is an active area of investigation. In particular, impaired bone healing as a result of 
indomethacin (non-selective COX inhibitor) administration has been reported following 
orthopedic procedures(M. R. Chen & Dragoo, 2013). Retrospective clinical studies have identified 
reduced tendon-to-bone healing following rotator cuff repair when NSAIDs were administered for 
analgesia(D. B. Cohen, Kawamura, Ehteshami, & Rodeo, 2006), although the quality of these 
results has been disputed(Duchman et al., 2019).  
The use of acetylsalicylic acid (also known as aspirin, a non-selective COX inhibitor) has 
been shown to reduce the immunomodulatory and functional remodeling effects characteristic of 
ECM bioscaffold implantation(Dearth et al., 2016). Multiple studies have demonstrated that 
inhibition of prostaglandin synthesis is associated with pro-inflammatory, M1-like phenotype 
activation, while administration of prostaglandins promotes an M2-like phenotype(Dearth et al., 
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2016; Na, Jung, Yoon, Lee, & Seok, 2015; Na, Yoon, et al., 2015; Na, Yoon, Son, & Seok, 2013). 
Thus, although the consequences of NSAID use tissue repair in humans remains poorly 
understood, their effects on macrophage phenotype present challenges to existing tissue 
engineering strategies and should be carefully considered. 
3.3.2 Steroidal Compounds 
The discovery of glucocorticoid immunosuppressants (GCs) has allowed for organ 
transplantation to be commonplace. Immunosuppression strategies have gradually transitioned 
from cell-centric, non-specific GC-based regimens towards more targeted pharmaceuticals with 
improved side-effect profiles(Kahan, 2003). Yet, GCs are among the most commonly used 
treatments for inflammatory and autoimmune diseases due to their suppressive effects. GCs 
mediate a broad variety of effects on cells of the adaptive and innate immune system through direct 
transcriptional regulation at glucocorticoid response elements(Ashwell, Lu, & Vacchio, 2000), 
transrepression of NF-kB and AP1(John et al., 2008; Jonat et al., 1990), and even non-
transcriptional effects(Stellato, 2004).  
The impact of GCs on T cells, in particular, has been the subject of intensive investigation. 
The ability to rapidly and sustainably reduce T cell number and function in autoimmune disease 
has clear therapeutic value(John et al., 2008; Jonat et al., 1990), however the impact of GCs on 
innate immune cells is less well characterized. However, studies have shown that myeloid cells 
may, similar to T cells, undergo apoptosis in certain circumstances in response to GCs(J. Zhang et 
al., 2009). Interesting, animal models of contact allergy, a T cell-dependent process, deletion of 
the glucocorticoid receptor in macrophages, but not T cells, exacerbates the disease(Tuckermann 
et al., 2007). Further, it has been shown that GC exposure during differentiation yields a unique 
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macrophage phenotype that was highly phagocytic and resembled both tumor-associated 
macrophages and myeloid-derived suppressor cells. In these studies, GC-educated macrophages 
displayed increased apoptotic cell clearance and promoted resolution of inflammation(Ehrchen et 
al., 2007; Varga et al., 2008). It is of note, however, that tumor-associated macrophages and 
myeloid suppressor cells have been shown to be distinct from M2-like, pro-healing macrophages 
with respect to their protein expression and tissue remodeling functions(Wolf et al., 2019). 
Specifically, the macrophage phenotype transition characteristic of the healing response to muscle 
injury requires sequential and coordinated activation of p38, MPK-1, and Akt signaling cascade 
for functional repair(Perdiguero et al., 2011), all of which have been shown to be reduced in 
response to GCs(Coutinho & Chapman, 2011). As a result, it is important to consider that GC-
educated macrophages may be functionally different than their IL-4-treated counterparts.  
The presence of macrophages in response to tissue injury is a critical requirement for 
wound healing. In one model of wound healing, prednisolone administration resulted in reduced 
accumulation of macrophages at the site of injury(Geurtzen et al., 2017), and another demonstrated 
that GC administration reduced macrophage migratory capacity(Prokic & Vilic, 1983). It is of note 
that macrophage recruitment deficits may contribute to reduced functional tissue repair in 
aging(Hachim et al., 2019), suggesting that impaired macrophage recruitment may, in fact, not be 
desirable. The impact of GC on macrophage function may be compounded in tissue engineering 
applications that provide an allogeneic cell source, as it has been shown that GCs can promote 
apoptosis of stem cells(Singleton, Baker, & Thorburn, 2000). Yet, the impact of GCs on 
macrophages in tissue engineering contexts has not been evaluated, but may prove to be a rich 
avenue of investigation. 
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3.3.3 Non-steroidal Immunosuppressive Drugs and Anti-rheumatic Biologics 
The metabolic and osteoporotic side effects of long-term glucocorticoid use prompted the 
development of more tailored immunosuppressive drugs that could similarly curb the rejection of 
allogeneic organs and reduce immune mediated tissue damage in autoimmunity(Briot & Roux, 
2015). In both organ transplantation and autoimmunity, therapeutic targets have overwhelmingly 
been T cells and cytokines. However, a significant body of evidence suggests that cells of the 
innate immune system play a significant role in both transplant rejection and autoimmunity. 
Specifically, it is becoming clear that the role of antigen presenting cell (APC) phenotype and 
expression of co-stimulatory molecules are central in shaping downstream immune 
responses(Mannon, 2012; Rowshani & Vereyken, 2012). Efforts to understand the 
pathophysiologic mechanisms underlying rejection have provided some insight into the often-
conflicting role that non-steroidal immunosuppressive drugs have on innate immune cells, in 
particular macrophages and dendritic cells. 
Macrophages and other antigen presenting cells (APCs) produce cytokines, co-stimulatory 
molecules and antigens to cells of the adaptive immune system, thereby contributing to rejection 
processes(J. Li et al., 2019; Vereyken et al., 2013). In both cardiac and kidney allografts, the 
presence of macrophages is a poor prognostic indication(Rowshani & Vereyken, 2012; L. Xu, 
Collins, Drachenberg, Kukuruga, & Burke, 2014). To address the unmet clinical need of 
macrophage suppression in transplant, efforts have identified that several existing anti-rejection 
drugs have moderate immunosuppressive activity on macrophage recruitment and cytokine 
secretion, namely mycophenolate mofetil, rapamycin inhibitors, and calcineurin inhibitors(Allison 
& Eugui, 2000; Howell et al., 2013; Wenink et al., 2012). The activity of these drugs, however, 
was not associated with decreased chronic allograft rejection, the primary outcome measure. In 
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Chron’s Disease and Rheumatoid Arthritis, antibodies specific to TNF- have been remarkably 
successful in reducing disease severity(Atzeni et al., 2005). Unexpectedly, evidence suggests that 
biologics have secondary mechanisms of action on macrophages through binding of the Fc-g 
receptor to the Fc region of these antibodies that potentiate their effects. Further, activation of the 
Fc-g receptor on macrophages by humanized monoclonal antibodies was shown to promote 
increased T cell apoptosis and promotion of an M2-like macrophage phenotype in vivo(Louis et 
al., 2004; Vos et al., 2011). It has been reported that anti-TNF- antibodies may have therapeutic 
value for chronic, non-healing wounds, however the role of these antibodies and others in tissue 
engineering and tissue healing has not been tested(Schreurs et al., 2020).  
Interestingly, evidence has emerged that innate immune cells exposed to certain antigens 
and stimuli may be capable of ‘antigen memory’ that can promote tolerogenic immune responses 
following repeat antigen exposure(Kleinnijenhuis et al., 2012; Yoshida & Ishii, 2016). 
Importantly, this antigen memory is sustained following ex vivo exposure and subsequent 
transplantation. Antigen memory is, at least in part, predicated upon the phenotype of the APC, 
which may be induced through the careful use of selected anti-rejection agents(Hutchinson, Brem-
Exner, et al., 2008). Ex vivo generation of tolerogenic dendritic cells and dendritic cell 
reprogramming in vivo have shown promise in in vitro and preclinical studies(Bluestone, 
Thomson, Shevach, & Weiner, 2007; McCurry, Colvin, Zahorchak, & Thomson, 2006; Rutella & 
Lemoli, 2004). In macrophages, two Phase I clinical trials have demonstrated that pre-operative 
treatment with a specific subset of donor-derived macrophages, termed tolerance-promoting cells 
(TAICs), is safe and, in select cases, patients were able to stop immunosuppressive therapies 
altogether for several months(Hutchinson, Riquelme, et al., 2008; Hutchinson, Roelen, et al., 
2008). Lower doses of anti-rejection drugs, longer graft survival, and broader donor sources make 
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the use of immunomodulatory APC cell therapies an attractive therapeutic target. In tissue 
engineered constructs, co-delivery of M2-like macrophages with a scaffold improved tissue 
remodeling outcomes in preclinical animal models, although these macrophages were activated 
through exogenously provided cytokines(Riabov et al., 2017). Taken together, insufficient 
evidence exists to fully characterize the innate immune response to non-steroidal 
immunosuppressive drugs as either harmful or beneficial. However, tissue engineering strategies, 
specifically those that involve allogeneic cell components, may benefit from incorporation of 
immunosuppressive agents to promote a tolerogenic state to increase transplanted cell acceptance 
by the host. 
3.4 Immunomodulatory Materials 
The development of ECM-based biologic scaffold materials, the relatively recent 
elucidation of innate immune cell plasticity and their derivatives, and a more in-depth 
understanding of the role of the immune response during development, normal wound healing, 
tissue homeostasis, and tissue/organ regeneration have sparked renewed interest in biomaterials as 
facilitators of functional tissue repair. Historically, materials used for surgical repair of tissue 
injuries were appropriated due to their ease of manufacturing, relatively low systemic 
consequences, and amenable mechanichal properties. However, permanent mesh materials such 
as polypropylene (PP), expanded polytetrafluoroethylene (ePTFE), and polyethylenepterepthalate 
(PET) suffer from a predisposition to infection, a chronic inflammatory response at the site of 
implantation, tissue erosion, fistula formation, and premature device failure, among other 
complications(A. I. Gilbert, 1989; Klinge & Klosterhalfen, 2012; Roth et al., 2015). To address 
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these issues, significant resources have been devoted to the development of novel biomaterials that 
address one or more of these issues. Today, scaffolds composed of biodegradable, biosynthetic, 
and biologic materials can be found on the market as a testament to this effort. Beyond material 
origin, a growing body of evidence suggests that tissue engineering strategies that incorporate 
immunomodulatory, rather than immunosuppressive, therapies offer significant advantages to 
traditional approaches. 
3.4.1 Exosomes 
Exosomes, first discovered 50 years ago, were initially believed to be debris from nearby 
cells(Keshtkar, Azarpira, & Ghahremani, 2018). It is now understood that exosomes represent a 
fundamental intercellular signaling mechanism and have quickly become attractive therapeutic 
targets. Exosomes and other extracellular vesicles (EVs) are heterogeneous, nanometer-sized, lipid 
membrane-bound particles released by cells to extracellular fluids with multiple bioactive cargos 
including nucleic acid cargos (i.e. RNA and DNA), proteins, and lipids(Raposo & Stoorvogel, 
2013). Therefore, exosomes have been to significantly impact processes in response to wound 
healing, including angiogenesis(C. Y. Chen et al., 2018), cell proliferation and 
differentiation(Lamichhane et al., 2015), and immunomodulation(Keshtkar et al., 2018; 
Lamichhane et al., 2015; Rani, Ryan, Griffin, & Ritter, 2015). The multifaceted effects of EVs 
have made their application to regenerative medicine and tissue engineering valuable therapeutic 
and research tools. 
As stem cell therapy interest grew, a particular cell type stood out as a promising candidate 
for tissue engineering applications, namely mesenchymal stem cells (MSCs) and related cell types. 
MSCs have been applied to numerous pathologies due to their multipotency, ease of isolation, and 
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virtually endless passage potential(Kariminekoo et al., 2016). Despite low engraftment and 
survival, MSC therapies showed consistent reductions in pro-inflammatory signaling that was 
subsequently attributed, at least in part, to MSC-derived exosomes(Rani et al., 2015). Importantly, 
EV cargo are plastic largely reflect the state of the parent cell and have therefore been engineered 
as gene and drug carriers for regenerative medicine(Bunggulawa et al., 2018; Hannafon & Ding, 
2013). Stated differently, EV may represent viable cell-free options for targeted tissue engineering 
applications, including immune cell phenotype modulation. 
3.4.2 Biomaterials 
The current standard of care for the repair of ventral hernia remains the use of scaffolds 
primary composed of polypropylene due to its ease of manufacture, low cost, and high mechanical 
properties(Faulk et al., 2014). However, as discussed above, non-resorbable mesh materials like 
polypropylene incur foreign body reactions associated with fibrous encapsulation, fistula 
formation, and tissue erosion. An improved understanding of the host response to implanted 
materials has led to a significant body of novel materials that address these sub-optimal clinical 
outcomes.  
Acellular bioscaffolds composed of extracellular matrix (ECM) have been used for decades 
in a wide variety of anatomical locations and are one of the earliest materials recognized to have 
immunomodulatory, rather than immunosuppressive, effects. Although multiple mechanisms have 
been implicated in ECM-mediated tissue repair, modulation of immune cell phenotypes, in 
particular the macrophage component, have emerged as one of the primary mechanisms for site-
appropriate tissue remodeling. Specifically, the use of ECM bioscaffolds in both preclinical animal 
models of muscle injury and a clinical cohort have demonstrated that these materials promote 
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improved function in treated patients through the recruitment of stem/progenitor cells and the 
promotion of an M2-like macrophage phenotype. Importantly, this effect was shown to be at least 
partially mediated by matrix-bound nanovesicles (MBV), a unique class of extracellular vesicles 
secreted to the matrix. Beyond macrophages, Sadtler et al. elegantly showed that ECM 
biomaterials also promote TH2 cell responses and cytokine production, which reinforced the ECM-
mediated promotion of an M2-like macrophage phenotype in a mouse model of volumetric muscle 
loss.  
Macrophages have frequently been the target of surface modification biomaterial 
strategies, as well. ECM-coated synthetic polymers have been investigated as a method to promote 
a regulatory/anti-inflammatory host response as opposed to an otherwise pro-inflammatory 
response. Specifically, ECM hydrogel coatings have been shown to mitigate the chronic 
inflammatory response and associated downstream scar tissue formation after implantation of 
polyprolyene mesh, the most commonly used synthetic material used to manufacture surgical mesh 
devices(Faulk et al., 2014). Faulk et al. reported that the addition of an ECM hydrogel coating 
decreased the number of pro-inflammatory CD86+/CD68+ macrophages in the vicinity of the 
polypropylene fibers 2 weeks after implantation. Six months after implantation, the coated 
polypropylene was associated with less collagen deposition (i.e. fibrosis) than was associated with 
uncoated polypropylene. In similar work, the use of a porcine dermal ECM hydrogel to coat 
polypropylene mesh reduced macrophage accumulation and formation of foreign body giant 
cells(Wolf, Carruthers, et al., 2014). At 35 days post-implantation, the ECM coating was fully 
degraded and replaced with a loose connective tissue.  
Attempts have also been made to reduce the inflammatory reaction through the use of drug-
eluting polymers. Polypropylene scaffolds that elute IL-4 have been investigated for their ability 
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to promote enhanced functional remodeling in a mouse model of muscle injury(Hachim, LoPresti, 
Yates, & Brown, 2017). Surface modification strategies have been developed that directly link 
cytokine(Hoque et al., 2009) or nucleic acid-containing nanoparticles to the surface(Boehler, 
Graham, & Shea, 2011; Tsianakas et al., 2012; Zelikin, 2010). Genes encoding IL-4(Butti et al., 
2008), IL-10(Peranteau et al., 2008), IB(Wilson et al., 2005), or decoy TNF- 
receptors(Ghivizzani et al., 1998) have been delivered using scaffolds to promote a local M2-like 
macrophage phenotype, however more work is needed to determine the viability of this approach. 
Recent pre-clinical data has shown that polycaprolactone microspheres can serve as a drug-elution 
mechanism with the potential to provide long term protection from infection(Guillaume et al., 
2011), and steroid-eluting polymers have been developed that suppress the inflammatory reaction 
elicited by polymeric materials(Brandt, Kammer, Fiebeler, & Klinge, 2011). It is important to note 
that surface modification techniques are not uniformly effective, the immunomodulatory effects 
of surface-active agents can be short lived, and pharmacokinetics of long-term drug release can be 
challenging(Vishwakarma et al., 2016). Biomaterial based strategies for the modulation of the 
immune response in tissue engineering and regenerative medicine applications have been 
expansive. Although relatively few of these strategies currently have clinical evidence, it is clear 
that targeting innate and adaptive immune cell functions to improve functional remodeling of 
tissue injuries is a sensible avenue of investigation. 
3.5 Conclusions and Future Directions 
A rich understanding of T cell biology has led to the development of highly diverse small 
molecule and biologic therapies to prevent T cell activation, survival, and proliferation. However, 
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a growing appreciation of the role of macrophages in tissue healing has led to the advent of 
numerous biomaterial strategies to foster a favorable, immunomodulatory microenvironment. 
Further, it is now understood that immunosuppression has an as yet poorly understood impact on 
macrophages and other cells of the innate immune system. To help address these unanswered 
scientific questions, prospective studies evaluating the impact of NSAIDs on tissue healing should 
be rigorously performed. Further, as immunosuppressive strategies have become more tailored and 
widespread, it remains to be seen what impact these therapies have on cells of the innate immune 
system. However, work by Sadtler et al. suggests that perturbation of the adaptive immune system 
is likely to have unexpected, if not detrimental, effects on macrophage phenotype(K. Sadtler, K. 
Estrellas, et al., 2016). Future tissue engineering and regenerative strategies that incorporate 
cellular components must not underestimate the significance of immunosuppressant choice, or 





Bioscaffolds composed of acellular mammalian extracellular matrix (ECM) have shown 
promise as a tissue engineering approach to the repair of skeletal muscle injuries. ECM 
bioscaffolds modulate multiple endogenous repair processes such as angiogenesis, stem/progenitor 
cell recruitment and differentiation, and immunomodulation to promote downstream functional, 
site appropriate tissue deposition. In particular, ECM bioscaffolds have been shown to promote a 
macrophage phenotype transition, away from a pro-inflammatory, M1-like macrophage phenotype 
towards a pro-healing, M2-like macrophage phenotype, a critical step in the functional repair of 
skeletal muscle injury. Although several components have been associated with aspects of ECM 
bioscaffold-mediated tissue remodeling, the mechanisms underlying ECM-mediated macrophage 
phenotype transition remain poorly understood. However, a recently discovered component of the 
ECM, matrix-bound nanovesicles (MBV), have been shown to partially recapitulate the effects of 
whole ECM on macrophage phenotype, but the mechanisms by which MBV promote an M2-like 
macrophage phenotype remain unexplored. The proposed study will investigate the role of MBV 
and recently identified protein cargo, IL-33, on macrophage phenotype both in vitro and in vivo, 
determine the mechanism of MBV-associated IL-33 uptake and intracellular localization, and will 
evaluate potential mechanisms of macrophage-stem cell cross-talk. 
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5.0 Central Hypothesis and Specific Aims 
Central Hypothesis: During the regenerative response to skeletal muscle injury, MBV-
associated IL-33 promotes a macrophage phenotype transition that supports myogenesis. 
Specific Aim 1: Establish the phenotypic and functional response in macrophages and 
myogenic precursor cells, respectively, to soluble vs. MBV-bound IL-33. 
Subaim 1.1: Determine the potential of macrophage-derived exosomes to promote 
differentiation of muscle stem cells (MuSC). 
Corollary Hypothesis: IL-33+ MBV will promote M2-like macrophage phenotype 
activation and differentiation of MuSC, but IL-33- MBV and rIL-33 will not. 
Corollary Hypothesis 1.1: M2-like macrophage-derived exosomes will promote 
differentiation of MuSC, but M1-like macrophage-derived exosomes will not. 
Rationale: It has been shown that MBV are at least partially responsible for the bioactivity 
of whole ECM on macrophage phenotype(L. Huleihel, J. G. Bartolacci, et al., 2017), but the 
specific cargo(s) mediating this cellular response is not currently known. It has also been shown 
that M2-like macrophage secreted products promote differentiation of MuSC(Dziki et al., 2018); 
however, the specific  product(s) underlying this effect is an active field of investigation. The 
secretion of growth factors, chemoattractants, and cytokines have been implicated in macrophage-
mediated myogenesis (Novak, Weinheimer-Haus, & Koh, 2014; Panduro, Benoist, & Mathis, 
2018), but studies that provided these cytokines via exogenous routes have failed to fully 
recapitulate what has been observed in vivo(Tidball et al., 2014; Zembron-Lacny, Krzywanski, 
Ostapiuk-Karolczuk, & Kasperska, 2012). The role of exosomes in immune cell signaling has been 
implicated as another mechanism by which cells, including macrophages, communicate with their 
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targets. Importantly, macrophage-derived exosome cargo is dependent on parent cell phenotype 
and has profound implications on target cell behavior(Ying et al., 2017; Zheng et al., 2018). It is 
plausible, therefore, that IL-33, an abundant cargo of MBV, may regulate macrophage phenotype, 
and MuSC fate by an exosome-mediated process. 
Specific Aim 2: Determine the mechanism of MBV uptake and intracellular IL-33 
trafficking in macrophages. 
Corollary Hypothesis: MBV are taken up by an endocytic route and subsequently 
trafficked to the nucleus. 
Rationale: Vesicular uptake has been shown to proceed by a variety of different 
mechanisms depending on the cell type being investigated and the origin of the vesicle(McKelvey, 
Powell, Ashton, Morris, & McCracken, 2015). Extracellular vesicle cargo must then be either be 
targeted away from the phagolysosomal system, or escape endocytic vesicles to the cytoplasm if 
it is to be bioactive on the target cell. Further, several studies have shown the that IL-33 was 
capable of modifying the gene expression profiles of certain cell types when it was in the nucleus, 
either through direct action on gene expression or by modification of the activity of signaling 
factors such as NFkB, but independent of ST2 activity(Ali et al., 2011; V. Carriere et al., 2007; 
Oshio et al., 2017). Stated differently, MBV-associated IL-33 may modify gene and protein 
expression through an ST2-independent mechanism that relies on the non-destructive uptake of 
MBV by target cells that has not been characterized. 
Specific Aim 3: Determine the effect of IL-33 on macrophage phenotype in a mouse model 
of acute muscle injury. 
Corollary Hypothesis: In the absence of IL-33, the macrophage response to acute skeletal 
muscle injury will be pro-inflammatory. 
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Rationale: The cellular response to muscle injury his highly orchestrated and is dependent 
upon macrophages to mobilize and subsequently differentiate the stem cell pool. Cardiotoxin 
injury models of muscle injury recapitulate the cellular responses to muscle injury, allowing for 
direct interrogation of immune cell phenotypes and progenitor cell dynamics in a controlled and 
reproducible setting. To date, a direct investigation of the role of IL-33 (either soluble or MBV-
bound) on skeletal muscle regeneration has not yet been performed. Studies have shown that IL-
33 plays a role in the recruitment and proliferation of TREG cells in both heart(Matta et al., 2016) 
and muscle tissue(W. Kuswanto et al., 2016), these studies were limited in their scope. Given the 
established role of macrophages in directing muscle stem cell behavior, it is plausible that IL-33 
may modulate macrophage phenotype in response to muscle injury. However, the impact of 
soluble and MBV-associated IL-33 on macrophage phenotype has not been described. It is possible 
that, during matrix degradation and turnover, macrophages release MBV and their IL-33 cargo 
during the remodeling process, which initiates a transition away from an M1-like phenotype and 
towards and M2-like, pro-remodeling phenotype. 
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6.0 Matrix-Bound Nanovesicle-Associated IL-33 Activates a Pro-remodeling Macrophage 
Phenotype Via a Non-Canonical, ST2-independent Pathway1 
6.1 Overview 
The regenerative healing response of injured skeletal muscle is dependent upon an 
appropriately timed switch from a local type-I to a type-II immune response. Biologic scaffolds 
derived from extracellular matrix (ECM) have been shown to facilitate a macrophage phenotype 
transition that leads to downstream site-appropriate functional tissue deposition and myogenesis. 
However, the mechanisms by which ECM directs the switching of immune cell phenotype are only 
partially understood. Herein, we provide the first evidence that matrix bound nanovesicles (MBV) 
embedded within ECM-scaffolds are a rich and stable source of interleukin-33 (IL-33), an 
alarmin/cytokine with emerging reparative properties. We show that IL-33 encapsulated within 
MBV bypass the classical IL33/ST2 receptor signaling pathway to direct macrophage 
differentiation into the reparative, pro-remodeling M2 phenotype, which in turn facilitates 
myogenesis of skeletal muscle progenitor cells. Our results suggest the potential of IL-33+ MBV 
as a clinical therapy to augment the restorative efficacy of existing ECM-based and non-ECM 
based approaches. 
 
1Portions of the following chapter have been adapted from the following publication:  
Hussey, G. S., Dziki, J. L., Lee, Y. C., Bartolacci, J. G., Behun, M., Turnquist, H. R., Badylak, S. F.. Matrix 
bound nanovesicle-associated IL-33 activates a pro-remodeling macrophage phenotype via a non-canonical, ST2-
independent pathway. J Immunol Regen Med 3, 26-35, doi:10.1016/j.regen.2019.01.001 (2019). 
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6.2 Introduction 
Skeletal muscle has a remarkable capacity for repair in response to mild trauma(Turner & 
Badylak, 2012). However, skeletal muscle damage associated with volumetric muscle loss (VML) 
overwhelms the regenerative process, ultimately resulting in scar tissue deposition, loss of 
function, and aesthetic deformities. There are very limited therapeutic options for massive loss of 
skeletal muscle tissue subsequent to trauma, surgical excision of neoplasms, and related 
conditions. Autologous muscle grafts or muscle transposition represent optional salvage 
procedures for restoration of muscle tissue, but these approaches have shown limited success and 
are plagued by the associated morbidity at the donor site. Alternatively, cell-based therapies have 
been explored, but legitimate issues remain associated with ES/iPS cell therapies such as 
immunogenicity, the desirable requirement for source, and a favorable environment to maintain 
cell viability(Herberts, Kwa, & Hermsen, 2011). Moreover, development of a therapy that avoids 
the collection, isolation and/or ex-vivo expansion and purification of autologous stem cells with 
subsequent re-introduction to the patient would almost certainly reduce the regulatory hurdles for 
clinical translation, reduce the cost of treatment, and avoid the risks associated with cell-based 
approaches. There is an unmet need for therapeutic strategies that can enhance the innate 
regenerative ability of skeletal muscle following VML. Acellular biologic scaffolds composed of 
mammalian (typically porcine) extracellular matrix (ECM) have been investigated in in-vitro 
studies(Dziki, Wang, et al., 2017), preclinical in-vivo models of VML(Dziki, Giglio, et al., 2017; 
J. L. Dziki et al., 2016; B. M. Sicari, J. P. Rubin, et al., 2014) and in a recent cohort study involving 
the use of ECM bioscaffolds in 13 patients with VML(Jenna Dziki et al., 2016; B. M. Sicari, J. P. 
Rubin, et al., 2014). Outcomes have shown partial restoration of both structure and function, and 
support the translational aspects of an ECM-bioscaffold based approach. These ECM-based 
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materials are most commonly xenogeneic in origin, and are prepared by the decellularization of a 
source tissue such as dermis, urinary bladder or small intestinal submucosa (SIS), among 
others(Timothy J. Keane, Swinehart, & Badylak, 2015). A significant body of work has shown 
that xenogeneic ECM scaffolds do not elicit an adverse innate or adaptive immune response, and 
in fact, support an anti-inflammatory and reparative innate and adaptive immune 
response(Badylak, Dziki, Sicari, Ambrosio, & Boninger, 2016; Stephen F Badylak, Jolene E 
Valentin, Anjani K Ravindra, George P McCabe, & Ann M Stewart-Akers, 2008; Brown, Valentin, 
Stewart-Akers, McCabe, & Badylak, 2009; Dziki, Huleihel, Scarritt, & Badylak, 2017; Luai 
Huleihel et al., 2017; Kaitlyn Sadtler et al., 2016; Sadtler et al., 2017; Sicari, Dziki, & Badylak, 
2015). Use of these naturally occurring biomaterials is typically associated with at least partial 
restoration of functional, site-appropriate tissue; a process referred to as “constructive 
remodeling”(Badylak, 2007). Arguably, the major determinant of downstream functional 
remodeling outcome is the early innate immune response to ECM bioscaffolds(Stephen F Badylak 
et al., 2008; Brown, Ratner, et al., 2012; Brown et al., 2009; Dziki, Huleihel, et al., 2017). ECM 
bioscaffolds, or more accurately, the degradation products of ECM bioscaffolds, have been shown 
to direct tissue repair by promoting a transition from a pro-inflammatory M1-like macrophage and 
Th1 T cell phenotype to a pro-remodeling M2-like macrophage and T helper Type 2 (TH2) cell 
response(Agrawal et al., 2010; Beattie, Gilbert, Guyot, Yates, & Badylak, 2009; Brown, Ratner, 
et al., 2012; Kaitlyn Sadtler et al., 2016). Numerous studies have shown that an appropriately timed 
transition in macrophage activation state is required for promotion of tissue remodeling and wound 
healing processes rather than scar tissue formation in numerous anatomic sites including skeletal 
muscle(Ludovic Arnold et al., 2007; James G Tidball & Michelle Wehling-Henricks, 2015), and 
cardiovascular systems(Matthias Nahrendorf et al., 2007; Troidl et al., 2009). Importantly, this 
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transition is not immunosuppression, but rather a constructive form of immunomodulation that 
promotes a phenotypic change in local macrophage phenotype(T. J. Keane et al., 2017; Fernando 
O Martinez & Siamon Gordon, 2014). 
Emerging evidence shows that degradation of the scaffold material and subsequent release 
of matrix-bound-nanovesicles (MBV), that harbor bioactive components which have been only 
partially defined, are critical for the activation of a reparative and anti-inflammatory M2 
macrophage phenotype(L. Huleihel, J. Bartolacci, et al., 2017; Huleihel et al., 2016). MBV are 
nanometer-sized, membranous vesicles that are embedded within the collagen network of the ECM 
and protect biologically active signaling molecules (microRNAs and proteins) from degradation 
and denaturation(Huleihel et al., 2016). We have previously shown that ECM bioscaffolds and 
their resident MBV can activate macrophages toward a M2-like, pro-remodeling phenotype(L. 
Huleihel, J. Bartolacci, et al., 2017; Huleihel et al., 2016). However, the molecular components of 
MBV and the mechanisms by which these nanovesicles direct the switching of immune cell 
phenotype are poorly understood. 
Herein, it is shown that MBV are a rich source of extra-nuclear interleukin-33 (IL-33). IL-
33 is an IL-1 family member that is typically found in the nucleus of stromal cells and generally 
regarded as an alarmin, or a self-derived molecule that is released after tissue damage to activate 
immune cells via the IL-33 receptor, ST2(Liew, Girard, & Turnquist, 2016). Emerging evidence, 
however, indicates that IL-33 may function as a promoter of skeletal muscle repair by stimulating 
ST2+ regulatory T cells (Treg)(Wilson Kuswanto et al., 2016). Intracellular IL-33 protein has been 
suggested to modulate gene expression through interactions with chromatin or signaling molecules 
via the IL-33 N-terminus(Liew et al., 2016; Serrels et al., 2017). As of yet, however, intracellular 
IL-33 activities have not been shown to control any immune cell functions. Herein, evidence is 
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provided that IL-33, protected from proteolytic cleavage by incorporation into the lumen of MBV, 
is a potent mediator of M2 macrophage activation through an uncharacterized, non-canonical ST2-
independent pathway. Specifically, MBV isolated from il33+/+ mouse tissue ECM, but not MBV 
from il33-/-, direct st2-/- macrophage activation toward the reparative, pro-remodeling M2 
activation state. Moreover, the secreted products from IL33+ MBV-treated macrophages promote 
myogenesis of skeletal muscle progenitor cells. In total, our results suggest that MBV can mediate 
receptor-free delivery of cytokine cargo to immune cells to orchestrate cell function. 
6.3 Materials and Methods 
6.3.1 Animals 
C57BL/6 (B6) and Bm12 mice were purchased from Jackson Laboratories. The il33−/− 
mice were a gift from S. Nakae (University of Tokyo, Tokyo, Japan)(Oboki et al., 2010). St2-/- 
mice were originally generated on a BALB/c background as described(Townsend, Fallon, 
Matthews, Jolin, & McKenzie, 2000) and obtained from Dr. Anne Sperling (University of 
Chicago) after they were backcrossed 7 times onto the C57BL/6 background. These mice were 
then backcrossed 3 additional times onto the C57BL/6 background here at the University of 
Pittsburgh before use in our experiments. Animals were housed in a specific pathogen-free facility 
maintained by the University of Pittsburgh. The studies conformed to the principles set forth by 
the Animal Welfare Act and the National Institutes of Health guidelines for the care and use of 
animals in biomedical research. 
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6.3.2 Decellularization of Mouse Intestines 
Mouse small intestine was decellularized as previously described(Oliveira et al., 2013) 
with minor modifications. Fresh small intestines were obtained from adult wt B6 mice or adult IL-
33-/- B6 mice. Small intestines were washed in phosphate buffered saline (PBS) to completely 
remove all the intestinal contents, and cut into 1.5 cm-length fragments for immediate 
decellularization. Samples were immersed in 5M NaCl for 72 hr under continuous soft agitation. 
The decellularization solution was replaced every 24 hr. Decellularized intestines were then 
washed three times in distilled water. The native and decellularized tissue was prepared for 
histologic analysis to determine decellularization efficacy by fixing in 10% neutral buffered 
formalin, or lyophilized and powdered using a Wiley Mill with a #40 mesh screen. 
6.3.3 Preparation of Small Intestine Submucosa (SIS) 
A SIS was prepared as previously described(Badylak, Lantz, Coffey, & Geddes, 1989). 
Briefly, jejunum was harvested from 6-month-old market-weight (~110 to ~120 kg) pigs and split 
longitudinally. The superficial layers of the tunica mucosa were mechanically removed. Likewise, 
the tunica serosa and tunica muscularis externa were mechanically removed, leaving the tunica 
submucosa and basilar portions of the tunica mucosa. Decellularization and disinfection of the 
tissue were completed by agitation in 0.1% peracetic acid with 4% ethanol for 2 hours at 300 rpm. 
The tissue was then extensively rinsed with PBS and sterile water. The SIS was then lyophilized 
and milled into particulate using a Wiley Mill with a #60 mesh screen. 
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6.3.4 Isolation of Matrix-Bound Nanovesicles (MBV) 
MBV were isolated as previously described(Huleihel et al., 2016) with minor 
modifications. Briefly, 100mg of powdered ECM was enzymatically digested with 100 ng/ml 
Liberase DL (Roche) in buffer (50mM Tris pH 7.5, 5mM CaCl2, 150mM NaCl) for 12 hr at room 
temperature on an orbital rocker. The digested ECM was then subjected to centrifugation at 10,000 
x g for 30 min to remove ECM debris, and the supernatant passed through a 0.22 µm filter 
(Millipore). The clarified supernatant containing the liberated MBV was then centrifuged at 
100,000 x g (Beckman Coulter Optima L-90K Ultracentrifuge) at 4°C for 70 min to pellet the 
MBV. The MBV pellet was then washed and resuspended in 1X PBS. MBV were isolated as 
previously described(Huleihel et al., 2016) with minor modifications. Briefly, 100mg of powdered 
ECM was enzymatically digested with 100 ng/ml Liberase DL (Roche) in buffer (50mM Tris pH 
7.5, 5mM CaCl2, 150mM NaCl) for 12 hr at room temperature on an orbital rocker. The digested 
ECM was then subjected to centrifugation at 10,000 x g for 30 min to remove ECM debris, and 
the supernatant passed through a 0.22 µm filter (Millipore). The clarified supernatant containing 
the liberated MBV was then centrifuged at 100,000 x g (Beckman Coulter Optima L-90K 
Ultracentrifuge) at 4°C for 70 min to pellet the MBV. The MBV pellet was then washed and 
resuspended in 1X PBS. Purification of MBV by SEC was performed as previously 
described(Böing et al., 2014). Briefly, 15 ml of Sepharose CL-2B resin (Sigma Aldrich) was 
stacked in a 1cm x 20cm glass column and equilibrated with 1X PBS. 1 ml of MBV were loaded 
onto the column and fraction collection (0.35 ml per fraction, and a total of 30 fractions collected) 
started immediately under gravity flow using PBS as the elution buffer. Eluted fractions were 
continuously monitored by UV 280nm using the Biologic LP system (BioRad). 
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6.3.5 Isolation and Activation of Macrophages 
Murine bone marrow-derived macrophages (BMDM) were isolated and characterized as 
previously described(Huleihel et al., 2016). Briefly, bone marrow was harvested from 6- to 8-
week-old B6 mice, or B6 ST2-/- mice. Harvested cells from the bone marrow were washed and 
plated at 2 × 106 cells/mL and were allowed to differentiate into macrophages for 7 days in the 
presence of macrophage colony-stimulating factor (MCSF) with complete medium changes every 
48 h. Macrophages were then activated for 24 h with one of the following: 1) 20 ng/mL Interferon-
γ (IFNγ) and 100 ng/mL lipopolysaccharide (LPS) (Affymetrix eBioscience, Santa Clara, CA; 
Sigma Aldrich) to promote an MIFNγ+LPS phenotype (M1-like); 2) 20 ng/mL interleukin (IL)-4 
(Invitrogen) to promote an MIL-4 phenotype (M2-like); 3) 20 ng/ml IL-33 (Peprotech), or 4) 
25 μg/mL of wt mouse MBV, IL-33-/- mouse MBV, or porcine SIS-MBV. After the incubation 
period at 37°C, cells were washed with sterile PBS and placed in blank DMEM for 5 hours to 
generate conditioned medias. After conditioned media was collected, lysates were prepared using 
RIPA buffer for immunoblot analysis or cells were fixed with 2% paraformaldehyde (PFA) for 
immunolabeling. Conditioned medias are defined by the treatment of the parent macrophage 
hereafter. 
6.3.6 Macrophage Immunolabeling 
To prevent nonspecific binding, the cells were incubated in a blocking solution composed 
of PBS, 0.1% Triton-X, 0.1% Tween-20, 4% goat serum, and 2% bovine serum albumin for 1 h at 
room temperature. The blocking buffer was then removed and cells were incubated in a solution 
of one of the following primary antibodies: 1) monoclonal anti-F4/80 (Abcam, Cambridge, MA) 
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at 1:200 dilution as a pan-macrophage marker; 2) polyclonal anti-inducible nitric oxide synthase 
(iNOS) (Abcam, Cambridge, MA) at 1:100 dilution as an M1-like marker, and 3) anti-Arginase1 
(Abcam, Cambridge, MA) at 1:200 dilution, as an M2-like marker. The cells were incubated at 
4°C for 16 h, the primary antibody was removed, and the cells washed with PBS. A solution of 
fluorophore-conjugated secondary antibody (Alexa donkey anti-rabbit 488 or donkey anti-rat 488; 
Invitrogen, Carlsbad, CA) was added to the appropriate well for 1 h at room temperature. The 
antibody was then removed, the cells washed with PBS, and the nuclei were counterstained using 
DAPI. Cytokine-activated macrophages were used to establish standardized exposure times 
(positive control), which were held constant throughout groups thereafter. CellProfiler (Broad 
Institute, Cambridge, MA) was used to quantify images. Data were analyzed for statistical 
significance using a one-way analysis of variance with Tukey's post-hoc test for multiple 
comparisons. Data are reported as mean ± standard deviation with a minimum of N = 3. p-values 
of <0.05 were considered to be statistically significant. 
6.3.7 Macrophage-derived Exosome Isolation 
Treatment-specific macrophage-derived exosomes were isolated as previously 
described(Hong, Funk, Muller, Boyiadzis, & Whiteside, 2016). Briefly, treatment-specific 
macrophage conditioned medias were concentrated using 100 kDa molecular weight cut-off spin 
columns (Millipore) to an approximate volume of ~1 mL. Concentrated samples were 
subsequently purified by size exclusion chromatography as described above. Collected fractions 
were subsequently collected and concentrated to ~250 ml using fresh 100 kDa molecular weight 
cut-off spin columns and their concentrations were determined using a NanoSight particle counter 
equipped with nanoparticle tracking analysis (NTA, NanoSight, Salisbury, UK). 
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6.3.8 Muscle Stem Cell (MuSC) Isolation and Culture 
Muscle stem cells were isolated from the hindlimb skeletal muscle of C57BL/6 mice. 
Harvested muscle tissue was washed using Wash Medium consisting of HBSS with 10% horse 
serum and 1% penicillin/streptomycin. Hair and tendon tissue were removed and the muscle tissue 
was minced until it could pass through a 10 mL stripette. Minced muscle tissue was then subjected 
to serial enzymatic digestion, beginning with 750 U/mL Collagenase II in Wash Medium (Gibco, 
Grand Island, NY) for 60 minutes at 37oC. Collagenase digested muscle was subsequently 
centrifuged at 900 rpm for 5 minutes, and the supernatant was removed. A solution of 2.4 U/mL 
Dispase neutral protease (Gibco) and 750 U/mL Collagenase II in Wash Medium was then added 
to the cell pellet. The cells were resuspended by repeated passage through a 10 mL stripette, and 
incubated for 45 minutes at 37°C. The mixture was then centrifuged at 900 rpm for 5 minutes, the 
supernatant removed, and a solution of 0.1% trypsin in Wash Medium added, and incubated at 
37°C for 30 minutes. After completing the final enzymatic digestion, the cell mixture was 
centrifuged again at 900 rpm for 5 minutes, the supernatant removed and the cells resuspended in 
Wash Medium. The cell suspension was subdivided for flow sorting. The primary sort tube was 
incubated for 1h with all antibodies used for selection: CD31/CD45-FITC, Sca1-APC, and ITGA7-
PeCy7 (all antibodies were purchased from Thermo Fisher Scientific, Waltham, MA). A second 
control tube was incubated with CD31/CD45-FITC alone, and a third tube was incubated with 
Propidium Iodide. Compensation beads (Ultracomp eBeads, ThermoFisher Scientific) were 
incubated for 30 minutes with individual antibodies and were used to establish gating parameters. 
MuSCs were isolated at > 95% purity by selecting for the CD31-/45-/Sca1-/ITGA7+ population. 
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6.3.9 Myogenesis Assay 
Upon reaching 80-90% confluence, medium was removed and primary murine MuSCs and 
murine C2C12 myoblasts were cultured in differentiation medium (DMEM containing 10% FBS, 
100 µg/ml streptomyocin and 100 U/ml penicillin) and one of the following treatments: 
macrophage conditioned media, 1E9 IL-33+ MBV/mL, 1E9 IL-33- MBV, 20 ng/ml rIL-33, or 1E9 
macrophage-derived exosomes/mL. Cells were maintained at 37 °C, 5% CO2. Myogenic 
differentiation potential was determined by examining the skeletal muscle myoblast fusion index, 
defined as the number of nuclei within myotubes containing > 3 nuclei per tube divided by the 
total of number of myotubes per field of view. For C2C12, a positive control group received 2% 
FBS 1% pen/strep in DMEM. For macrophage-mediated differentiation, MuSCs or C2C12 were 
incubated with a 1:1 solution of macrophage supernatants and 20% FBS media (final concentration 
equivalent to differentiation medium). Following 2 and 5 days, cells were fixed for 
immunolabeling with 2% paraformaldehyde. Fixed cells were blocked according to the previous 
described protocol for 1 h at room temperature and incubated in anti-sarcomeric myosin primary 
antibody (Developmental Studies Hybridoma Bank) at a dilution of 1:500 for 16 h at 4 °C. 
Following primary incubation, cells were washed with PBS and incubated in Alexa Fluor donkey 
anti-mouse 488 secondary antibody at a dilution of 1:200 for 1 h at room temperature and 
counterstained with DAPI. Images of three 20× fields were taken for each well (n = 3 biological 
replicates) using a Zeiss Axiovert microscope, and the number of myotubes was quantified and 
averaged. The data were then analyzed by one-way ANOVA followed by Tukey’s Multiple 
Comparison’s Test, with a p < 0.05 considered significant. 
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6.4 Results 
6.4.1 IL-33+ MBV Activate a Pro-Remodeling Macrophage Phenotype via a Non-
Canonical, ST2-independent Pathway 
It was hypothesized that encapsulation of IL-33 prevents binding to its cognate ST2 
receptor, suggesting the presence of an ST2-independent transduction mechanism. To investigate 
this scenario, bone marrow-derived macrophages (BMDM) isolated from B6 wt or st2-/- mice were 
stimulated with interferon-γ (IFN-γ) and lipopolysaccharide (LPS) to induce an M1-like 
macrophage phenotype, interleukin-4 (IL-4) to induce an M2-like phenotype, recombinant IL-33, 
MBV isolated from decellularized wt (IL33+ MBV) or il33-/- (IL33- MBV) mouse intestine, or 
MBV isolated from porcine small intestinal submucosa (SIS MBV). Results showed that 
macrophages expressed Arginase 1 (Arg-1) in response to SIS MBV and IL33+ MBV, similar to 
the expression pattern of the IL-4–stimulated (M2) cells. In contrast, IL33- MBV induced the 
expression of iNOS but not Arg-1 (Figure 1A-C). A similar effect was observed with macrophages 
isolated from st2-/- mice. Specifically, IL33+ MBV, but not IL33- MBV, directed st2-/- macrophage 
activation into the reparative, pro-remodeling M2-like phenotype (Figure 1A-C). 
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Figure 1. MBV containing luminal IL-33 activate a pro-remodeling macrophage phenotype (F4/80+iNOS-
Arg+) via a non-canonical ST2-independent pathway. (A) MBV containing luminal IL-33 activate a pro-
remodeling macrophage phenotype (F4/80+iNOS-Arg+) via a non-canonical ST2-independent pathway. (A, B) 
Bone Marrow-Derived Macrophages (BMDM) harvested from wt (A) or st2−/− (B) mice were untreated (control) or 
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treated with the following test articles for 24 hours: IFNɣ+LPS, IL-4, IL-33, MBV isolated from decellularized wt 
mouse intestine (IL33+ MBV), MBV isolated from decellularized il33−/− mouse intestine (IL33- MBV), or MBV 
isolated from porcine small intestinal submucosa (SIS MBV). Cells were immunolabeled with F4/80 (macrophage 
marker), iNos (M1 marker), or Arg1 (M2 marker). (C) Quantification of iNOS immunolabeling (** indicates p < 
0.01; compared to negative control, error bars represent SEM, n=3 biological replicates analyzed in triplicate). (D) 
Quantification of arginase immunolabeling (**indicates p < 0.01; * indicates p < 0.05 compared to negative control, 
error bars represent SEM, n=3 biological replicates analyzed in triplicate). 
6.4.2 MBV-Associated IL-33 is Required for Macrophage-mediated Myogenesis 
It has been shown that the secretome associated with alternatively activated M2 
macrophages is myogenic for skeletal muscle myoblasts(Bo Deng, Michelle Wehling-Henricks, S 
Armando Villalta, Ying Wang, & James G Tidball, 2012; Daniela Ruffell et al., 2009). Previously, 
we have shown that media conditioned by ECM-treated macrophages promoted myotube 
formation and sarcomeric myosin expression of C2C12 myoblasts(Brian M Sicari et al., 2014). The 
present study shows similar results in that media conditioned by macrophages stimulated with 
IL33+ MBV, but not IL33- MBV, promoted myotube formation of C2C12 myoblasts similar to the 
biologic activity of IL-4-induced M2-like macrophages (Figure 2A,B). Primary MuSCs exposed 
to macrophage conditioned media or direct exposure to rIL-33, IL-33+ MBV, or IL-33 shows that 
direct MBV treatment results in no significant increase in myogenic differentiation compared to 
macrophage-mediated myogenesis (Figure 2C,D) 
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Figure 2. Secreted products of IL-33+ MBV-treated macrophages are pro-myogenic. (A) Experimental design. 
C2C12 myoblasts were cultured to confluence and treated with high serum proliferation media, low serum 
differentiation media, or proliferation media supplemented with media conditioned by st2-/-macrophages stimulated 
with the indicated test articles. (B) C2C12 cells were allowed to differentiate in the presence of macrophage secreted 
products for 2 or 5 days and were immunolabeled for sarcomeric myosin. (C) Primary MuSC were differentiated in 
the presence of macrophage secreted products and were immunolabeled for sarcomeric myosin. (D) Primary MuSC 
were differentiated in the presence of 20 ng/mL rIL-33, 1E9 IL-33- MBV, or 1E9 IL-33+ MBV and were 
immunolabeled for sarcomeric myosin. (*** indicates p <0.001, ** indicates p < 0.01; * indicates p < 0.05, error 
 59 
bars represent SEM (C2C12) or 95% CI of the mean (MuSC), n=3 biological replicates analyzed in triplicate 
(C2C12), and n = 1 biological replicate, technical triplicate (MuSC). 
6.4.3 M2-like Macrophage-derived Exosomes are Pro-Myogenic 
Although macrophages are known to interact with stem cells in a wide variety of clinical 
contexts, the secreted products that account for this cross-talk are incompletely understood. 
Exosomes have an accepted role in the maintenance and repair of skeletal muscle myofibers, and 
emerging evidence suggests that immune cell-derived exosomes may play a role in this process, 
but these studies were not definitive(Bittel & Jaiswal, 2019; Guescini et al., 2017). To assess the 
role of macrophage-derived exosomes in mediating myogenic differentiation, treatment-specific 
exosomes from st2-/- macrophages were added to MuSC in vitro. Results show that exosomes 
derived from M2-like macrophages (IL-4 and IL-33+ MBV-treated macrophages) promoted 
greater expression of sarcomeric myosin, a terminal differentiation marker, than those derived 
from M1-like macrophages (p < 0.05, ) 
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Figure 3. Macrophage-derived exosomes promote myogenesis in a phenotype-dependent manner M2-like 
macrophage-derived exosomes are pro-myogenice. Exosomes derived from M2-like macrophages (IL-4 and IL-
33+ MBV-treated macrophages) increase expression of terminal myogenic differentiation marker, sarcomeric 
myosin (** indicates p < 0.01, * indicates p < 0.05, error bars represent SEM, n = 1 biological replicate, technical 
quadruplicate). 
6.5 Discussion 
In the present study, we provide the first evidence that IL-33, stably stored within the ECM 
and protected from proteolytic cleavage by incorporation into MBV, is a potent mediator of M2-
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like macrophage activation through an uncharacterized, non-canonical ST2-independent pathway. 
Specifically, we show that IL33+ MBV, but not IL33- MBV, direct st2-/- macrophage activation 
towards a reparative, pro-remodeling M2-like phenotype. IL33- MBV instead activated a pro-
inflammatory M1-like phenotype. In total, our studies establish that IL-33 encapsulated within 
lipid-membrane nanovesicles mediates the differentiation of myeloid cells away from pro-
inflammatory subsets independent of the classical ST2 receptor.  
Biologic scaffold materials composed of ECM and configured as surgical meshes, 
powders, and hydrogels have been successfully used in a variety of tissue engineering/regenerative 
medicine and general surgery applications both in preclinical studies and in clinical 
applications(George S. Hussey, Dziki, & Badylak, 2018). If not chemically crosslinked, such 
scaffolds are readily degradable and associated with favorable tissue remodeling properties 
including angiogenesis, stem cell recruitment, and modulation of macrophage phenotype toward 
an anti-inflammatory effector cell type(George S. Hussey et al., 2018). However, the biologic 
mechanisms by which these events and functional tissue restoration are mediated are largely 
unknown. Separate from the mechanical and structural functions of ECM-scaffolds, the molecular 
components of ECM, including growth factors, cytokines, and matricryptic peptides, have been 
extensively investigated for their ability to confer bioactivity(George S Hussey, Keane, & Badylak, 
2017). However, there is legitimate controversy concerning not only the relevant importance of 
these biochemical and structural components, but also the potential influence that the 
decellularization, disinfection, and sterilization methods used during the manufacturing process 
have on their biological activity. We have recently shown that MBV are a potent bioactive 
component of ECM scaffolds, and that these MBV shield their cargo from degradation and 
denaturation during the ECM-scaffold manufacturing process(Huleihel et al., 2016).  Given their 
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location within the ECM of soft tissue, and their incorporation into the collagen network of the 
matrix itself, MBV can be separated from the matrix only after enzymatic digestion of the ECM-
scaffold material, similar to the functional activity attributed to the degradation of implanted 
biologic scaffolds used in clinical applications. These findings suggest that MBV are only 
available for cellular uptake during matrix remodeling events, such as those that occur during 
normal physiologic processes like wound healing and mechanical stress, or during degradation 
initiated by the host response to implanted biologic scaffolds.  
The early macrophage response to biomaterials has been shown to be a critical and 
predictive determinant of downstream outcomes(Brown, Londono, et al., 2012; Brown, Ratner, et 
al., 2012). When properly prepared (i.e. thoroughly decellularized and not chemically crosslinked), 
bioscaffolds composed of mammalian ECM have been shown to promote a transition in 
macrophage behavior from a pro-inflammatory to a regulatory/anti-inflammatory phenotype, 
which in turn has been associated with constructive and functional tissue repair(George S. Hussey 
et al., 2018). This macrophage phenotype transition is critically important in skeletal muscle as 
macrophages exert local paracrine effects on local stem/progenitor cell populations to promote 
their recruitment, proliferation, and subsequent differentiation as a function of their phenotype(L. 
Arnold et al., 2007; Bittel & Jaiswal, 2019; J. L. Dziki et al., 2016; Tidball, 2005). Although these 
phenomena are well known, the secreted product(s) by which macrophages exert these  effects are 
incompletely understood.due to the phenotype-dependent We have previously shown that MBV 
are critical for the activation of macrophages towards a M2-like, pro-remodeling phenotype(L. 
Huleihel, J. Bartolacci, et al., 2017; Huleihel et al., 2016). Results from the present study support 
earlier findings and suggest that a single MBV cargo, IL-33, plays a critical role in this phenotypic 
transition, and lend credence to previous reports that macrophage-derived exosomes contribute to 
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differentiation of myogenic cells during the host response to injury. Further characterization of the 
role of these secreted extracellular vesicles in tissue remodeling may offer new avenues for 
therapeutic intervention.  
Conceptually, the discovery that MBV embedded within ECM-scaffolds are a rich source 
of extra-nuclear IL-33, is novel in itself and has not been previously reported. Full length IL-33 is 
generated as an approximately 32 kDa protein with an IL-1 family C-terminal cytokine domain 
and an N-terminal domain consisting of a non-classical nuclear localization sequence and a DNA 
binding domain, as well as a chromatin-binding domain(Baekkevold et al., 2003; Lingel et al., 
2009). Given this N-terminus and the lack of a secretion signaling sequence, current dogma is that 
IL-33 is found only in the nucleus and released upon necrotic cell death(Pichery et al., 2012). Thus, 
IL-33 is defined as an alarmin, or an endogenous molecule that alerts the immune system to cell 
injury and tissue damage. IL-33 released from necrotic cells has been shown to activate the 
canonical ST2 signaling pathway in a variety of ST2+ immune cells to drive broad immune 
responses that include Type 1, Type 2, and regulatory immune responses(Kakkar & Lee, 2008; 
Liew et al., 2016). Full length IL-33 is fully capable of activating ST2-dependent signaling, but 
can be converted by inflammatory proteases to an 18 kDa cytokine that is a more potent activator 
of ST2 signaling(Lefrancais et al., 2014; Lefrancais et al., 2012). The ST2-dependent functions of 
IL-33 are negatively regulated by the apoptotic caspases-3 and -7, which cleave IL-33 in the 
cytokine domain, and a soluble and antagonistic form of ST2(Liew et al., 2016). More recently, it 
was revealed that soluble IL-33 released into the extracellular environment is rapidly oxidized to 
inactivate the cytokine domain and limit its range and duration of action(E. S. Cohen et al., 2015). 
Several studies have shown that cytokines that lack a signal peptide sequence can be packaged and 
secreted within extracellular vesicles, including the IL-1 family members IL-1β, IL-1α, and IL-
 64 
18(Berda-Haddad et al., 2011; Gulinelli et al., 2012; Hasegawa, Thomas, Schooley, & Born, 2011; 
MacKenzie et al., 2001). IL-33 has been reported to be present in exosomes released from Epstein-
Barr Virus (EBV)-infected cells as a strategy to reduce innate immunity activation(Ansari et al., 
2013). Furthermore, it was previously demonstrated that IL-33 can efflux from the nucleus where 
it is packaged within membrane vesicles in the cytosol(Rahul Kakkar, Hillary Hei, Stephan 
Dobner, & Richard T Lee, 2012). In the present study, we provide the first evidence that IL-33 can 
also be stably compartmentalized within the extracellular matrix through incorporation into the 
lumen of MBV thereby preventing IL-33 degradation and inactivation.  
The findings of the present study show that MBV-mediated delivery of IL-33 to immune 
cells can upregulate Arginase-1 expression. Conversely, we show that IL-33 deficient MBV 
support M1-like macrophage activation, which suggests that the absence of IL-33 within MBV 
may either drive uncharacterized gene expression or that IL-33 may repress genes leading to M1 
macrophage activation after MBV uptake. Previous reports have shown that epigenetic regulation 
of histone modification, including acetylation/deacetylation and chromatin remodeling are 
mechanistically important for activation of the M2 macrophage phenotype(Ishii et al., 2009; 
Kapellos & Iqbal, 2016). Although it has been reported that IL-33 binds chromatin and may act as 
a transcriptional repressor(Virginie Carriere et al., 2007), to date, no bona fide IL-33 regulated 
genes have been identified. Future studies aimed at a rigorous molecular characterization of IL-33 
regulated genes will be required to fully explore the biology of not only MBV, but also IL-33, and 
will yield important information on their potential use in not only regenerative medicine 
applications, but also in the mitigation of adverse tissue responses; for example, to promote 
allograft survival following heart transplant. Given our finding that MBV can mediate receptor-
free delivery of protein cargo to immune cells and orchestrate their function, it is easy to appreciate 
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how the present study may support the development of tailored vesicles (e.g., MBV, exosomes, or 
engineered liposomes) as next generation immunomodulatory therapeutics. Separately, the use of 
ECM-based therapies can now be examined by new directions and will help guide the design of 
next generation ECM-based materials. 
6.6 Conclusions 
Results of the present study suggest that IL-33 is a critical mediator of primary bone 
marrow derived macrophage phenotype activation. Specifically, MBV containing IL-33 promoted 
expression of the M2-associated marker, Arg1, while MBV deficient in IL-33 did not. Further, IL-
33+ promoted a pro-myogenic macrophage secretome, which is in accordance with previously 
reported behavior of M2-like macrophages. These data suggest that MBV and their associated IL-
33 cargo may underly the immunomodulatory bioactivity of whole ECM bioscaffolds observed in 
vitro and in vivo. 
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7.0 Extracellular IL-33 Enters Target Cells via a Clathrin and PI3K-dependent Endocytic 
Mechanism and Translocates to the Nucleus 
7.1 Overview 
Numerous preclinical animal studies and clinical data have shown that bioscaffolds 
composed of extracellular matrix (ECM) effectively promote functional, site-appropriate tissue 
remodeling in a variety of clinical contexts(Badylak et al., 2011; J. Dziki et al., 2016; T. J. Keane 
et al., 2017; Saldin et al., 2019; Seif-Naraghi et al., 2013; Singelyn et al., 2009). Numerous ECM 
components have been associated with induction of endogenous repair processes; however, a 
mechanism by which ECM bioscaffolds promote modulation of immune cell phenotypes, in 
particular macrophages, has remained elusive. Recent studies suggest that matrix-bound 
nanovesicles (MBV), extracellular vesicle components of ECM, may be at least partially 
responsible for ECM-mediated macrophage phenotype activation(L. Huleihel, J. G. Bartolacci, et 
al., 2017). Although MBV contain a myriad of bioactive components, evidence supports non-
canonical IL-33 signaling as a potential mechanism by which MBV promote a pro-healing 
macrophage phenotype(G. S. Hussey et al., 2019). Results of the present study show that MBV-
associated IL-33 is functionally delivered to target cells by a clathrin and phosphatidylinositol 3-
kinase (PI3K)-dependent mechanism. Within target cells, IL-33 rapidly translocates to the nucleus 
where it engages in multiple protein-protein interactions. A result of these interactions, IL-33 is 
required for the promotion of M2-associated marker, Arg1, and inhibition of M1-associated 




Biologic scaffolds derived from a variety of mammalian tissues and composed of 
extracellular matrix (ECM) have been used as surgical meshes to repair a variety of soft tissue 
defects (Agrawal et al., 2010; Badylak et al., 2011; J. Dziki et al., 2016; T. J. Keane et al., 2017). 
The in vivo degradation and remodeling of these ECM-based materials are associated with 
constructive and functional, site appropriate healing events such as angiogenesis(Bornstein, 2009; 
F. Li et al., 2004), immunomodulation (Brown, Londono, et al., 2012; J. L. Dziki et al., 2016; L. 
Huleihel, J. G. Bartolacci, et al., 2017; L. Huleihel, J. L. Dziki, et al., 2017; G. S. Hussey et al., 
2019; B. M. Sicari, J. L. Dziki, et al., 2014), and stem cell recruitment and differentiation(Agrawal, 
Kelly, et al., 2011; J. L. Dziki et al., 2016; Huleihel et al., 2016) among others. The molecular 
signaling effectors responsible for these events have been attributed to embedded chemokines and 
cytokines(Mewhort et al., 2017; Michalopoulos, 2010; Peloso et al., 2015), cryptic 
peptides(Adams & Watt, 1989; Agrawal et al., 2010; Agrawal, Kelly, et al., 2011; Agrawal, Tottey, 
et al., 2011; Brennan et al., 2006), and various ligand-receptor interactions (Bissell & Aggeler, 
1987; Dzobo, Vogelsang, & Parker, 2015; Grasman et al., 2015; Mammoto, Jiang, Jiang, & 
Mammoto, 2013), but convincing and definitive studies that show cause-effect relationships are 
lacking. Arguably, modulation of innate immune cell phenotypes, in particular the macrophage 
component, is the most critical of these processes but the least understood. 
Recently, matrix bound nanovesicles (MBV) have been identified within the 
ECM(Huleihel et al., 2016). MBV are a distinct class of nanoscale, lipid-bound extracellular 
vesicles that contain a myriad of signaling molecules(L. Huleihel, J. G. Bartolacci, et al., 2017; 
Huleihel et al., 2016; G. S. Hussey et al., 2019). MBV are distinct from liquid-phase exosomes 
with respect to both their surface lipid membrane composition and intravesicular cargo(George S. 
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Hussey et al., 2020). MBV have been shown in vitro to modulate macrophage phenotype(L. 
Huleihel, J. G. Bartolacci, et al., 2017; Huleihel et al., 2016; G. S. Hussey et al., 2019), induce 
stem cell differentiation(J. L. Dziki et al., 2016; T. J. Keane et al., 2017; Schreurs et al., 2020), and 
to contain gene print transcripts that regulate an impressive array of constructive and tissue 
remodeling processes(L. Huleihel, J. G. Bartolacci, et al., 2017; Huleihel et al., 2016; G. S. Hussey 
et al., 2019; George S. Hussey et al., 2020; van der Merwe et al., 2019). Further, MBV have been 
shown to have favorable in vivo therapeutic effects in the preservation of retinal structure and 
function following injury through modulation of microglia and astrocyte phenotypes(van der 
Merwe et al., 2019) in a rat model of acute glaucoma. MBV miRNA cargo were shown to mediate, 
at least in part, the effects of MBV on neuronal cells(van der Merwe et al., 2017) and studies on 
primary murine bone marrow derived macrophages (BMDM) have shown that miRNA may 
contribute to MBV-mediated macrophage phenotype activation(L. Huleihel, J. G. Bartolacci, et 
al., 2017). However, the bioactivity of MBV protein cargo(s) is not fully understood. Specifically, 
recent in vitro studies have shown that MBV are an ample source of extracellular IL-33, an IL-1 
superfamily member typically considered to be a pro-inflammatory alarmin(Ali et al., 2011; V. 
Carriere et al., 2007; Cayrol & Girard, 2014; G. S. Hussey et al., 2019; Milovanovic et al., 2012). 
Nonetheless, MBV-associated IL-33 has been shown to play a significant role in pro-healing, M2-
like macrophage phenotype activation via a non-canonical, ST2-independent pathway(G. S. 
Hussey et al., 2019). Such in vitro and in vivo findings are logically dependent upon the attachment 
and intracellular trafficking of these information rich nanovesicles. 
The objective of the present study was to determine the molecules involved in the uptake 
of MBV by macrophages, as well as the intracellular compartmentalization of delivered cargo. 
Results of fluorescently labeled MBV uptake studies show that the clathrin aggregation inhibitor, 
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Pitstop2, and a phosphatidylinositol-3-kinase (PI3K) inhibitor, LY294002, markedly reduced 
MBV uptake compared to uninhibited controls. To investigate the mechanism of IL-33 modulation 
of macrophage phenotype, the location of MBV-associated IL-33 was determined at several 
timepoints following exposure of il33-/- macrophages to IL-33+ MBV. The cytosolic and nuclear 
compartments were assayed by western blot directed against IL-33. Results show that IL-33 can 
be detected within the cytoplasm of exposed cells within 1 hour of exposure and within the nuclei 
within 3 hours. The appearance of IL-33 within target cells correlated with increased expression 
of Arg1 protein expression, an M2-like macrophage associated marker, that was not observed after 
exposure of macrophages to IL-33- MBV. These results suggest that IL-33 is responsible for the 
expression of M2-associated genes. Co-immunoprecipitation against IL-33 at all timepoints 
showed that IL-33 has dynamic protein interactions in the nucleus by 3h that were maintained 
through the remainder of the investigation period. Together, these data suggest that MBV uptake 
is non-destructive to protein cargo(s) and may regulate an M2-like macrophage phenotype through 
direct protein-protein interactions. Stated differently, results of the present study suggest that 
MBV-associated IL-33 may represents a novel paradigm for gene expression regulation by a 
cytokine.  
7.3 Materials and Methods 
7.3.1 Preparation of SIS-ECM 
The jejunum was harvested from market weight (~240 lbs) pigs (Animal Biotech 
Industries, Doylestown, PA) or from C57bl6-arg1gfp or C57bl6-arg1gfp/il33-/- mice and was 
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decellularized via mechanical and chemical methods as previously described(Badylak et al., 1989; 
Badylak et al., 1995; Prevel et al., 1995). Briefly, the tunica serosa, tunica muscularis externa, and 
the superficial layers of the tunica mucosa were mechanically removed, leaving only the tunica 
submucosa and basilar portions of the tunica mucosa. Decellularization and disinfection of the 
tissue were completed by agitation in 0.1% peracetic acid with 4% ethanol for 2 hours at 300 rpm. 
The tissue was then extensively rinsed with PBS and sterile water, frozen, and ultimately 
lyophilized. The resultant SIS-ECM was then milled into particulate using a Wiley Mill with a #60 
mesh screen. 
7.3.2 Matrix-Bound Nanovesicle (MBV) Isolation, Purification, and Quantification 
SIS-MBV were isolated from SIS-ECM as previous described(L. Huleihel, J. G. 
Bartolacci, et al., 2017). Briefly, SIS-ECM was solubilized using Liberase DL (Sigma Aldrich, St 
Louis, MO), Immediately following solubilization, SIS-ECM samples were sequentially 
centrifuged at 500xg for 10 min (one time), 2,500xg for 20 min (one time), and 10,000xg for 30 
min (3 times) to remove collagen fibrils and other insoluble remnants. The supernatants were 
recovered between each centrifugation step, while the pellets were discarded. Following 
centrifugation, the supernatants were filter-sterilized with a 0.22 µm filter (Millipore, Burlington, 
MA) and concentrated to a volume of 1 mL using 100 kDa molecular weight cut-off columns at 
4,000xg. Concentrated samples were then subjected to SEC as previously described(Hong CS., 
2017). Briefly, columns were prepared in 1.5 cm x 12 cm mini-columns (Bio-Rad, Hercules, CA, 
USA; Econo-Pack columns), to which Sepharose 2B (Sigma-Aldrich) was added to a final bed 
height of 10 ml, and finally by a porous frit to protect the column bed disruption during sample 
elution. The Sepharose column was maintained in 1X PBS at all times during column preparation, 
 71 
and washed with 20 ml of 1X PBS prior to sample addition. Following column preparation, the 
concentrated digest (1 ml) was then loaded onto the column and 7 fractions of 1 mL were collected. 
Fractions 3, 4 and 5 were combined, concentrated using fresh 100 kDa cut-off columns until the 
final volume was ~500 mL. For MBV uptake assays, 6 ml of PKH26 (Sigma Aldrich) was added 
to the 1 mL and incubated in the dark for 5 minutes at room temperature. PKH-labeled MBV were 
then purified by SEC. MBV size and concentration were determined using a Nanoparticle Tracking 
Analysis (NTA) equipped Nanosight LM10 (Malvern Panalytical)(Filipe, Hawe, & Jiskoot, 2010) 
as previously described(Webber & Clayton, 2013). 
7.3.3 Macrophage Isolation and Activation 
Primary bone marrow-derived macrophages were isolated as previously described(Englen, 
Valdez, Lehnert, & Lehnert, 1995; B. M. Sicari, J. L. Dziki, et al., 2014). Briefly, female 6 to 8-
week old C57bl/6 mice (Jackson Laboratories, Bar Harbor, ME) were euthanized via CO2 
inhalation and cervical dislocation. Femurs, tibia, and fibula were harvested and washed in 3x in 
macrophage Complete Medium consisting of 10% FBS (Invitrogen, Carlsbad, CA), 10% L929 
supernatant, 10 mM non-essential amino acids (Gibco, Grand Island, NY), 10 mM HEPES 
(Gibco), 2 mM L-glutamine (Gibco), 100 U/mL penicillin (Gibco), 100 mg/mL streptomycin 
(Gibco) and 0.1% b-mercaptoethanol in DMEM high glucose (Gibco). Complete medium was 
flushed through the medullary space of harvested bones and cells plated at 2 x 106 cells/mL into 6 
well plates (Corning) or 4 x 104 cells/mL into chambered slides (Nunc Lab-Tek II Chamber Slide 
System, Thermo Fisher Scientific, Waltham, MA). Medium was supplemented 24h after plating 
and complete media replacement every 48 hours thereafter for 7 days. For macrophage activation 
studies, mature macrophages were treated at 37oC and 5% CO2 with 1 ml of the following 
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treatments for in 10% FBS 1% pen/strep in DMEM: PBS (vehicle control), 1 x 109 IL-33+ MBV 
(WT MBV), or 1 x 109 IL-33- MBV (KO MBV). After 1.5h, an additional 1 ml of one of the 
following treatments was added for 16h: 20 ng/ml IFN-g + 100 ng/ml LPS (M1), or PBS. Cells 
were subsequently washed with PBS and lysed in RIPA buffer containing protease inhibitor 
cocktail. Lysates were stored at -20oC until use for immunoblotting. 
7.3.4 MBV Uptake Assay 
Mature bone marrow derived macrophages cultured in chambered slides were exposed to 
inhibitors of cellular uptake processes as previously described(Carter, Bernstone, Baskaran, & 
James, 2011; Svensson et al., 2013; Yao et al., 2018). All treatments were delivered in DMEM 
containing 10% FBS and 1% pen/strep. Briefly, macrophages exposed to one of the following 
treatments at 37oC and 5% CO2: 0.5% DMSO (vehicle control), 25 mM Pitstop 2 (Clathrin 
aggregation inhibitor; Abcam), 25 mM LY294002 (PI3K inhibitor; Selleck Chemicals, Houston, 
TX), 25 mM Go 6894 (Protein Kinase C inhibitor; Selleck Chemicals), 5 mM methyl-b-
cyclodextrin (lipid raft disruptor; Sigma), 100 mM amiloride (sodium ATPase inhibitor; Selleck 
Chemicals), 1 mg/ml Filipin iii (lipid raft disruptor; Selleck Chemicals), or 48 nM Latrunculin A 
(actin polymerization inhibitor; Abcam). After 1h, 1 x 109 PKH26-labeled MBV/well were added 
to each inhibitor group, or an equivalent volume of PBS was delivered (negative control). 
Following 1h of incubation with fluorescently labeled MBV, treatments were removed, the cells 
washed with PBS, and subsequently fixed in 4% paraformaldehyde (PFA) at room temperature for 
20 minutes. PFA was then removed, the cells washed 3x in PBS, and the cytoskeleton and nuclei 
were counterstained using AF488-conjugated phalloidin (Invitrogen, Carslbad, CA) and 4′,6-
diamidino-2-phenylindole (DAPI), respectively. Five images per treatment group were acquired 
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at 32X magnification using a Zeiss Axiovert microscope (Carl Zeiss, Oberkochen, GE). 
Fluorescence channel images were processed using CellProfiler (Broad Institute, Cambridge, MA) 
and cells with > 1 fluorescently labeled MBV were considered positive. N = 3 biological replicates 
were performed and percent MBV-positive cells as a function of treatment was the primary 
outcome measure. Differences between groups was assessed using one-way ANOVA followed by 
post-hoc testing (GraphPad, San Diego, CA). Results are presented as mean + standard error of 
the mean and the 95% confidence intervals for all comparisons are presented. A multiple 
comparisons-corrected p < 0.05 was considered significant. 
7.3.5 Subcellular Fractionation 
Mature il33-/- bone marrow-derived macrophages cultured in 6-well tissue culture plates 
(Corning) were exposed to 1 x 109 IL-33+ MBV/ml in macrophage Complete Medium for 0 
(negative control), 1, 3, 6, or 24h. At the designated endpoint, treatments were removed,1 ml of 
PBS was added and the cells were collected through mechanical scraping. Collected cells were 
subsequently centrifuged at 1500 xg for 5 minutes, the PBS removed and 100 ml of hypotonic 
lysis buffer (20 mM HEPES pH = 7.4, 10 mM KCl, 2 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 
mM DTT, and protease inhibitor cocktail tablet) was added on ice with intermittent vortexing. 
Following 30 minutes, cell lysates were passed through a 27-gauge syringe ten times and then 
centrifuged at 4oC for 20 minutes at 12000 xg. The cytosolic supernatant was collected and stored 
at -20oC or used fresh. The nuclear pellet was washed 3x in ice cold PBS and then 0.1% SDS in 
TBS supplemented with 1 mM DTT and a protease inhibitor cocktail tablet was added to lyse 
nuclear membranes. After 30 minutes, samples underwent immersion sonication (FisherbrandTM 
Model 120 Sonic Dismembrator, Thermo Fisher) for 3 seconds at 30% amplitude to shear 
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chromatin. Sonicated nuclear lysates were then centrifuged at 12000 xg for 20 minutes at 4oC. 
Nucleosol supernatants were collected and stored at -20oC or used fresh. 
7.3.6 Immunoblotting 
Nucleosolic and cytosolic fractions were quantified by detergent compatible Bradford 
assay (Thermo Fisher) or BCA (Bio-Rad), respectively. 100 mg total protein in Laemmli buffer 
containing 5% b-mercaptoethanol were loaded to 4-20% polyacrylamide MiniPROTEAN TGX 
pre-cast gels (Bio-Rad) and run at 150 V for ~45 minutes in Tris-Glycine running buffer. Upon 
completion, wet transfer was performed using polyvinylidene difluoride membranes in Tris-
Glycine transfer buffer with 20% methanol at 300 mAmp on ice. After 45 minutes, membranes 
were removed from the transfer chamber, washed for 10 minutes in TBST, and blocked for 1h in 
TBST with 5% bovine serum albumin (Sigma). After blocking, membranes were incubated 
overnight at 4oC with: 0.1 mg/ml goat-anti-IL-33 (AF3626; R&D Biosystems, Minneapolis, MN), 
0.1 mg/ml mouse-anti-b-actin (sc-47778, Santa Cruz Biotechnologies, Dallas, TX), 0.1 mg/ml 
rabbit-anti-histone H3 (ab18521, Abcam), 0.1 mg/ml rabbit-anti-arginase 1 (ab91279, Abcam), or 
0.1 mg/ml rabbit-anti-iNOS (PA3-030A, Thermo Fisher). Following primary antibody incubation, 
membranes were washed 3x in TBST and subsequently incubated for 1h at room temperature with 
rabbit-anti-goat, goat-anti-mouse, or goat-anti-rabbit HRP-conjugated antibodies (Dako Affinity 
Purified; Agilent, Santa Clara, CA) diluted 1:1000 in TBST with 5% BSA. Membranes were then 
washed 3x with TBST and incubated in chemiluminescent substrate (Clarity ECL Substrate; Bio-
Rad) for 5 minutes and subsequently imaged (ChemiDoc Touch; Bio-Rad). Acquired images were 
analyzed using ImageJ and all groups were normalized to the appropriate loading control. N = 2 
biological replicates, densitometry results were averaged across replicates and means were 
 75 
compared using two-way ANOVA (GraphPad) to determine row effects (time). Significance was 
set as p < 0.05. 
7.3.7 Co-Immunoprecipitation 
Co-immunoprecipitation of nucleosolic fractions was performed as previously 
described(C. Lee, 2007). Briefly, 10 mg/mg goat-anti-IL-33 (R&D Biosciences) or 10 mg/mg of 
isotype control antibody (Cell Signaling Technologies) were covalently conjugated to M-270 
Epoxy Dynabeads (Thermo Fisher) according to manufacturer’s instructions. 50 mg/reaction by 
total protein of nucleosol from each timepoint was incubated with dynabead-conjugated antibodies 
overnight at 4oC with agitation. Samples were subsequently washed 3x in cold PBS and eluted in 
50 ml of 2% SDS in PBS. 20 ml of each eluted sample was loaded in Laemmli buffer with 5% b-
mercaptoethanol to 4-20% Mini-PROTEAN TGX pre-cast gels and run at 150 mV for ~45 
minutes. Gels were then collected and washed in distilled H2O. After washing, gels were stained 
with Pierce Silver Stain for Mass Spectroscopy kit (Thermo Fisher) according to manufacturer’s 
instructions and imaged using ChemiDoc Touch (Bio-Rad). To confirm the identity of eluted 
products, 20 ml of eluate in Laemmli buffer were subjected to SDS-PAGE as described above and 
membranes were incubated with anti-IL-33 antibodies. 
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7.4 Results 
7.4.1 MBV Uptake is Clathrin and PI3K Dependent 
MBV-associated IL-33 was previously shown to signal through an ST2-independent, 
STAT6-independent mechanism(G. S. Hussey et al., 2019), however the nature of this non-
canonical signaling mechanism was not completely elucidated. Determining the molecules by 
which MBV interact with target cells was, therefore, a critical starting point to begin to understand 
what cellular processes might be affected. Results of MBV uptake assays show that two inhibitors, 
Pitstop 2 and LY294002, significantly reduced MBV uptake with respect to uninhibited controls 
(p < 0.001 and p < 0.01, respectively, Figure 4). No significant changes in uptake were detected 




Figure 4. MBV uptake by macrophages is dependent upon clathrin and PI3K. (A) Representative 32x image 
showing fluorescently labeled MBV (red) within bone marrow-derived macrophages. (B) Quantification of three 
biological replicates of uptake experiments. (Top panel) Mean + SEM show that LY294002 (PI3K inhibitor) and 
PitStop2 (clathrin aggregation inhibitor) significantly reduce MBV uptake (p < 0.01 and p < 0.001, respectively). 
(Bottom panel) Post-hoc testing showing 95% CI about comparison means differences. (*** denotes p < 0.001, ** 
denotes p < 0.01 by one-way ANOVA followed by post-hoc testing, N = 3 biological replicates). 
7.4.2 MBV-associated IL-33 Translocates to the Nucleus Promotes an M2-like Macrophage 
Phenotype, and Forms Protein-Protein Interactions 
As a member of the IL-1 superfamily, IL-33 contains an N-terminus nuclear translocation 
sequence that promotes IL-33 localization to chromatin. Further, it has been suggested that IL-33 
may have transcriptional repressor activity through interactions with NF-B(V. Carriere et al., 
2007). However, the behavior of MBV-associated IL-33 in target cells has not been characterized. 
Results of subcellular localization assays show that MBV are rapidly and non-destructively taken 
up by target cells, evidenced by detectable IL-33 in both cytoplasmic and nuclear compartments 
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by 1 hour after treatment. Cytoplasmic and nuclear concentration of delivered IL-33 peaked at 1 
and 3 hours after treatment, respectively (p < 0.05, Figure 5B) and remained detectable by 24h.  
 
Figure 5. MBV-associated IL-33 is rapidly taken up by target cells and translocates to the nucleus. (A) 
Representative immunoblots of il33-/- bone marrow-derived macrophage cytosolic and nucleosolic fractions 
assessed for MBV-associated IL-33 by western immunoblotting and Arg1 expression. (B) Quantification of IL-33 in 
the cytoplasmic and nuclear compartments. Statistically significant increases in detected IL-33 by 3h with respect to 
0h (data are presented as mean + SEM, two-way ANOVA). (N = 3, * denotes p < 0.05 by two-way ANOVA). 
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As an important control, expression of Arg1, an M2-like macrophage phenotype marker, 
was measured as a function of time after treatment with MBV by immunoblotting. Results show 
that Arg1 expression increases with time after MBV (Figure 5A), reaching maximum expression 
by 24h. Further, results show that pretreatment of macrophages with IL-33+ MBV, but not IL-33- 
MBV, reduced IFN-g and LPS-mediated iNOS expression and increased expression of Arg1, an 
M2-associated marker (Figure 6). 
 
Figure 6. IL-33 is required for an M2-like macrophage phenotype in the presence of inflammatory cytokines. 
Immunoblotting against iNOS, Arg1 and -actin of il33+/+ macrophages exposures to PBS, IL-33+ MBV (WT 
MBV), or IL-33- MBV (KO MBV) for 1.5h followed by addition of IFN+LPS or PBS for 16h shows IL-33+ MBV 
promote reduced iNOS expression and increased Arg1 expression in the presence of inflammatory cytokines. (n=1, 
3 pooled technical replicates). 
 
In order to determine whether these IL-33 effects were mediated through interactions with 
intracellular transcription factors as has been suggested, co-immunoprecipitation of MBV-
delivered IL-33 was performed. Results show that IL-33 undergoes direct protein interactions 
beginning at 3h in the nuclear compartment, and increasing protein associations were observed 
between hours 6-24 (Figure 7A). 
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Figure 7. IL-33 interacts with target cell proteins. (A) Silver stain of proteins eluted from co-
immunoprecipitation directed against IL-33 shows increasing complexity of interactions as a function of time (red 
arrowheads). (B) Confirmation of IL-33 presence in the eluted proteins. 
7.5 Discussion 
Modulation of immune cell phenotypes, in particular macrophages, is an established 
consequence of the use of ECM bioscaffolds, both in vitro and in vivo, and is predictive of 
downstream functional and constructive tissue remodeling(Brown, Londono, et al., 2012; J. L. 
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Dziki et al., 2016; L. Huleihel, J. L. Dziki, et al., 2017; K. Sadtler, K. Estrellas, et al., 2016). 
However, the mechanisms by which ECM bioscaffolds promote a pro-healing macrophage 
phenotype have remained poorly understood. Studies have shown that MBV play a significant role 
in ECM-mediated macrophage phenotype activation(L. Huleihel, J. G. Bartolacci, et al., 2017; G. 
S. Hussey et al., 2019; van der Merwe et al., 2019), and, more recently, that MBV-associated IL-
33 may underly this bioactivity(G. S. Hussey et al., 2019). The present work shows that IL-33 
rapidly enters target cells in a clathrin-dependent manner. Upon entering target macrophages, IL-
33 forms direct interactions with other proteins, its intracellular distribution is dynamic, and may 
reduce pro-inflammatory cytokine-mediated iNOS expression. Stated differently, MBV-
associated IL-33 promotes upregulation of M2-associated markers and may inhibit pro-
inflammatory cytokine-mediated iNOS expression through protein-protein interactions in the 
nucleus. 
The manner by which extracellular material enters cells in large part dictates its fate. 
Particulate taken up by phagocytosis, as is common for cellular debris after injury by macrophages, 
is rapidly degraded(Pauwels, Trost, Beyaert, & Hoffmann, 2017), while other pathways such as 
clathrin-mediated endocytosis, employed frequently following receptor activation, have more 
varied outcomes for internalized products(McKelvey et al., 2015). It was imperative to determine 
the mechanism by which MBV are taken up by target cells to subsequently postulate which cellular 
process(es) may be exploited for functional cargo delivery. It is logical, therefore, that endocytosis 
is the mechanism by which MBV enter target cells due to the potential for vesicle membrane fusion 
and preservation of protein function, as has been reported for exosomes(Svensson et al., 2013; Yao 
et al., 2018). Further, the role of PI3K in this process was unexpected, although not surprising, due 
to its known roles in modulating vesicular trafficking and internalization(Bhattacharya, 
 82 
McElhanon, Gushchina, & Weisleder, 2016; Heath, Stahl, & Barbieri, 2003). The decision to 
choose 1 hour as the timepoint after which MBV were removed from cells was made on the 
observation that, in uninhibited cells, nearly 100% of cells had taken up at least one fluorescently 
labeled particle and would provide a reproducible rate against which to compare inhibited groups. 
The current understanding of intracellular IL-33 behavior suggests that a dynamic balance 
of cytoplasmic and nuclear localization occurs in living cells. IL-33 has been reported to shuttle in 
and out of the nucleus through the nuclear pore complex and subsequently bind to euchromatin. 
However, within the cytoplasm, IL-33 has been shown to reside within secretory vesicles (R. 
Kakkar, H. Hei, S. Dobner, & R. T. Lee, 2012). Results of the present study show a rapid cellular 
uptake of MBV and associated cargo, with near simultaneous transport to the nucleus. Similar to 
uptake assays, MBV IL-33 cargo was detected within the nucleus and cytoplasm by 1h after 
treatment and remained detectable for the duration of the study period. It is of note that IL-33 
levels in different cellular compartments was in a state of apparent flux, oscillating between peaks 
and nadirs from its maximum concentration in both compartments at 1h. MBV-associated IL-33 
cargo is delivered in its functional, ~32 kDa form and promoted upregulation of Arg1, an M2-like 
macrophage phenotype marker. It is evident that the functional domains of IL-33 are preserved 
following incorporation into MBV, and future studies will be needed to determine the contribution 
of IL-33 subdomains, such as the N-terminus, on MBV-associated IL-33 intracellular trafficking. 
It is possible that Arg1 expression could be a result of internalization of extracellular material 
rather than the bioactivity of IL-33, however, this possibility is unlikely, as macrophages treated 
with IL-33+ MBV reduced IFN-g and LPS-induced iNOS expression, while IL-33- augmented 
iNOS expression. 
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These findings are in accordance with previous studies in which it was shown that 
macrophages treated with MBV or parent ECM, following pre-treatment with LPS+IFNg, had 
lower expression of iNOS, an M1-like macrophage associated marker, and increased expression 
of M2-like macrophage associated markers, Arg1 and Fizz1(L. Huleihel, J. G. Bartolacci, et al., 
2017; L. Huleihel, J. L. Dziki, et al., 2017). It has also been shown that when endothelial cells 
overexpressing IL-33 were treated with IL-1b, the production and secretion of TNF-a and IL-6, 
downstream of NF-kB signaling, were reduced. In these studies, IL-33 physically interacted with 
p65 on chromatin and reduced its ability to increase gene expression(V. Carriere et al., 2007). It is 
plausible, though untested, that p65 may represent one of the proteins co-eluted with IL-33. It is 
plausible, therefore, that IL-33, when delivered by MBV, may regulate the activity of p65, thereby 
reducing the expression of pro-inflammatory molecules. 
Several studies suggest that IL-33 may promote changes in the epigenetic landscape of 
cells, either as a result of interaction with NFkB or indirectly through activation of ST2 
signaling(Ali et al., 2011; Oshio et al., 2017; F. Zhang et al., 2014). Specifically, it was 
hypothesized that IL-33 may assist in the recruitment of, or alter the activity of, chromatin 
modifiers such as histone deacetylases or histone acetyltransferases (HDACs or HATs, 
respectively). Importantly, epigenetic landscape regulation is an emerging field of investigation 
with regards to macrophage polarization and has been shown, in particular, to play a role in 
macrophage phenotype transition from a pro-inflammatory M1-like macrophage towards a pro-
healing M2-like macrophage phenotype(S. Chen, Yang, Wei, & Wei, 2020). Determination of the 
role of MBV-associated IL33 in regulating the epigenetic landscape of cells would be an important 




MBV and their cargo are immune active components of ECM bioscaffolds. MBV-
associated IL-33 rapidly enters cells through an endocytic route that preserves its function and 
results in the promotion of an M2-like macrophage phenotype. Within target cells, IL-33 forms 
direct interactions with host cells molecules that may contribute to its immunomodulatory 
function. Further, IL-33 was required for MBV-mediated downregulation of iNOS expression 
induced by type 1 cytokines. These findings corroborate previously reported findings and offer 
mechanistic insight into ECM bioscaffold mediated immunomodulation in vitro. 
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8.0 Extracellular IL-33 Modulates Macrophage Phenotype in Response to Skeletal Muscle 
Injury 
8.1 Overview 
Injuries to skeletal muscle are among the most common injuries in civilian and military 
populations, accounting for nearly 60% of extremity injuries(Corona et al., 2015; J. Dziki et al., 
2016; Grogan et al., 2011). During the wait period between injury and treatment, inflammation in 
the damaged tissues exacerbates the original injury, often leading to extensive fibrosis, increasing 
the possibility of necessary amputation. The standard of care for extremity injury has therefore 
been focused upon limb salvage procedures, utilizing grafts or orthotics in conjunction with 
rehabilitation in attempts to avoid amputation. Limb salvage approaches such as these do not 
address the underlying lack of muscle tissue and therefore, even with this standard of care 
treatment, patients are left with persistent strength and functional deficits that permanently impact 
their quality of life. However, results of clinical cohort studies have shown that restoration of 
contractile, skeletal muscle tissue and preservation of neuromuscular activity in volumetric muscle 
loss (VML) patients can be achieved by implantation of an extracellular matrix (ECM) biologic 
scaffold, which promotes endogenous stem/progenitor cell recruitment when combined with a 
targeted physical rehabilitation protocol (J. Dziki et al., 2016; Dziki et al., 2018). ECM-mediated 
skeletal muscle repair involves a beneficial spatiotemporal macrophage activation state switch 
corresponding to myogenic progenitor cell proliferation and differentiation, a process required for 
a switch from fibrosis to myogenesis (Tidball, 2005; Tidball & Villalta, 2010). Though the promise 
of regenerative rehabilitation protocols using ECM placement and physical therapy have reached 
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clinical cohort studies, to date only incremental improvements in overall patient population have 
been achieved. The present study addresses this shortcoming and aims to accelerate VML recovery 
by identifying a novel mechanistic driver behind the clinical use of ECM-based biomaterials: the 
immunomodulatory effects of ECM-based biomaterials and, more specifically, the effect of ECM 
subcomponents upon inflammation resolution. Results show nanosized vesicles embedded within 
ECM, matrix-bound nanovesicles (MBV) serve as a protected source of matrix-associated 
interleukin-33 (IL-33). MBV embedded in the ECM act as a stable and bioactive source of IL-33 
which supports skeletal muscle regeneration by controlling local inflammation through ST2-
independent macrophage activation towards a pro-remodeling phenotype. Genomic deletion of IL-
33 profoundly alters the macrophage response to injury in an established mouse model of severe 
skeletal muscle injury. il33-/- mice showed a sustained pro-inflammatory macrophage response to 
injury that was absent in wild-type littermates, and culminated in impaired functional recovery 
(i.e. force generation) by 14 days post-injury. Importantly, exogenous provision of IL-33+ MBV 
successfully reduced the M1-like macrophage response to injury observed in untreated il33-/- mice, 
promoting an M2-like:M1-like macrophage phenotype ratio similar to wild-type animals. Taken 
together, these data suggest that MBV and their associated IL-33 cargo may represent a novel 
homeostatic signaling mechanism that contributes to skeletal muscle repair. Furthermore, IL-33-
mediated events may represent an attractive therapeutic target for modulating macrophage 
phenotype following muscle injury. 
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8.2 Introduction 
Skeletal muscle tissue inherently regenerates following injury(Appell, Forsberg, & 
Hollmann, 1988; Baghdadi & Tajbakhsh, 2018; Glass, 2003), a capacity that relies on the 
coordinated recruitment, activation, and differentiation of resident stem/progenitor cells(Tidball, 
2005; Tidball & Villalta, 2010). Spatiotemporal control of this stem/progenitor cell activity is 
orchestrated in large part by several  infiltrating immune cell types, which are themselves regulated 
by microenvironmental cues(Glass, 2003; Mammoto et al., 2013). The injury response begins with 
a robust infiltration of neutrophils within the first hours of injury, followed by the recruitment of 
pro-inflammatory, ‘M1-like’ macrophages. These pro-inflammatory macrophages promote 
expansion of the activated myoblast pool via the cytokine and chemokine effects of their secretome 
upon resident stem/progenitor cells(Novak et al., 2014; Tidball, 2005). These pro-inflammatory 
macrophages transition to a pro-regenerative, ‘M2-like’ macrophage phenotype between 4- and 
14-days post-injury(Tidball, 2005). The secretome of the M2-like macrophages promotes 
myoblast differentiation into myotubes, in conjunction with the appearance of adaptive immune 
cells(B. Deng et al., 2012; J. L. Dziki et al., 2016; D. Ruffell et al., 2009; Tidball, 2005). It has 
been suggested that phagocytosis of apoptotic neutrophils may contribute to this macrophage 
phenotype transition, but a definitive mechanism for this process has not been convincingly 
established(Ariel & Serhan, 2012). The spatiotemporal switch from M1-like to M2-like 
macrophages is required for functional muscle repair(L. Arnold et al., 2007; Brown, Londono, et 
al., 2012), and a failure to transition has been associated with delayed healing(B. Deng et al., 2012).  
The central role of macrophages in skeletal muscle healing is exemplified in the aberrant 
immune response observed following volumetric muscle loss (VML) injuries. The endogenous 
repair processes that underly skeletal muscle’s characteristically regenerative response to injury 
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are overwhelmed in VML. Sustained pro-inflammatory signaling, a disrupted native extracellular 
matrix architecture, and reduced satellite cell availability all contribute to morbidity in VML 
patients. As a result, tissue engineering strategies for the repair of VML must, at a minimum, 
promote restoration of the skeletal muscle stem/progenitor cell niche and modulation of immune 
cell phenotypes. In particular, the M1-like to M2-like macrophage phenotype transition is notably 
absent, replaced instead by a persistent pro-inflammatory response that results in fibroadipogenic 
tissue deposition(Dziki et al., 2018; J. L. Dziki et al., 2016). It has been shown that the ratio of 
pro-inflammatory to pro-regenerative macrophages during the early post-injury phase is a 
predictor of clinical outcomes(Brown, Londono, et al., 2012). Preclinical studies show that 
acellular bioscaffolds composed of extracellular matrix (ECM) effectively promote an M1-like to 
M2-like macrophage phenotype transition in vivo with associated improvements in functional 
outcomes(J. L. Dziki et al., 2016; L. Huleihel, J. L. Dziki, et al., 2017; Huleihel et al., 2016; B. M. 
Sicari, J. L. Dziki, et al., 2014). Clinical cohort studies using ECM bioscaffolds to treat VML 
resulted in an average ~37% increase in force production and ~250% increase in functional 
activity(J. Dziki et al., 2016). Stated differently, ECM bioscaffolds promote endogenous functional 
repair of skeletal muscle and an associated robust immunomodulatory response through direct and 
indirect mechanisms. 
Despite its known immunomodulatory properties, the bioactive component(s) within ECM 
that promote an M2-like pro-healing macrophage phenotype remain only partially understood. The 
topographical ligand landscape(Grasman et al., 2015), the release of growth factors and 
matricryptic peptides(Agrawal et al., 2010; Agrawal, Kelly, et al., 2011), and mechanical 
cues(Mammoto et al., 2013) have all been shown to play a role in ECM-mediated cell behavior. 
Recently, an extracellular vesicle subtype associated with the ECM, identified as matrix-bound 
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nanovesicles (MBV), was shown to recapitulate many of the immunomodulatory effects of the 
parent ECM on macrophage phenotype(L. Huleihel, J. G. Bartolacci, et al., 2017). MBV show 
tissue-specific profiles of miRNA, lipid, and protein cargo, many of which could plausibly 
contribute to the influence of MBV on target cell bioactivity(L. Huleihel, J. G. Bartolacci, et al., 
2017; Huleihel et al., 2016; George S. Hussey et al., 2020; Saldin et al., 2019; van der Merwe et 
al., 2017). Specifically, MBV are a rich source of extracellular IL-33, an IL-1 superfamily member 
cytokine with known roles in skeletal muscle healing(G. S. Hussey et al., 2019; W. Kuswanto et 
al., 2016). Of note, MBV-associated IL-33 effects upon macrophage phenotype are independent 
of the ST2 receptor(G. S. Hussey et al., 2019), the canonical cognate receptor, suggesting an 
alternative intracellular signaling pathway with distinctive effects upon cell behavior. 
The present study describes a role for MBV in ECM bioscaffold-mediated constructive 
tissue remodeling and homeostatic repair processes. Previous studies suggest that IL-33, signaling 
through the ST2 receptor, promote accumulation of regulatory T cells that contribute to 
endogenous repair processes(W. Kuswanto et al., 2016). However, results of the present work 
show that extracellular IL-33 plays a central role in modulation of the macrophage response during 
muscle healing. In vivo, genomic deletion of IL-33 profoundly altered the macrophage response 
and impaired functional recovery from acute muscle injury. Importantly, macrophage phenotype 
and functional recovery could be partially restored following exogenous delivery of IL-33+ MBV. 
Together, these data show that IL-33, an interleukin most commonly identified as a pro-
inflammatory alarmin, can promote an anti-inflammatory macrophage phenotype that contributes 
to functional skeletal muscle repair when delivered in the form of MBV. 
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8.3 Materials and Methods 
8.3.1 Animal Use 
Congenic C57BL/6-arg1gfp and C57BL/6-il33-/-arg1gfp mouse strains were raised in 
accordance with the University of Pittsburgh Institutional Animal Care and Use Committee 
guidelines. Colony maintenance, including bedding and cage changes, was provided by the 
University of Pittsburgh Division of Laboratory Animals in Research on a weekly basis. Litters 
were weaned at 21 days of age and intermittent genotyping of all breeding pairs was performed to 
maintain the integrity of the strains. Animals were used as experimental subjects or as a source of 
tissues and cells. For animals undergoing surgical manipulation, pain management was achieved 
using buprenorphine hydrochloride twice daily for 3 days and infection prevention was maintained 
for 3 days using Baytril (Henry Schein). Euthanasia was performed in accordance with guidelines 
using 20-30% v/v inhaled CO2 for 8-10 minutes until signs of life were no longer detectable and 
death was ensured using cervical dislocation.  
 
 
8.3.2 MBV Isolation and Quantification 
Small intestine was isolated from experimentally naïve C57BL/6 and C57BL/6-il33-/- mice 
between 6-8 weeks of age. Contents were removed manually and the intestine cut into ~3 cm long 
segments, placed in phosphate buffered saline (PBS) (Sigma, St. Louis, MO) and placed on a 
rotating tube rack for 6h to remove remnant blood. The intestines were then removed and the 
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external muscular layers removed by manual scraping and placed in fresh PBS for 1h. PBS was 
then removed and the resulting tissue was subsequently digested overnight at 37oC while rotating 
using 0.01 mg/mL solution of Liberase DL (Sigma) in a buffer consisting of 50 mM tris (pH 8), 5 
mM CaCl2, and 200 mM NaCl. Crude digest mixtures were then subjected to progressive 
centrifugation: 3x10 minutes at 500 xg, 3x20 minutes at 2500 xg, and 3x30 minutes at 10000 xg. 
Digests were then passed through a 0.22 mm syringe filter and ultracentrifugated at 100,000xg for 
2h at 4 oC (Beckman Coulter Optima L-90K ultracentrifuge, Brea, CA). Following 
ultracentrifugation, supernatants were discarded and the pellet resuspended in 1 mL of particle-
free PBS and further purified via size exclusion chromatography with a 10 cm column height and 
1 mL fraction volume (Sepharose CL-2B beads, Sigma). Purified MBV, contained in fractions 3-
5, were collected and concentrated using 100 kDa molecular weight cut-off spin columns 
(Millipore Sigma, Burlington, MA). Particle concentration of each sample was determined using 
a NanoSight particle counter equipped with nanoparticle tracking analysis (NTA, NanoSight, 
Salisbury, UK). 
8.3.3 Cardiotoxin Injury Model 
Cardiotoxin muscle injury model was used as previously described(Hardy et al., 2016). 
Briefly, a small incision was made in the skin overlying the tibia of anesthetized mice in the supine 
position. Blunt dissection of the adjacent subcutaneous region was used to expose the tibialis 
anterior (TA) muscles and 25 ml of 10 µM cardiotoxin (Naja Pallida, Sigma Aldrich) was 
administered to the left and right hindlimbs. The incision was subsequently closed using resorbable 
sutures and the animals allowed to recover. 
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8.3.4 Immune Cell Analysis by Flow Cytometry 
Isolated infiltrating leukocytes were incubated with heat-inactivated goat-serum (5%) to 
block FcR, and then labelled with different combinations of fluorochrome-conjugated antibodies 
(BD Bioscience, Biolegend, eBioscience or MD Biosciences) to distinguish myeloid and T cell 
populations (CD45(30-F11), CD45.2(104), F4/80(BM8), CD8(53-6.7), CD38(90/CD38), 
CD4(RM4-5), Foxp3(FJK-16S), Ly6C(AL-21), B220(RA3-6B2), iNOS(CXNF7), 
CD206(MR5D3), CD3(17A2), CD11b(M1/70), MHCII(2G9), Ly6G(1A8), CD11c(N418), 
ST2(U29-93,DIH9), EGR2(erongr2), GFP(FM264G)). Data was acquired with an Aurora and 
LSRFortessa flow cytometer (BD, Bioscience) and analyzed using FlowJo, Version 10.1 (Tree 
Star). 
8.3.5 Skeletal Muscle Immunolabeling 
Harvesting of the tibialis anterior was performed at 3, 7, and 14-day post-injury. Each 
muscle was fixed in 10% neutral-buffered formalin and embedded in paraffin. 5 mm sections were 
cut and mounted onto glass slides. Slides were deparaffinized using xylene and ethanol gradients 
(100-70% EtOH). Slides were stained with Masson’s trichrome staining or subjected to antigen 
retrieval and immunolabeling. Immunofluorescence was performed on serial sections for each 
subject and timepoint to assess the phenotypes of immune and satellite cell populations. After 
deparaffinization, the slides were placed in citrate antigen retrieval buffer (10 mM citric acid 
monohydrate, pH 6.0), microwaved at 100% power for 45 seconds, followed by 15 minutes at 20% 
power. The slides were then cooled in copper sulfate solution (10mM CuSO4, 50mM ammonium 
acetate, pH 5.0) for 20 minutes. Sections were then rinsed three times in Tris buffered saline/Tween 
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20 solution (TBST) and then incubated for 1 hour at room temperature in blocking buffer 
containing 0.1% Triton-X 100, 0.1% Tween, 2% goat serum, and 1% bovine serum albumin. The 
blocking buffer was then removed and the sections were incubated overnight at 4oC in a humidified 
chamber with 1:200 rabbit-anti-CD11b (Abcam), a pan-macrophage marker. Following overnight 
incubation, each slide was washed in TBST for 3x2 minutes. A 1:200 solution of goat-anti-rabbit 
horseradish peroxidase conjugated secondary antibody (DAKO) in blocking buffer was 
subsequently applied and microwaved at 40% power for 3 minutes in a humidified chamber and 
allowed to cool for 2 minutes before washing in TBST. After washing, sections were incubated 
with a 1:200 solution of red fluorescent HRP substrate (OPAL 570, Perkin Elmer) in 1x 
Amplification Diluent (Perkin Elmer) for 10 minutes and then washed in TBST. To remove anti-
CD11b and anti-rabbit antibodies, sections were subjected to a second round of antigen retrieval 
in citrate antigen retrieval buffer, followed by cooling copper sulfate solution, and blocked as 
described above. For each slide, one section was incubated with a 1:200 solution of rabbit-anti-
iNOS antibody (Invitrogen) in blocking buffer, and one section was incubated with a 1:200 
solution of rabbit-anti-RELMa (PeproTech). Slides with the primary antibodies were then placed 
on a raised waterbath and microwaved at 40% power for 3 minutes, followed by 2 minutes of 
cooling. Slides were then washed in TBST solution and a 1:200 solution of goat-anti-rabbit HRP-
conjugated secondary antibody was placed on the sections. Slides with secondary antibody 
solutions were then placed in the waterbath and microwaved at 40% power for 3 minutes, followed 
by 2 minutes of cooling. After cooling, slides were washed in TBST and a 1:200 solution of green 
fluorescent HRP substrate in 1x Amplification Diluent (520 Opal, Perkin Elmer) was placed over 
each section and incubated in a dark humidified chamber for 10 minutes at room temperature. The 
sections were then washed in TBST, incubated with 4′,6-diamidino-2-phenylindole (DAPI) 
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nuclear counterstain for 5 minutes. The sections were washed with TBST and subsequently 
mounted for imaging by fluorescence microscopy.  
8.3.6 In Situ Contractile Testing 
14 days post-cardiotoxin injury (POD-14), in situ contractile testing protocol was 
implemented to evaluate the muscle’s force producing capacity, 14 days following injury(Sahu et 
al., 2018; C. Zhang et al., 2016). Contractile testing was performed using an in situ testing 
apparatus (Model 809B, Aurora Scientific Inc, Canada), stimulator (Model 701C, Aurora 
Scientific Inc, Canada), and force transducer (Aurora Scientific Inc, Canada). Animals were 
anesthetized with 2% isoflurane. Through a small incision lateral to the knee, the animal’s peroneal 
nerve was isolated and exposed. The Achilles tendon was surgically cut using a scalpel prior to 
placing the animal supine on a 37oC-heated platform. The foot being tested was taped to the 
footplate with a surgical cloth tape, with the ankle position at 20o of plantarflexion (the position 
that we determined to result in the greatest force output). The needle electrodes were inserted 
beneath the skin, over the peroneal nerve. The single-twitch protocol was implemented to evaluate 
muscle cross-sectional area (CSA), muscle peak twitch, time to peak twitch, and half-relaxation 
time. Next, a force-frequency protocol was implemented by eliciting stimulations at 10, 30, 50, 
80, 100, 120, 150 Hz, with a 2-minute rest between each contraction. Note that the output from the 
machine is torque (mN-m). Force was calculated by dividing the torque by the length of the foot 
plate (0.03 m). The mean CSA of the muscle was obtained using the formula: Mean CSA= (weight 
of TA in mg/ (length of TA in mm * density of the muscle)), where muscle density is assumed to 
be 1.06 g/cm3. The specific force was then obtained by dividing the force by the mean CSA. The 
TA muscles were subsequently harvested and fixed in formalin for histological analysis.  
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8.3.7 Exogenous MBV Delivery 
2 days post-cardiotoxin injury (POD-2), il33-/- mice were anesthetized using 2% inhaled 
isoflurane and the original incision used for CTX injection was reopened. 30 mL of IL-33+ MBV 
were gradually delivered to both hindlimb TAs intramuscularly while retracting the needle from 
distal to proximal tendon. Pressure was applied to prevent leakage and the skin was subsequently 
closed with resorbable sutures and the animals were allowed to recover under supervision on a 
heated surface.  
8.3.8 Statistical Analysis 
Dependent variables were assessed using one or two-way ANOVAs, or independent 
samples t-tests. Tukey’s HSD post-hoc means comparisons were performed with an applied alpha 
of 0.05. Data are presented as means + SEM unless otherwise specified. Statistical testing was 
performed using Graphpad Prism 8 (Graphpad, La Jolla, CA).   
8.4 Results 
8.4.1 Genomic Deletion of IL-33 Results in an Early Pro-Inflammatory Macrophage 
Response to Muscle Injury Associated with Reduced Functional Recovery from 
Injury 
Cardiotoxin (CTX) injury of the anterior TA compartment musculature of mice between 
6-8 weeks of age was used to induce a reproducible, regenerative muscle injury. The injured 
skeletal muscle of CTX-treated animals was harvested at sequential timepoints, namely post-
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operative day (POD) 3, POD-7, and POD-14. The mononuclear immune cells present in injured 
muscle at these timepoints were separated by FACS. Results showed that the CD45+CD3-B220-
CD11b+Ly6G-F480+iNOS+ M1-like macrophage population was nearly 2x was greater in muscle 
tissue from il33-/- mice than il33+/+ littermates at POD-3 (10% vs. 5%, respectively, p < 0.01). The 
macrophage infiltrate at POD-7 was also predominantly M1-like in il33-/- mice (~20%) compared 
to il33+/+ mice (~15%), however these differences were not statistically significant (Figure 8). 
Notably, a population of CD11b+MHCII+, with variable expression of ST2, antigen presenting 
cells were absent macrophages (Figure 8), across two separate experiments, in il33-/- compared to 
il33+/+ mice (p < 0.01). Finally, CD45+CD3+B220-CD4+Ly6G-FoxP3+ST2- TREG cells were 





Figure 8. Genomic deletion of IL-33 promotes increased inflammatory macrophage presence and decreased 
ST2+ Treg accumulation. Cardiotoxin muscle injury surgeries were performed on IL-33 expressing Arg-1GFP 
(WT B6) or IL-33 deficient Arg-1GFP B6 (KO B6). On POD3 and POD7, injured TA muscles were harvested, and 
infiltrating leukocytes were assessed by flow cytometric analysis. (A-B) Representative dot plots and frequency for 
inflammatory macrophages in the CD45+CD3-B220-CD11b+Ly6G- gate. (C-D) Representative dot plots and 
frequency for ST2+ Treg in the CD45+CD3+B220-CD4+ gate. All p-values were calculated using one-way 
ANOVA. *P<0.05, **P<0.01, ***P<0.005, ****P<0.001. 
 
Flow cytometry results were corroborated by immunolabeling in situ. Macrophages 
comprised ~5% of all cells within the tissue regardless of strain, however the phenotypic 
composition of the macrophage population was strikingly different. CD11b+Fizz1+ M2-like 
macrophages represented a greater percentage of macrophages at all timepoints in il33+/+ mice 
compared to their il33-/- counterparts (p < 0.001, p < 0.001, and p < 0.05 for POD-3, POD-7, and 
POD-14, respectively). Further, the macrophage infiltrate in il33-/- mice consisted of 
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CD11b+iNOS+ M1-like macrophages to a much greater extent than il33+/+ mice at POD-3 and 
POD-7 (p < 0.01, and p < 0.05, respectively, Figure 9). 
 
 
Figure 9. IL-33 deletion reduces M2-like:M1-like ratio at all timepoints. (A) Quantification of immunolabeling 
for CD11b+Fizz1+ M2-like macrophages at POD-3, 7, and 14 (N = 3 biological replicates for POD-3 and 7, N = 6 
for POD-14, n > 5 images per replicate). (B) Quantification of CD11b+iNOS+ M1-like macrophages at POD-3, 7, 
and 14 (N = 3 biological replicates for POD-3 and 7, N = 6 for POD-14, n > 3 images per replicate). (*p<0.05, 
**p<0.01, ***p<0.001, p values were calculated using two-tail student’s t-tests). 
 
In situ contractile testing results show that loss of IL-33 severely impacts force generation 
after cardiotoxin injury, with il33-/- mice generating less specific and peak specific force (p < 0.05 
and p < 0.01, respectively, Figure 10A-B). Further, the time to maximum contraction was shorter 
in il33+/+ mice, with a similar trend in the half relaxation time, suggesting that the composition of 
regenerated fibers may be skewed toward Type 2A fast-twitch muscle fibers in il33-/- mice (p < 
0.01, Figure 10C-D), rather than the Type 2B prevalent in the TA of wild-type animals. 
Unexpectedly, the physiologic CSA of il33-/- animal TAs was less than that measured in il33+/+ 
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littermates (p < 0.01). Taken together, these data show that depletion of IL-33 results in an inferior 
regenerative response compared to IL-33 containing animals. 
 
Figure 10. IL-33 is required for functional repair of injured skeletal muscle. (A-B) In situ contractile testing of 
TA tetanic force generation as a function of frequency at POD-14 post-cardiotoxin injury shows significant 
reductions in functional output in mice lacking IL-33 (p<0.05, n = 6). (C-D) Twitch response of TA muscles at 
POD-14 after muscle injury shows that healed muscle of il33-/- mice had significantly different properties compared 
to il33+/+ littermates (p < 0.01, n = 6). (D) Comparison of the computed physiologic cross-sectional area of TA 
muscles of il33-/- vs il33+/+ mice (p < 0.01, n = 6). * p < 0.05, ** p < 0.01, Force-Frequency analysis was analyzed 
by repeated measures two-way ANOVA with post-hoc testing, all other comparisons were performed using 
independent samples t-tests. 
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8.4.2 Exogenous Provision of MBV-Associated IL-33 Reduces M1-like Macrophage 
Response to Muscle Injury, Improves Function, and Normalizes Physiologic Cross-
Sectional Area 
To determine if MBV and their associated cargo play a role in modulation of macrophage 
phenotype in vivo, IL-33+ MBV were intramuscularly administered to the tibialis anterior muscles 
of cardiotoxin-injured il33-/- mice on POD-2. Results of macrophage immunolabeling show that 
injection of 5E10 MBV resulted in a peak specific force that was increased compared to their 
untreated il33-/- counterparts (p < 0.05) by POD-14 (Figure 11A). Twitch response analysis 
revealed that the time to half relaxation and physiologic cross-sectional area were significantly 
reduced in treated animals compared to untreated il33-/- littermates (p < 0.0001 and p < 0.01, 




Figure 11. Exogenous provision of IL-33+ MBV improves functional recovery. (A) In situ contractile testing of 
TA tetanic force generation at POD-14 post-cardiotoxin injury shows improved peak force production following 
exogenous provision of IL-33+ MBV compared to untreated counterparts (p < 0.05, n = 5 (untreated il33-/-) and n = 
6 (IL-33+ MBV-treated animals, one-tailed t-test) (B) Twitch response of TA muscles at POD-14 after muscle injury 
shows that healed muscle of untreated il33-/- mice and il33-/- mice treated with IL-33+ MBV had significantly 
different half relaxation times and physiologic cross-sectional areas (p < 0.0001 and p < 0.01, respectively, one-tail 
t-test). **** p < 0.0001, ** p < 0.01, *p < 0.05. 
 
Upon completion of the functional testing regimen, TA muscles used for in situ contractile 
testing were harvested and used for immunolabeling of macrophage infiltrate, activated satellite 
cells and FoxP3 TREG cells. Results show that IL-33
+ MBV delivery results in significantly more 
macrophages overall and fewer CD11b+iNOS+ M1-like macrophages than in untreated il33-/- mice 
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(p < 0.01 and p < 0.05, respectively). Finally, there were significantly fewer CD11b+Fizz1+ 
macrophages in IL-33+ MBV-treated animals compared to il33+/+ mice (p < 0.05, Figure 12). 
 
 
Figure 12. Exogenously delivered IL-33+ MBV increased total macrophages and partially normalize M2:M1 
ratio. (A) Quantification of immunolabeling against CD11b+iNOS+ M1-like macrophage population shows 
significant reductions in total iNOS+ macrophages as a result of MBV administration (N = 6, one-way ANOVA). 
(B) Quantification of immunolabeling against CD11b+Fizz1+ M2-like macrophage population shows MBV do not 
increase total Fizz1+ cells (N = 6, one-way ANOVA). (C) Total CD11b+ macrophages were significantly elevated 
following MBV administration (N = 6, one-way ANOVA). **p < 0.01, *p < 0.05. 
 
8.5 Discussion 
IL-33 has long been considered to be a nuclear cytokine that functions as an alarmin upon 
necrotic cell death(Cayrol & Girard, 2014). Following loss of cell integrity, IL-33 is released to 
the extracellular space where it is cleaved by proteases to produce active soluble IL-33 that 
complexes with the ST2 receptor on infiltrating immune cells(Cayrol et al., 2018). In turn, MyD88 
and p65 are activated with pro-inflammatory consequences(Milovanovic et al., 2012). The IL-
33/ST2 axis is essential for the recruitment and activation of TREG cells in skeletal muscle 
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healing(W. Kuswanto et al., 2016); however, recent reports show that MBV-associated IL-33 may 
mediate macrophage phenotype through an as yet undetermined mechanism(G. S. Hussey et al., 
2019). Results of the present study suggest that MBV-associated IL-33 promotes a marked 
reduction in pro-inflammatory macrophage accumulation in vivo, which has clear implications for 
skeletal muscle repair.  
In vivo results show that genomic deletion of IL-33 is associated with a profound pro-
inflammatory state following skeletal muscle injury, especially in the acute post-injury phase. 
Notably, the il33-/- macrophage response to injury was comprised predominantly of pro-
inflammatory M1-like macrophages, with lesser numbers of pro-reconstructive M2-like 
macrophages than their il33+/+ littermates. As a consequence of this M2-like:M1-like distribution 
imbalance, il33-/- mice showed dysregulated satellite cell activation, culminating in reduced 
functional recovery from injury by POD-14. Moreover, twitch responses revealed faster times to 
maximum contraction in IL-33 deficient mice, suggesting enrichment in Type 2A fibers rather 
than the Type 2B fibers prevalent in wild-type mouse TA (Kammoun, Cassar-Malek, Meunier, & 
Picard, 2014). These results suggest that macrophages not only interact differentially with satellite 
cells depending on their phenotype, but that appropriate macrophage phenotype transition is 
necessary for site-appropriate skeletal muscle fiber subtyping following injury. Results of MBV-
treated animals also suggest that suppression of the pro-inflammatory macrophage population 
alone is not sufficient to fully recapitulate the wild-type healing response, and promotion of an 
M2-like phenotype may be required for complete restoration of muscle function. 
Although ECM bioscaffolds have been repeatedly shown to promote an M2-like 
macrophage response in mouse models of muscle injury(J. L. Dziki et al., 2016; Dziki, Wang, et 
al., 2017; K. Sadtler, K. Estrellas, et al., 2016; Wolf et al., 2019), the present study offers the first 
 104 
evidence that a single component of the ECM can modulate macrophage phenotype in vivo 
independent of the parent biomaterial. These data strongly suggest that multiple mechanisms of 
action exist for IL-33 in the context of muscle healing, namely, an ST2-independent effect on 
macrophage phenotype and a previously reported ST2-dependent mechanism on TREG cells (W. 
Kuswanto et al., 2016; Panduro et al., 2018). Evidence for an ST2-independent, direct effect on 
macrophage phenotype stems from the observation that the CD11b+iNOS+ macrophage population 
was reduced in the IL-33+ MBV-treated animals compared to untreated counterparts. Further, 
MBV treatment resulted in an increased recruitment of macrophages overall, suggesting that 
macrophages are a primary target of MBV, and their cargo have an impact on the phenotype of 
target cells. 
Previous work has shown that macrophage phenotype is plastic and can transition from 
M1-like macrophages toward an M2-like macrophage phenotype in vitro upon stimulation with 
MBV(Dziki, Wang, et al., 2017; L. Huleihel, J. L. Dziki, et al., 2017; H. Liu et al., 2015), however 
the bioactive cargo responsible for this effect remained unidentified. The present study shows that 
a single MBV cargo component, IL-33, can modulate macrophage phenotype in vivo. The 
regulatory role of TREG cells is likely synergistic with the functions of MBV-associated IL-33 
observed in the present work, although given the effect that MBV and their cargo play at early 
timepoints following injury and the low frequency of TREG cells until ~7-14 days, it is plausible 
that macrophages initiate remodeling. MBV were delivered two days after injury because previous 
studies showed a robust macrophage infiltration at this time and these M1-like, pro-inflammatory 
macrophages would have had an opportunity to promote expansion of the MuSC pool. The dose 
of 5E10 MBV/muscle was based on the observation that 1E9 MBV/mL was sufficient to activate 
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2E6 macrophages in vitro, but optimization of delivery dose and dose regimen will be important 
avenues of future work.  
In summary, findings of the present study show the critical role for IL-33 in skeletal muscle 
healing. IL-33, contained within MBV, is required for the promotion of a constructive macrophage 
phenotype via an ST2-independent mechanism. Changes in macrophage phenotype at POD-2 were 
predictive of functional tissue remodeling outcomes at POD-14 and the healing deficiencies noted 
in il33-/- mice could be rescued by provision of IL-33-containing MBV. Taken together, these data 
suggest MBV and their IL-33 cargo are required for ECM-mediated immunomodulation and 
functional tissue remodeling. 
8.6 Conclusion 
The results of the present work substantiate the relevance and importance of IL-33 
signaling in MBV-mediated, and by extension ECM bioscaffold-mediated, macrophage phenotype 
modulation in the context of skeletal muscle healing. Further, this work demonstrates that 
modulation of macrophage phenotypes in response to skeletal muscle injury is a viable approach 
that may narrow the gap between existing therapies and complete skeletal muscle regeneration 
with important implications for cytokine signaling and offers new avenues of investigation for 
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9.0 Summary of Milestones and Future Directions 
The central hypothesis addressed in this thesis is that MBV-associated IL-33 promotes a 
macrophage phenotype transition that supports constructive remodeling of skeletal muscle tissue 
by a non-canonical mechanism. The following milestones were achieved: 
 
Milestone 1: The macrophage phenotype and muscle stem cell response to IL-33 was 
determined. 
Summary Milestone 1: ECM bioscaffolds treatment of skeletal muscle injury promotes a 
pro-inflammatory to pro-healing macrophage phenotype transition, which is notably absent in 
untreated cases of critically-sized injuries like volumetric muscle loss, and this switch is 
subsequently followed by an increase in functional tissue remodeling and functional output. The 
mechanism(s) underlying this macrophage phenotype transition, however, are poorly understood. 
Recent studies have shown that MBV recapitulate the effects of whole ECM on macrophage 
phenotype, but a causal mechanism for this effect was not described. Chapter 7 clearly shows that 
IL-33, bound within MBV, are central to MBV-mediated macrophage phenotype activation and 
for the secretion of pro-myogenic molecules, including macrophage-derived exosomes.  
Future Directions Milestone 1:  The present study was incapable of testing the effects of 
ECM deficient in MBV due to the inability to extract MBV from the parent ECM bioscaffold 
without fundamentally destroying the integrity of the material. As such, investigations of MBV 
biogenesis may offer new insights that could allow for the production of MBV-depleted ECM in 
order to test the contribution of MBV to whole ECM bioscaffold-mediated macrophage phenotype 
activation and constructive tissue remodeling. Further, the macrophages and muscle stem cells 
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used in these investigations were all derived from young mice. It is possible that MBV, whose 
cargo may also change as a function of aging, elicit a different response in cells derived from older 
animals. Interrogation of the role of MBV in aging may offer new mechanistic insights to reduced 
muscle healing and sarcopenia of aging. 
 
Milestone 2: The mechanism of MBV uptake by macrophages and the subcellular 
localization of MBV-associated IL-33. 
Summary Milestone 2: ECM-mediated constructive tissue remodeling has been associated 
with a modulation of macrophage phenotype at early time points and a growing body of work 
suggests that MBV contribute to this process. In general, MBV treatment promotes a pro-
remodeling, M2-like macrophage phenotype and suppression of pro-inflammatory markers as 
evidenced through gene expression, surface marker and protein expression, and functional activity 
(Appendix 10.1,10.2). However, the molecules and mechanisms underlying this effect have not 
been described. Chapter 7 and 8 offer show that IL-33 is required for the promotion of an MBV-
mediated M2-like macrophage phenotype, in an ST2-independent manner, through endocytic 
delivery of functional IL-33, which forms protein-protein interactions in the nucleus and modulates 
gene expression as a function of time. 
Future Directions Milestone 2: An endocytic uptake mechanism is commonly utilized by 
ligand-activated receptors. Studies have also shown proteinase K treatment of MBV to remove 
surface antigens, reduces uptake by macrophages (manuscript under review). It is plausible, then, 
that molecules on the lipid membrane of MBV mediate target cell specificity and non-destructive 
uptake. It is also possible that molecules on the surface of MBV mediate endocytic vacuole release. 
Future investigations should focus on identification of the surface antigens on MBV that mediate 
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this process, identification of macrophage receptors that may mediate their uptake, and optimize 
isolation methods for the preservation of MBV surface antigens. Further, results shown in Chapter 
7 suggest that MuSC are not a target of MBV, but this work did not quantify MBV uptake by these 
cells. Future experiments should focus on characterizing the cell types for which MBV have an 
affinity, for example through the use of co-culture systems. Results of Chapter 8 also suggest that, 
once inside target cells, IL-33 translocates to the nucleus where it forms protein-protein 
interactions. Characterization of these intracellular binding partners would help further 
understanding IL-33 biology and could provide new avenues for therapeutic intervention to 
modulate immune cell function. 
 
Milestone 3: The effect of IL-33 deletion on macrophage phenotype and functional 
recovery in a mouse model of acute skeletal muscle injury, and the ability of MBV to modulate 
macrophage phenotype in vivo were determined.  
Summary Milestone 3: The use of ECM bioscaffolds in preclinical animal studies and in 
clinical cohort studies shows that their application supports a macrophage phenotype transition 
that is critical to downstream functional remodeling outcomes, but the component of the ECM that 
mediates this effect is poorly understood. Chapter 9 shows that IL-33 deletion results in a 
profoundly altered macrophage response to skeletal muscle injury at early timepoints and impairs 
functional muscle recovery. These events were also associated with a reduced accumulation of 
FoxP3+ TREG cells, in accordance with previous studies. Further, it is shown that exogenous 
provision of IL-33+ MBV reduce pro-inflammatory macrophage accumulation and improve 
functional recovery by 14d post-cardiotoxin injury compared to untreated il33-/- counterparts. 
These data show that MBV and their associated IL-33 cargo are a critical extracellular mediator 
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of macrophage phenotype and provides mechanistic insight to whole ECM bioscaffold-mediated 
macrophage phenotype transition. 
 
Future Directions Milestone 3:  Results of the present study show that MBV and their cargos 
reduce the expression of M1-associated marker, iNOS, and improve functional recovery in vivo. 
These findings suggest that MBV may be a viable therapeutic intervention for inflammatory-
driven pathology such as psoriasis. Of note, it is interesting that a single dose of MBV resulted in 
a sustained reduction in M1-like macrophages up to 12 days. It is plausible, though untested, that 
this sustained phenotypic modulation could be due to MBV activity on a monocyte progenitor cell, 
or that the macrophage epigenetic landscape has been altered in response to MBV treatment. 
Further study is needed to determine an optimal dose and dose regimen, as well as the in vivo 
cellular targets and tissue distribution of exogenously delivered MBV. Further, it is now well 
accepted that a single macrophage phenotype marker may not fully capture the details of the 
macrophage activation state, and a growing body of literature suggests that macrophages, in 
response to skeletal muscle injury, do not fall into the traditional M1-like or M2-like macrophage 
classifications and are instead a unique subpopulation. Future studies should make use of in vivo 
single cell RNA-sequencing analysis to characterize MBV-treated macrophages in greater detail. 
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Appendix A : Matrix-bound nanovesicles recapitulate Extracellular Matrix effects on 
macrophage phenotype2 
Appendix A.1 Overview 
The early macrophage response to biomaterials has been shown to be a critical and 
predictive determinant of downstream outcomes. When properly prepared, bioscaffolds composed 
of mammalian extracellular matrix (ECM) have been shown to promote a transition in macrophage 
behavior from a proinflammatory to a regulatory/anti-inflammatory phenotype, which in turn has 
been associated with constructive and functional tissue repair. The mechanism by which ECM 
bioscaffolds promote this phenotypic transition, however, is poorly understood. The present study 
shows that matrix-bound nanovesicles (MBV), a component of ECM bioscaffolds, are capable of 
recapitulating the macrophage activation effects of the ECM bioscaffold from which they are 
derived. MBV isolated from two different source tissues, porcine urinary bladder and small 
intestinal submucosa, were found to be enriched in miRNA125b-5p, 143-3p, and 145-5p. 
Inhibition of these miRNAs within macrophages was associated with a gene and protein expression 
profile more consistent with a proinflammatory rather than an anti-inflammatory/regulatory 
 
2 Portions of this chapter were adapted from the following publication:  
Huleihel L, Bartolacci J, Dziki J, Vorobyov T, Arnold B, Scarritt M, Pineda Molina C, LoPresti S, 
Brown B, Naranjo JD, Badylak SF. Matrix-bound nanovesicles recapitulate extracellular matrix effects on 
macrophage phenotype. Tissue Engineering Part A. November 2017.  
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phenotype. MBV and their associated miRNA cargo appear to play a significant role in mediating 
the effects of ECM bioscaffolds on macrophage phenotype. 
Appendix A.2 Introduction 
Biologic scaffolds composed of mammalian extracellular matrix (ECM) have been used in 
a variety of anatomic sites including the gastrointestinal tract(T. J. Keane et al., 2016), body 
wall(Alicuben & DeMeester, 2014), and cardiovascular system(Seif-Naraghi et al., 2013), among 
others, to promote the formation of site appropriate, functional tissue following injury. These 
bioscaffold materials influence the default tissue healing response by mitigating inflammation and 
scar tissue formation(J. L. Dziki et al., 2016; T. J. Keane et al., 2016), promoting an accumulation 
of endogenous stem/progenitor cells at the site of scaffold placement(Agrawal et al., 2012; Beattie 
et al., 2009), and perhaps most importantly, modulating the local innate and adaptive immune 
response(Brown, Londono, et al., 2012; K. Sadtler, K. Estrellas, et al., 2016; B. M. Sicari, J. L. 
Dziki, et al., 2014). Specifically, implantation of ECM bioscaffolds has been shown to enhance 
the ratio of anti-inflammatory/regulatory (M2-like) macrophages to pro-inflammatory (M1-like) 
macrophages at the site of implantation(K. Sadtler, K. Estrellas, et al., 2016). This effect upon 
macrophage phenotype has been positively correlated with constructive and functional tissue 
remodeling outcomes in animal models of soft tissue repair(Brown, Londono, et al., 2012; Valentin 
et al., 2009).   
Macrophage phenotype plasticity is well established(Mantovani et al., 2004) and the 
importance of, in fact necessity of, a transition from a pro-inflammatory to an anti-
inflammatory/regulatory phenotype for normal functional tissue repair has been shown in many 
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different body systems(L. Arnold et al., 2007; Daley, Brancato, Thomay, Reichner, & Albina, 
2010; Mahdavian Delavary et al., 2011; M. Nahrendorf et al., 2007). However, the intercellular 
and intracellular signaling mechanisms responsible for macrophage phenotype transition in normal 
wound healing, tissue homeostasis and development, and biomaterial-mediated tissue repair are 
not fully understood. Reasonable explanations for cell-matrix interactions and the associated 
effects upon cell behavior include integrin-mediated responses to the topographical ligand 
landscape(Mammoto et al., 2013; Ruoslahti, 1996), mechanical cues(Bissell & Aggeler, 1987; T. 
W. Gilbert, Stolz, Biancaniello, Simmons-Byrd, & Badylak, 2005), and release of embedded 
growth factors/cytokines/cryptic peptides from the bioscaffold(Agrawal, Tottey, et al., 2011; 
Reing et al., 2010). While these factors are all suspected to contribute to the bioactivity attributed 
to the ECM, a specific mechanism by which ECM promotes a constructive macrophage phenotype 
has not been established. Recently, the presence of matrix-bound nanovesicles (MBV) within 
ECM bioscaffolds has been reported(Huleihel et al., 2016), and the miRNA cargo within these 
MBV has been associated with essential biologic processes such as normal tissue and organ 
development, inflammation, and immune cell regulation, among others(Adammek et al., 2013; 
Chaudhuri et al., 2011; Cordes et al., 2009; Y. S. Lee, Kim, Chung, Kim, & Dutta, 2005; Parisi et 
al., 2016; Rangrez, Massy, Metzinger-Le Meuth, & Metzinger, 2011; Xin et al., 2009). Three 
miRNA that are preferentially overexpressed in M2-like macrophages(Y. Zhang, Zhang, Zhong, 
Suo, & Lv, 2013) were chosen as targets in the present study and these miRNA have been shown 
to play a role in macrophage functions such as phagocytosis, NO production, and alteration of their 
secretome(Banerjee et al., 2013). The present study investigates the role of MBV in ECM 
bioscaffold-mediated macrophage activation. 
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Appendix A.3 Materials and Methods 
Appendix A.3.1 Chemicals and Reagents 
Pepsin (MP Biomedicals, Santa Ana, CA), collagenase from Clostridium histolyticum 
(Sigma-Aldrich, St. Louis, Missouri), proteinase-K, and RNase A (Thermo Fisher Scientific, 
Waltham, MA) were confirmed by transmission electron microscopy (TEM) to be free of 
contaminating extracellular vesicles. 
Appendix A.3.2 ECM Bioscaffolds Production 
Urinary bladder matrix (UBM) was prepared from market-weight pigs (Tissue Source; 
LLC, Lafayette, IN) as previously described(B. M. Sicari, J. L. Dziki, et al., 2014). Briefly, the 
tunica serosa, muscularis externa, submucosa, and muscularis mucosa were removed by 
mechanical delamination, and the urothelial cells of the tunica mucosa were dissociated from the 
basement membrane by washing with deionized water. The remaining basement membrane and 
the lamina propria (collectively referred to as UBM) were decellularized by agitation in 0.1% 
peracetic acid with 4% ethanol for 2 h at 300 rpm followed by phosphate-buffered saline (PBS) 
and type 1 water washes. UBM was then lyophilized and milled using a Wiley Mill with a #60 
mesh screen. Preparation of small intestinal submucosa (SIS) bioscaffold has been previously 
described(Lantz, Badylak, Coffey, Geddes, & Blevins, 1990). Briefly, jejunum was harvested from 
market-weight pigs (Tissue Source; LLC). The superficial layers of the tunica mucosa, the tunica 
serosa, and tunica muscularis externa were mechanically removed after the jejunum was split 
longitudinally. The tunica submucosa, muscularis mucosa, and basilar portion of the tunica mucosa 
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(stratum compactum) remain intact (collectively referred to as SIS). The tissue was agitated in 
0.1% peracetic acid with 4% ethanol for 2 h at 300 rpm and then extensively rinsed with PBS and 
sterile water. The SIS was then lyophilized and milled using a Wiley Mill with a #60 mesh screen. 
Appendix A.3.3 Enzymatic Digestion of ECM Samples 
Enzymatic digestion was performed by treating each sample (100 mg dry weight) with 
either proteinase K or collagenase (0.1 mg/mL) for 24 h at room temperature in 50 mM Tris (pH 
8), 5 mM CaCl2, and 200 mM NaCl buffer. Pepsin (1 mg/mL) digestion was performed in 0.01 M 
HCl solution for 24 h in room temperature. Before addition of ECM, all enzymatic solutions were 
passed through a 0.22-μm filter (Millipore, Oak Brook, IL). 
Appendix A.3.4 MBV Isolation 
MBV were isolated as previously described175. Collagenase was used for isolating MBV 
that were used for treating cells. Proteinase-K was used for isolating MBV that were used for RNA 
isolation or for visualization by TEM. Enzymatically digested ECM was subjected to successive 
centrifugations at 500 g (10 min), 2500 g (20 min), and 10,000 g (30 min). Supernatant was then 
centrifuged at 100,000 g (Beckman Coulter Optima L-90K ultracentrifuge, Brea, CA) at 4°C for 
70 min. Pellets were washed and suspended in 500 μL of PBS and passed through a 0.22-μm filter 
(Millipore). 
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Appendix A.3.5 MBV Imaging 
TEM imaging was conducted on MBV loaded on carbon-coated grids and fixed in 1% 
uranyl acetate. Grids were imaged at 80 kV with a JEOL 1210 microscope. 
Appendix A.3.6 RNA Isolation 
RNA was isolated from 2 × 106 cells using the miRNeasy Mini Kit (Qiagen, Valencia, CA) 
according to the manufacturer's instructions. Reverse transcription of 500 ng of RNA to cDNA 
was performed via a high-capacity RT kit (ABI, Foster City, CA) according to the manufacturer's 
instructions. RNA was isolated from, at a minimum, 50 μL of MBV using the SeraMir Kit (System 
Biosciences) according to the manufacturer's instructions. Before RNA isolation, MBV samples 
were treated with RNase A (10 μg/mL) (Applied Biosystems, Palo Alto, CA) at 37°C for 30 min 
to degrade any contaminating free RNA that may have remained as a result of the tissue 
decellularization process. RNA concentration was determined using a NanoDrop 
spectrophotometer (NanoDrop, Wilmington, DE). SYBR Green gene expression assays (premade 
sequences, ABI) were used to determine the relative expression levels of the following genes from 
DNA harvested from murine bone marrow-derived macrophages (BMDM): inos, tnf-α, stat1, 
stat2, stat5, irf3, irf4, irf5, il1rn, cd206, tgm2, stat3, stat6, klf4, klf6, fizz-1, arg1, bfkbf3, glut1, 
hif1α, hk3, pgk1, pdk4, rpia, ldha, pck2, g6pc3, and pparδ. Results were analyzed by the ΔΔCt 
method using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) to normalize the results. Fold 
change was calculated using untreated macrophages (M0) as the baseline. Results are displayed in 
a heat map format created by Java Treeview (Oracle, Redwood City, California). TaqMan 
MicroRNA assays (ABI) were used to determine the relative levels of mmu-miR-145-5p, mmu-
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miR-143-3p, and mmu-miR-125b-5p inhibitors. These three miRNAs were found to be enriched 
in MBV and have been suggested as mediators of macrophage activation364,370,372,374,375. 
mmu-SNO-55 was used to normalize the results. 
Appendix A.3.7 RNA Sequencing and Data Analysis 
RNA sequencing and data analysis were performed as previously described175. Briefly, 
small RNA libraries were prepared using Ion Total RNA-Seq Kit version 2, according to the 
manufacturer's instructions. Following bead-based size selection of RNA (10- to 20-nt range), 
cDNA was created. Amplified library was again size-selected using a bead-based method. Library 
size distribution was verified using Agilent Bioanalyzer (Agilent, Santa Clara, CA). The Ion One 
Touch 2 System was used to perform automated emulsion polymerase chain reaction of the 
prepared libraries and templated Ion Sphere Particle enrichment. Sequencing was performed on 
the Ion Proton platform using a single P1 sequencing chip. Obtained data were imported into CLC 
Genomics Workbench 8 (Qiagen). The adaptors were trimmed, and all reads that had two 
ambiguous nucleotides, had a Phred score <30, or were lower than 15 nt, or above 100 nt were 
removed. Conserved reads were then aligned to the human genome (hg38) to verify valid reads. 
Reads were extracted, counted, and then annotated on miRBase v.21 (human genome reference); 
a 2-nt mismatch was allowed per read. Only sequences that matched a mature miRNA were used 
for downstream analysis. 
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Appendix A.3.8 MBV Fluorescent Labeling 
MBV nucleic acid cargo was labeled using Exo-Glow (System Biosciences), according to 
the manufacturer's instructions. Briefly, 500 μL of resuspended MBV was labeled with Exo-Glow 
and incubated at 37°C for 10 min. ExoQuick-TC (100 μL) was added to stop the reaction, and 
samples were placed on ice for 30 min. Samples were then centrifuged for 10 min at 14,000 g. The 
supernatant was removed and the pellet was resuspended with 500 μL of 1 × PBS, and 50 μL of 
this MBV suspension was added to BMDM cell culture. The cells were cultured for 4 h, and the 
transfer of the MBV cargo to the cells was determined by imaging using a 100 × objective and 
Axio Observer Z1 microscope. 
Appendix A.3.9 Cell Culture 
Murine BMDM were isolated and characterized as previously described319. Briefly, bone 
marrow was harvested from 6- to 8-week-old C57bl/6 mice. Harvested cells from the bone marrow 
were washed and plated at 1 × 106 cells/mL and were allowed to differentiate into macrophages 
for 7 days in the presence of macrophage colony-stimulating factor (MCSF) with complete 
medium changes every 48 h. 
Appendix A.3.10 Macrophage Activation 
Macrophages were activated for 24 h with one of the following: (1) 20 ng/mL interferon-γ 
(IFNγ) and 100 ng/mL lipopolysaccharide (LPS) (Affymetrix eBioscience, Santa Clara, CA; 
Sigma Aldrich) to promote an MIFNγ+LPS phenotype (M1-like), (2) 20 ng/mL interleukin (IL)-4 
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(Invitrogen) to promote an MIL-4 phenotype (M2-like), (3) 250 ug/mL of UBM-ECM, or SIS-ECM 
to promote an MECM phenotype, or (4) 25 μg/mL of UBM-MBV or SIS-MBV to promote an 
MMBV phenotype. The concentration of MBV was determined by bicinchoninic acid assay. 
Pepsin (1 mg/mL) and collagenase (0.1 mg/mL) were used as baseline controls for ECM and MBV, 
respectively. After the incubation period at 37°C, cells were washed with sterile PBS and fixed 
with 2% paraformaldehyde (PFA) for immunolabeling, or harvested with TRIzol lysis reagent 
(Thermo Fisher) for protein/RNA assessment, respectively. Macrophage function was evaluated 
by assays for phagocytosis and NO production. 
Appendix A.3.11 Transfection 
BMDM were transfected with 50 nM mmu-miR-154-5p, mmu-miR-143-3p, and mmu-
miR-125b-5p inhibitor or a cocktail mix of the inhibitors (Thermo Fisher), as well as a scrambled 
negative control (Thermo Fisher), using Lipofectamine RNAiMAX (Thermo Fisher) according to 
the manufacturer's instructions. miRNA inhibitors were transfected for 4 h in Opti-MEM media. 
Cells were then washed and incubated overnight with Dulbecco's modified Eagle's medium 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (P/S). 
Appendix A.3.12 NO Quantification 
Following 24 h of treatment with test articles, macrophage supernatants were transferred 
to a 96-well plate and frozen at −80°C. Fifty microliters of samples or internal assay standards 
consisting of sodium nitrite from 100 to 1.56 μM in a 1:2 serial dilution was added to the plate. 
The wells were treated with 50 μL of 1% sulfanilamide in 5% phosphoric acid for 10 min, followed 
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by addition of 50 μL of 0.1% N-1-napthylethylenediamine dihydrochloride in water for 10 min. 
The wells were then read at 540 nm and compared to the standard curve. Cells were counted using 
Cell Profiler software using 4’6-diamidino-2-phenylindole (DAPI) nuclear staining. NO values 
were normalized to the number of cells per well. 
Appendix A.3.13 Phagocytosis Assay 
Following 24h of treatment with the test articles, macrophages were incubated with the 
Vybrant Phagocytosis Kit (Thermo Fisher) FITC-labeled Escherichia coli beads for 2 h. Wells 
were then washed once with 1 × PBS and fixed with 2% PFA for 30 min. Wells were washed three 
times with PBS, then stained with DAPI for 10 min, and washed again three times with PBS. Wells 
were imaged using an automated Live Cell Scope and quantified for mean fluorescence intensity 
of the cells using Cell Profiler software. 
Appendix A.3.14 Macrophage Immunolabeling 
Cells were fixed with 2% PFA for 45 min at room temperature, then washed with PBS, 
followed by immunolabeling to determine surface marker expression. To prevent nonspecific 
binding, the cells were incubated in a blocking solution composed of PBS, 0.1% Triton-X, 0.1% 
Tween-20, 4% goat serum, and 2% bovine serum albumin for 1 h at room temperature. The 
blocking buffer was then removed and cells were incubated in a solution of one of the following 
primary antibodies: (1) monoclonal anti-F4/80 (Abcam, Cambridge, MA) at 1:200 dilution as a 
pan-macrophage marker, (2,3) polyclonal anti-inducible nitric oxide synthase (iNOS) and anti-
tumor necrosis factor-α (TNF-α) (Abcam, Cambridge, MA) at 1:100 dilution, each as M1-like 
 121 
markers, and (4,5) polyclonal anti-Fizz1 (Peprotech, Rocky Hill, NJ) and anti-Arginase1 (Abcam, 
Cambridge, MA) at 1:200 dilution, each as M2-like markers. The cells were incubated at 4°C for 
16 h, the primary antibody was removed, and the cells washed with PBS. A solution of 
fluorophore-conjugated secondary antibody (Alexa donkey anti-rabbit 488 or donkey anti-rat 488; 
Invitrogen, Carlsbad, CA) was added to the appropriate well for 1 h at room temperature. The 
antibody was then removed, the cells washed with PBS, and the nuclei were counterstained using 
DAPI. Cytokine-activated macrophages were used to establish standardized exposure times 
(positive control), which were held constant throughout groups thereafter. CellProfiler (Broad 
Institute, Cambridge, MA) was used to quantify images. 
Appendix A.3.15 Statistical Analysis 
Data were analyzed for statistical significance using either an unpaired Student's t-test, 
through which treated macrophages were compared to the appropriate M0 media control, or a one-
way analysis of variance with Tukey's post-hoc test for multiple comparisons. Data are reported 
as mean ± standard deviation with a minimum of N = 3. p-values of <0.05 were considered to be 
statistically significant. For gene expression data represented as a heat map, the p-values were 
generated by Student's t-tests comparing treated macrophages with M0 media control. 
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Appendix A.4 Results 
Appendix A.4.1 MBV Imaging and Gene Expression Signature of MBV-treated Cells 
Particulate UBM-ECM or SIS-ECM was enzymatically digested for 16 h at room 
temperature with proteinase-K or 0.1% collagenase solution. The solubilized ECM samples were 
then subjected to centrifugation at increasing g forces to isolate MBV. MBV were visualized at 
100,000 × magnification using TEM (Figure 13A). Cellular uptake of MBV was determined by 
labeling MBV with acridine orange. Labeled MBV were visible within BMDM 2 h after their 
addition to the culture media (B). The effect of MBV on macrophage activation was evaluated by 
quantitative polymerase chain reaction (qPCR) analysis of more than 25 commonly used markers 
of macrophage activation, including surface markers, cytokines, transcription factors, and 
metabolic markers. The gene expression profile of macrophages treated with MBV was 
qualitatively very similar to the gene expression profile of macrophages treated with ECM (Figure 
13C). Little to no effect on gene expression was observed after exposing the macrophages to pepsin 
or collagenase indicating that these enzymes, which are used to digest ECM before extraction of 
MBV, are not responsible for macrophage activation. Exposure of BMDM to IFNγ+LPS 
(MIFNγ+LPS) or IL-4 (MIL-4) led to distinct gene expression profiles consistent with previous 
studies(Mantovani et al., 2004; F. O. Martinez & S. Gordon, 2014; Martinez, Sica, Mantovani, & 




Figure 13. MBV imaging and gene expression signature of MBV-treated macrophages. (A) MBV isolated 
using proteinase-K digestion were visualized by transmission electron microscopy at 100,000 × magnification. (B) 
Following exposure of BMDMs (counterstained with DAPI) to MBVs whose nucleic acid content was labeled with 
acridine orange, the cells were visualized using fluorescence microscopy at 200 × magnification. MBV are seen 
within the cytosol of cells after a 2-h incubation. (C) Gene expression analysis of cells exposed to either ECM or 
their respective MBVs was evaluated using qPCR. Results are presented in a heatmap form that was generated using 
Treeview software; all fold changes are with respect to media control (N = 3). Scale bar scoring system is 
demonstrated as follows: less than 0.1-fold change (darkest purple), 0.1–0.29-fold change (intermediate purple), 
0.3–0.69-fold change (light purple), 0.7–1.29-fold change (gray), 1.3–1.9-fold change (light yellow), 2.0–4.9-fold 
change (intermediate yellow), greater than 5.0-fold change (bright yellow). 
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Table 1. Statistically significant gene expression changes in MBV-treated BMDM. Gene expression changes in 




Appendix A.4.2 MBV Treatment Increases M2-like Protein Expression 
Immunolabeling was performed to evaluate protein expression of BMDM (Figure 14). 
Similar to the gene expression results, MBV-treated groups had a qualitatively similar protein 
expression profile as the ECM-treated groups. Both ECM groups, as well as their corresponding 
MBV groups, had protein expression profiles similar to MIL-4 cells. Macrophage treatment with 
SIS-ECM and UBM-ECM and their corresponding MBV resulted in expression of Fizz-1 and Arg-
1 (markers that are associated with the MIL-4 phenotype). Low levels of iNOS expression were 
detected in the SIS-MBV group. TNF-α was detectable only in the UBM-MBV group. Both TNF-
α and iNOS are markers associated with the MIFNγ+LPS phenotype. No expression of these proteins 
was noted in the control groups. The majority of cells expressed F4/80, confirming their 
macrophage differentiation state. Quantification of immunolabeling images using CellProfiler 




Figure 14. MBV treatment increases M2-like protein expression. BMDM were exposed for 24 h to media control, 
1 mg/mL pepsin or 0.1 mg/mL collagenase controls, 250 μg/mL ECM, 25 μg/mL MBVs, or the cytokine controls 
IFNγ+LPS or interleukin (IL)-4. Cells were then fixed with 4% PFA .The cells were then incubated with anti-murine 
antibody for markers of the M1-like phenotype TNFα and iNOS, or markers of the M2-like phenotype Fizz1 and 
Arginase1. All images for the same antibody were taken at the same exposure time normalized to the positive control. 
Cell nuclei were stained with DAPI. Images were taken at 200 × magnification (N = 3). 
Appendix A.4.3 MBV Treatment Affects BMDM Function More Than ECM Treatment 
To determine the effect of MBV on macrophage function, NO production and phagocytosis 




Figure 15. MBV treatment affects BMDM function more than ECM treatment. Macrophages were exposed for 
24 h to MCSF control, 250 μg/mL ECM, 25 μg/mL MBVs, or the cytokine controls IFNγ+LPS or IL-4. (A) 
Macrophage supernatants were mixed with 1% sulfanilamide in 5% phosphoric acid for 10 min, followed by addition 
of 0.1% N-1-napthylethylenediamine dihydrochloride in water. The solutions were read in a spectrophotometer at 
540 nm and compared to the standard curve of sodium nitrite to assess nitric oxide production levels. Values: 
mean ± standard deviation, N = 6, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one-way analysis of 
variance (ANOVA) with Tukey's post-hoc test. (B) Treated macrophages were incubated with Vybrant Phagocytosis 
Kit FITC-labeled Escherichia coli beads for 2 h. Cells were fixed and stained with DAPI. Using fluorescence 
microscopy, the cells were visualized and quantified for mean fluorescence intensity of the cells using Cell Profiler 
software. Values: mean ± standard deviation, N = 6, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one-way 
ANOVA with Tukey's post-hoc test. 
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Appendix A.4.4 Nitric Oxide Production 
NO was assessed in MBV-exposed BMDM. NO production was not detectable in naive 
and MIL-4 macrophages, consistent with the findings of previous studies(Hachim, LoPresti, et al., 
2017; Hachim, Wang, et al., 2017). MIFN-γ+LPS macrophages produced a significant increase in NO. 
BMDM treated with MBV derived from UBM was the only treatment group to increase NO 
production (Figure 15B). 
Appendix A.4.5 Phagocytosis 
A basal level of phagocytosis as measured by uptake of FITC-E. coli particles was shown 
by all macrophages. Treatment with IFN-γ+LPS resulted in a significant increase in phagocytic 
activity compared to MCSF (M0). ECM and MBV treatment resulted in a significant increase in 
phagocytic uptake compared to MCSF (M0). When compared to their parent ECM bioscaffolds, 
exposure to MBV alone led to greater phagocytosis. Whereas there was no significant difference 
in phagocytosis between macrophages treated with UBM or SIS, UBM-MBV caused an increase 
in macrophage phagocytosis compared to macrophages treated with SIS-MBV (Figure 15B). 
Appendix A.4.6 miRNA Inhibition Reverse Gene Expression Patterns Compared to MBV-
exposed BMDM 
Sequencing results revealed expression of 240 different miRNAs in UBM-MBV and 53 in 
SIS-MBV(Huleihel et al., 2016) (Figure 16A-C). miRNAs with the greatest expression in UBM-
MBV and SIS-MBV are listed in Table 2. miRNAs highlighted in red were selected for 
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downstream analysis based on previous studies that showed their involvement in macrophage 
activation. 
 
Figure 16. miRNA inhibition reverses gene expression patterns compared to MBV-exposed BMDM. 
Macrophage miRNA inhibition. (A–C) Selective inhibition of specific miRNAs, miR-145-5p, miR-145-3p, and 
miR-125-b-5p using 50 nM of inhibitor for each. Relative abundance of miRNA levels following inhibition was 
determined by TaqMan miRNA qPCR assays. Values: mean ± standard deviation, N = 3, *p < 0.05 by Student's t-
test. Data represents fold change in comparison to M0. (D) Gene expression analysis of cells exposed to MBVs, or 
transfected with scrambled control miRNA inhibitor, mmu-miR-154-5p inhibitor, mmu-miR-143-3p inhibitor, mmu-
miR-125b-5p inhibitor, or a combination of all three inhibitors was evaluated using qPCR. Results are presented in a 
heatmap form that was generated using Treeview software; all fold changes are with respect to media control. Scale 
bar scoring system is demonstrated as follows: less than 0.1-fold change (darkest purple), 0.1–0.29-fold change 
(intermediate purple), 0.3–0.69-fold change (light purple), 0.7–1.29-fold change (gray), 1.3–1.9-fold change (light 
yellow), 2.0–4.9-fold change (intermediate yellow), and greater than 5.0-fold change (bright yellow). 
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Figure 17. Quantification of macrophage immunolabeling. (A) Percent positive macrophages as a function of 
treatment were assessed using CellProfiler and compared to M0 controls. (B) Quantification of immunolabeled 
macrophages in which select miRNA were inhibited through siRNA. 
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miR-145-5p, miR-143-3p, and miR-125b-5p were inhibited in BMDM to determine their role in 
macrophage expression of activation markers. The degree of inhibition of each miRNA was 
determined by qPCR (Figure 16A-C). miR-145 expression was reduced by more than 70%, miR-
143 expression was reduced by 65%, and miR-125b expression was reduced by more than 95%. 
qPCR analysis of MBV-treated and miRNA inhibitor-treated cells showed that 6 of 27 genes had 
a markedly different expression pattern (Figure 16D and Table 3). Interestingly, the six genes 
whose expression was increased by miRNA inhibition were the same as those that were decreased 
by MBV treatment. Importantly, KLF4, which is a transcription factor associated with macrophage 
activation and also a known target of miR-145-5p, shows an opposite expression pattern for all the 
inhibited miRNA treatment groups compared to both UBM-MBV- and SIS-MBV-treated cells. 
These results suggest that inhibition of KLF4 may be a target of the miRNA cargo within MBV. 
Appendix A.4.7 miRNA Shows Opposite Protein Expression in BMDM 
Immunolabeling was performed to evaluate protein expression of BMDM in which miRNA 
had been selectively inhibited. Similar to the gene expression results, treatment with miRNA 
inhibitors led to an opposite protein expression profile compared to MBV-treated groups (Figure 
18). Inhibition of miRNA-125b-5p led to an increase in iNOS expression, whereas inhibition of 
miRNA-143-3p led to an increase in the expression of TNF-α and Fizz1 compared to uninhibited 
controls. The majority of cells expressed F4/80 consistent with a macrophage differentiation state. 
Quantification of immunolabeling images using CellProfiler software supported the qualitative 
interpretation of the results (Figure 18).  
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Figure 18. miRNA inhibition shows opposite protein expression compared to MBV. BMDM were exposed for 
4 h to 50 nM of one of the following: scrambled control, mmu-miR-125b-5p inhibitor, mmu-miR-143-3p inhibitor, or 
miR-145-5p. Treatment media were then changed to normal growth media for an additional 18 h. Cells were then 
fixed with 4% PFA. Cells were then incubated with anti-murine antibody for markers of the M1-like phenotype TNFα 
and iNOS, or markers of the M2-like phenotype Fizz1 and Arginase1. Exposure times were established based on a 
negative isotype control and cytokine-treated controls and kept constant for each marker tested. Cell nuclei were 
stained with DAPI. Images were taken at 200 × magnification. The percentage of cells positive for each stain was 
quantified using Cell Profiler software and is presented in Supplementary Figure S1B. The results show that miRNA 
inhibition is capable of impacting the expression of several probed proteins, implicating the role of miR-125b-5p, 
miR-143-3p, and miR-145-5p in the formation of the MMBV phenotype. 
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Appendix A.5 Discussion 
A The results of the present study show that MBV can largely recapitulate the effects of 
ECM upon macrophage phenotype. MBV were rapidly internalized by macrophages and direct 
inhibition of specific miRNAs cargo (found in high abundance in MBV) within these macrophages 
notably affected the macrophage phenotype. Macrophage gene and protein expression, cell surface 
markers, and functional capacity as determined by phagocytic activity, nitric oxide production, 
and antimicrobial activity were most representative of a regulatory/anti-inflammatory phenotype 
following treatment with MBV, which is consistent with previous reports describing the effects of 
ECM bioscaffolds upon macrophage phenotype(S. F. Badylak et al., 2008; Brown et al., 2009; 
Dziki, Wang, et al., 2017). These findings provide a plausible explanation of at least one 
mechanism by which MBV embedded within ECM bioscaffolds can regulate the macrophage 
component of the innate immune response during matrix remodeling events.  
Macrophages have been shown to be important, in fact necessary, regulators of normal 
healing following injury, and/or in normal tissue development(Lavin, Mortha, Rahman, & Merad, 
2015). Specifically, a transition in macrophage activation state from a pro-inflammatory to an anti-
inflammatory and pro-remodeling phenotype is required for initiation and resolution of the healing 
process and a return to homeostasis(B. M. Sicari, J. L. Dziki, et al., 2014; Tidball, 2011; Tidball 
& Villalta, 2010; Wolf, Dearth, et al., 2014). Failure of this transition is associated with chronic 
inflammation, impaired wound healing, and dysregulation of the microenvironmental niche(B. Deng 
et al., 2012; Novak & Koh, 2013; Tidball et al., 2014), and has been suggested to play a causal role in conditions 
such as inflammatory bowel disease, muscular dystrophy, and kidney disease(Guiteras, Flaquer, 
& Cruzado, 2016; Novak & Koh, 2013; Rogler et al., 1997). While the importance of this 
phenotypic switch is recognized, the specific endogenous signals regulating spatiotemporal 
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patterns of macrophage phenotype are poorly understood. Phagocytosis of neutrophils as the cause 
of the phenotype switching in macrophages has been suggested(Fadok et al., 1998), but definitive 
studies have been lacking.  
Extracellular matrix harvested from many different tissues and commercially available 
biomaterials composed of ECM consistently and reproducibly promote an M2-like regulatory 
macrophage phenotype(Brown, Londono, et al., 2012; J. L. Dziki et al., 2016; Dziki, Wang, et al., 
2017; Piccoli et al., 2016), a process that drives downstream constructive and functional tissue 
remodeling. ECM bioscaffolds have thus far been shown to promote this phenotype activation by 
at least two mechanisms: 1) a direct transmembrane process involving intracellular pathways such 
as COX1/2(Dearth et al., 2016); and 2) an indirect effect through stem / progenitor cell paracrine 
signaling(J. L. Dziki et al., 2016). Macrophages have been shown to be necessary for the 
degradation of ECM bioscaffolds in vivo(Valentin et al., 2009). It is plausible that during 
degradation of the ECM, MBV are released, internalized by the local macrophage population, and 
facilitate transition to an anti-inflammatory/regulatory phenotype. It is also logical to hypothesize 
that these events occur not only in the presence of ECM bioscaffolds, but also during normal 
wound healing events; however additional work is required to test such a hypothesis. The profile 
of markers used in the present study to characterize macrophage activation state included 
transcription factors, surface markers, gene and protein expression, and functional assays. Stated 
differently, the activity of MBV was characterized on many levels, and it was shown that they 
mimic or even outperform ECM bioscaffolds with regard to macrophage activation in certain 
assays. These results suggest that MBV are a key bioactive component within ECM.   
Sequencing of MBV nucleic acid cargo from UBM-ECM and SIS-ECM showed that 
specific miRNA are particularly enriched in these nanovesicles, depending upon the ECM tissue 
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source. Three of these miRNA, 125b-3p, 143-3p, 145-5p, were highly expressed within MBV and 
these specific miRNA have been implicated in macrophage activation and phenotypes(Banerjee et 
al., 2013; Chaudhuri et al., 2011; Y. Zhang et al., 2013). These miRNA were therefore targeted in 
the present study for closer scrutiny. There is not a consensus in the literature with respect to 
known functions of the particular miRNA investigated in the present study. It has been reported 
that, in murine Raw 264.7 macrophages(Tili et al., 2007), miRNA-125b-5p targets TNF- and 5-
lipoxygenase, negatively regulating the inflammatory response(H. M. Lee, Kim, & Jo, 2016). 
However, in isolated murine peritoneal macrophages, miRNA-125b-5p was shown to enhance the 
inflammatory response in certain contexts by targeting IRF4(Chaudhuri et al., 2011). In the present 
study, inhibition of miR-125b-5p did not lead to increases in TNF-, however, a reduction in IRF4 
gene expression levels was noted in both miR-125b-5p inhibition and MBV treated macrophages. 
This incongruity suggests that IRF4 regulation isn’t dependent solely on miR-125-5p, and likely 
represents the net actions of various miRNA and proteins present in the MBV cargo. Discrepancies 
observed between the results of the current study and previous reports with respect to miRNA-
125b-5p could arise from the use of macrophages derived from different tissue sources. 
Additionally, it has been shown that miRNA-143/145 are elevated in M2-like macrophages 
and downregulated in M1-like macrophages, implying their role in macrophage activation(Y. 
Zhang et al., 2013). Moreover, it has been shown that miRNA-145-5p is capable of activating the 
epigenetic IL-10 gene silencer, HDAC11, in murine macrophage cell lines. The previous report 
showed that downregulation of miRNA-145-5p expression as a result of IFN- signaling directly 
contributes to pro-inflammatory macrophage activity and phenotype(L. Lin et al., 2013). However, 
miRNA-143-3p is less well studied in the context of innate immunity and its targets within 
macrophages are poorly described. Nonetheless, inhibition of both miRNA-143-3p and miRNA-
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145-5p in naïve macrophages resulted in increased expression of the macrophage surface marker 
associated with an M1-like phenotype, TNF-, which is consistent with the findings of the 
previous report(Y. Zhang et al., 2013). These results are further corroborated by the finding that 
MBV treatment led to increased expression of M2-like markers, Fizz1 and Arg1, which are 
associated with a reconstructive macrophage phenotype; however, there are a multitude of miRNA 
within MBV that could be similarly contributing to this downregulation of pro-inflammatory 
markers. Taken together, the results of the miRNA inhibition and MBV treatments corroborate 
previous reports that miRNA-145-5p contributes to a downregulation of the inflammatory 
phenotype and suggest that both miRNA-143/145 contribute to the macrophage phenotype in 
response to MBV and ECM bioscaffolds. 
Further analysis of gene and protein expression assays of naïve BMDM in which these 
miRNA were inhibited showed that their inhibition resulted in opposite patterns of expression in 
nearly 25 percent of the genes that were investigated. Among these genes are members of the KLF, 
STAT, and IRF families of transcription factors. Interestingly, KLF4 was consistently 
downregulated by both ECM and MBV treatment. Inhibition of miR-145-5p resulted in an increase 
of KLF4. The regulation of KLF4 by miR-145-5p has been shown to be an effector of macrophage 
activation(Cordes et al., 2009; H. Liu et al., 2013; N. Xu, Papagiannakopoulos, Pan, Thomson, & 
Kosik, 2009), which together with findings of the present study, suggests its role in this process. 
Importantly, inhibition of the different miRNAs led to a similar gene expression profile. Using 
TargetScan software we identified 18 mutual genes that are predicted being regulated by miR-145-
5p, miR-143-3p and miR125-5p. Among those genes is QKI, which was previously identified as 
a macrophage differentiation regulator(Fu et al., 2012; Wang et al., 2015). We postulate that 
mutual target genes are being regulated by these miRNAs, effecting specific pathways. 
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Overall, these results strongly suggest that MBV and their miRNA cargo are at least partially 
responsible for the macrophage response that is observed when ECM bioscaffolds facilitate 
functional tissue repair. 
MBV treatment also impacted macrophage function, with effects that were greater in 
magnitude than the parent ECMs on all metrics. The rate of phagocytosis in UBM-MBV exposed 
macrophages rose to a level indistinguishable from that of MIFN+LPS macrophages, significantly 
greater than all other treatment groups. Labeling MBV with ExoRed showed that MBV were 
internalized by macrophages within 2 hours. This finding does not differentiate between 
phagocytosis and endocytosis as the major route of uptake however, and this represents an area of 
future study.  
While miRNA-125/143/145 appear to modify macrophage activation state, there are 
greater than 200 miRNAs present within the MBV, which have the potential to affect macrophage 
activation or the behavior of other cell types(Huleihel et al., 2016). Additionally, the effect of 
MBV protein cargo upon macrophage activation has yet to be determined. The present work did 
not utilize an MBV-depleted ECM control due to the inability to remove MBV without destroying 
all remaining ECM constituents. 
Appendix A.6 Conclusions 
The results of the present study clearly show the ability of MBV to recapitulate many 
effects of ECM on macrophage activation, which is an important bioactive property of ECM 
bioscaffolds. Furthermore, specific miRNAs within MBV play a role in this process, which 
provides a plausible mechanism by which ECM promotes a transition in macrophage phenotype 
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and downstream constructive tissue remodeling not only with the use of ECM bioscaffolds but 
also during normal tissue repair processes. A more comprehensive understanding of the role of 
additional miRNAs present in the MBV cargo is an important area of future study. 
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Appendix B : Genes Uniquely Differentially Expressed in Response to MBV-associated IL-
33 and Causal Network Analysis 
Appendix B.1 Materials and Methods 
Appendix B.1.1 Macrophage Isolation and Activation.  
Bone marrow was isolated as previously described(L. Huleihel, J. L. Dziki, et al., 2017). 
Briefly, wild-type C57BL/6 or C57BL/6-st2-/- were sacrificed using inhaled carbon dioxide and 
cervical dislocation. Femurs, tibia, and fibula were then harvested and washed 3x in macrophage 
Complete Medium composed of 10% FBS (Invitrogen, Carlsbad, CA), 10% L929 supernatant, 10 
mM non-essential amino acids (Gibco), 10 mM HEPES (Gibco), 2 mM L-glutamine (Gibco), 100 
U/mL penicillin, 100 mg/mL streptomycin and 0.1% b-mercaptoethanol in DMEM high glucose 
(Gibco). Complete medium was flushed through the medullary space of harvested bones and plated 
at 2E6 cells/mL into 6 well plates (Corning) for 7 days until mature macrophages were obtained. 
Medium was supplemented 24h after plating and changed every 48 hours thereafter. Mature 
macrophages were subsequently treated at 37oC and 5% CO2 for 16h with Complete Medium 
containing one of the following treatments: 1E9 IL-33+ MBV/ml, 1E9 IL-33- MBV/ml, 20 ng/ml 
rIL-33, or no treatment (control). Following treatment, cells were washed in PBS and used for 
RNA isolation. 
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Appendix B.1.2 RNA Isolation and RNA Sequencing 
RNA isolated from wildtype or st2-/- macrophages treated with 20 ng/mL rIL-33, 1E9 
MBV/mL IL-33- MBV/mL, or IL-33+ MBV/mL using TRIzol reagent according to manufacturer’s 
recommendations. Isolated RNA purity was then assessed using a Bioanalyzer and used for whole 
transcriptome sequencing using Illumina NovaSeq 6000 (Illumina, San Diego, CA). Following 
quality control and pre-processing, reads with > 35 bp after trimming were aligned to the most 
recent murine genome, GRCm38. Downstream read count analysis was performed using R, 
version 3.6.1. For visual exploration of the data, the obtained read counts were normalized using 
the regularized log transformation function of R package DESeq2, version 1.24.0. For Ingenuity 
Pathway Analysis and Causal Network Analysis, genes uniquely differentially expressed by MBV-
associated IL-33 was defined by removing genes common to IL-33+ and IL-33- MBV treatment in 
st2-/- macrophages, and strain differences were accounted for by removing genes unique to IL-33+ 
MBV treatment of st2-/- macrophages compared to IL-33+ MBV treatment of wild-type 
macrophages. Three biological replicates were performed for each treatment group and Wald test 
was used for statistical testing with 0.05 set as the significance cutoff used for optimizing the 
independent filtering and with the null hypothesis being that the log2 fold changes between 
contrast groups are equal to zero. P-values were adjusted for multiple testing using the Benjamini-
Hochberg procedure. The obtained results were then post-hoc filtered using thresholds of 0.05 for 
adjusted p-value and 1 for absolute log2 fold change. 
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Appendix B.2 Results 
Appendix B.2.1 MBV-associated IL-33 Reduces M1-Associated Pathway Activation 
Analysis of gene expression changes in treated macrophages showed 137 significantly 
differentially expressed genes (DEG) unique to IL-33+ MBV, of which 99 were downregulated 
and 48 were upregulated (adjusted p: 0.044 < p < 1E-18), the most differentially upregulated and 
downregulated protein coding genes are presented in Table 4. IPA Core Analysis (IPA, Qiagen) 
of unique DEGs was used for causal network analysis. Results show that four pathways were 
significantly enriched, of which the top two related to immune cell mobilization and extravasation 
(Granulocyte Adhesion and Diapedesis (p = 2.38E-5), and Agranulocyte Adhesion and Diapedesis 
(p = 3.73E-5, Figure 19A). Using the Causal Networks algorithm, DEGs were used to predict 
master regulator and upstream regulator molecules whose combined activities could explain the 
observed expression changes. Results show that the top two causal networks were governed by 
IRF3 (activation z-score = -5.425, network bias-corrected p < 0.0001) and Trim21 (activation z-
score = -5.048, network bias-corrected p < 0.0001, Figure 19B-C). Of note, the three upstream 
signaling molecules most significantly predicted to be inhibited by these master regulators were 
molecules associated with M1-like macrophage phenotype activation, namely: TLR4 (activation 
z-score = -3.202, p = 1.26E-11), IRF7 (activation z-score = -3.094, p = 1.8E-9), and NFkB 
(activation z-score = -3.440, p = 4.21E-9). 
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Figure 19. MBV-associated IL-33 inhibits M1-associated pathways and networks. (A) Pathways enriched by 
MBV-associated IL-33 uniquely differentially expressed genes (adj. p values shown beneath each pathway). (B-C) 
Top predicted causal networks for MBV-associated IL-33 differentially expressed genes. 
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Table 4. Top protein-encoding genes significantly regulated by MBV-associated IL-33. 
 
Appendix B.3 Discussion 
A IL-33 has long been considered to be a nuclear cytokine that functions as an alarmin 
upon necrotic cell death(Cayrol & Girard, 2014). Following loss of cell integrity, IL-33 is released 
to the extracellular space where it is cleaved by proteases to produce active soluble IL-33 that 
complexes with the ST2 receptor on infiltrating immune cells(Cayrol et al., 2018). In turn, MyD88 
and p65 are activated with pro-inflammatory consequences(Milovanovic et al., 2012). The IL-
33/ST2 axis is essential for the recruitment and activation of TREG cells in skeletal muscle 
healing(W. Kuswanto et al., 2016); however, recent reports show that MBV-associated IL-33 may 
mediate macrophage phenotype through an as yet undetermined mechanism(G. S. Hussey et al., 
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2019). Results of the present study suggest that MBV-associated IL-33, which traffics into cells 
independent of the ST2 receptor, a markedly reduced pro-inflammatory macrophage phenotype 
than that propagated by the IL-33/ST2 pathway(G. S. Hussey et al., 2019), which has clear 
implications for macrophage phenotype modulation. 
RNA sequencing analysis shows that MBV-associated IL-33 promotes a range of gene 
expression changes consistent with inhibition of M1-associated signaling pathways, including 
NFkB, TLR4, and IRF7, by way of activity on master regulators IRF3 and TRIM21. This gene 
expression profile could not be fully explained by the effect of MBV treatment or strain 
differences, demonstrating that IL-33 is capable of exerting modulatory effects in the absence of 
the ST2 receptor. The net macrophage phenotype elicited by IL-33+ MBV is broadly anti-
inflammatory. It is of note that TLR4 and ST2 receptor signaling pathways share several secondary 
messengers, including MyD88, IRAKs, TRAFs, and p65, a component of NFkB(Kakkar & Lee, 
2008; Kuzmich et al., 2017). It is plausible, though untested, that MBV-associated IL-33 may 
feedback on target cells to inhibit ST2-dependent signaling. In the context of muscle healing, these 
results strongly suggest ST2-independent IL-33 signaling may contribute to the timely transition 
from an M1-like macrophage phenotype towards an M2-like macrophage phenotype. 
Appendix B.4 Conclusions 
MBV-associated IL-33 elicits a unique pattern of gene expression that could not be 
accounted for by the effect of MBV treatment alone or due to source animal strain effects. The 
pathways and networks enriched in IL-33-unique genes are associated with an M1-like phenotype 
and are markedly inhibited as a result of MBV treatment. 
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